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1.1  Colorectal cancer  
 
Colorectal cancer (CRC) is a malignancy found in either the colon or the rectum, and it is the 
third most common cancer in the world. With approximately 1.4 million new diagnoses and 
700,000 deaths worldwide in 2012, CRC is the fourth leading cause of cancer-related deaths 
worldwide (Haggar and Boushey, 2009). There were 41,112 diagnoses and 15,903 deaths due 
to bowel cancer in the UK in 2013 (CRUK, 2013b). Incidence is 25-fold higher in developed 
Western countries (including the US, Australia and New Zealand) than in Africa and Asia 
(WCRF, 2013). Colorectal cancer risk depends on both genetic predisposition and 
environmental contributions. Of the environmental, or non-genetic, factors, the ageing 
process is a major risk factor. Between 2011 and 2013, over 60% of all new diagnoses were in 
people aged 70 years or older. The highest rates were observed in people older than 85 years, 
and incidence was generally higher in men than in women (CRUK, 2013b). CRC is considered 
a preventable disease by many specialists in the field, due to numerous modifiable lifestyle 
risk factors that are reported to be causally linked with the disease. These include low dietary 
fibre, folate deficiency, high consumption of red and processed meats and fats, smoking, high 
alcohol intake (WCRF, 2010), obesity, low levels of physical activity and diabetes (Wei et al., 
2009). Apart from the lifestyle and dietary factors, chronic bowel disease including ulcerative 
colitis and Crohn’s disease have been associated with a predisposition to CRC (Mattar et al., 
2011). 
 
Unfortunately, by the time of diagnosis, over 50% of all colorectal cancers have spread from 
the colon or the rectum to surrounding tissues (37%) and, in some cases, to distant organs 
(20%) (Ferlay et al., 2015). The mean five-year survival for people diagnosed with CRC is 
approximately 40% and is influenced by staging at initial diagnosis (Veigl et al., 1998).  
 
Most CRCs are classified histologically as adenocarcinomas and develop from adenomatous 
polyps. Between 1 and 10 % of polyps will progress to adenocarcinomas, and this process is 
strongly influenced by polyp size, villous component and severity of dysplasia. Adenomas are 
clinically and histologically heterogeneous and are classified as tubular, tubulovillous or 
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villous (Kufe, 2003). In some cases, adenocarcinomas are thought to develop from 
hyperplastic polyps via a serrated adenoma intermediate. Hyperplastic polyps, generally 
measuring between 5 and 10 mm, are usually found in the distal colon and rectum and, 
though they were previously believed to be benign and clinically insignificant, hyperplastic 
polyps have been discovered to share molecular similarities with adenomatous polyps 
(Morimoto et al., 2002). The earliest characterisable lesions are formed when the epithelium 
from the normal healthy colon hyperproliferates into aberrant crypt foci (ACF) and 
subsequently progresses to adenoma before transforming into invasive cancer (Kufe, 2003). 
Adenomas are clonal; they display low-grade dysplasia with hyperchromatic enlargement and 
elongation of the nuclei along the basement membrane, and they can also display apoptosis. 
Adenomatous polyps are thought to progress through a “top-down” mechanistic progression. 
The villous component of tubular adenomas (simple dysplasia with crypt-like glands) is less 
than 25%. In tubulovillous adenomas (considered intermediate lesions) the villous 
component ranges from 25-75% and in villous adenomas it comprises more than 75% of the 
tumour. Large or predominantly villous adenomas are classified as advanced adenomas (Shih 
et al., 2001). 
 
Surgery remains the initial treatment of choice for CRC, and five year survival after resection 
is approximately 40% (Scholefield et al., 2002). Patients who do not undergo resection and 
whose disease progresses metastatically have five-year survival rates of 11% (CRUK, 2013a). 
Radiation is an additional treatment option but it is normally limited to the rectum. Until the 
middle of the 1990s, chemotherapy options were restricted to combinations of either 
leucovorin or fluorouracil and the median overall survival (OS) (from date of diagnosis to 
death) was only 10-12 months. Between 1996 and 2002, irinotecan and oxaliplatin were 
approved, and combinations of these cytotoxic drugs improved the median OS to 14-16 
months (Gonzalez-Zulueta et al., 1995). Furthermore, the advent of molecular targeted 
biologics, bevacizumab and cetuximab, administered in combination with standard 
chemotherapy options, further improved survival (Veigl et al., 1998). Despite advances in 
chemotherapy combinations and molecular-targeted agents, as well as an emphasis on 
increased screening and early detection, the outcomes in CRC remain poor for the majority 
of patients. Those who do undergo chemotherapy and CRC targeted therapy have a high 
chance of experiencing severe and incapacitating side effects, while in many cases patients 
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do not respond (Fearon and Vogelstein, 1990). Poor survival has prompted an emphasis on 
measures to prevent this disease. 
 
Clinical research interest in chemoprevention is increasing, and research indicates that non-
steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors may 
reduce CRC risk (Cooper et al., 2010). Additionally, a growing body of research into diet-
induced CRC risk has led to an increased interest in micronutrients, including folate, vitamin 
D, calcium, and fibre as chemopreventatives which target multiple pathways in the 
developmental stages of CRC (Du et al., 2010). 
 
1.2 Heritability of colorectal cancer 
 
Approximately 20-25% of all CRCs occur in patients with a family history of CRC, and 5-6% of 
cases are due to single-gene defects (CRC genetic syndromes). The two major heritable forms 
of CRC are familial adenomatous polyposis (FAP) and Lynch syndrome/hereditary non-
polyposis colorectal cancer (HNPCC), both of which display autosomal dominant inheritance. 
FAP arises from mutations in the adenomatous polyposis coli (APC) tumour suppressor gene 
and is characterised by hundreds or even thousands of precancerous polyps. These normally 
appear by the age of 35 years and will almost certainly cause colorectal cancer if the colon is 
not removed (Jasperson and Burt, 1993). HNPCC arises from inherited mutations that cause 
defective DNA mismatch repair and lead to microsatellite instability (MSI). Most HNPCC cases 
are caused by mutations in the DNA mismatch repair pathway, including the MLH1 and MSH2 
genes (Yuan et al., 2002). 
 
Various studies, typically employing a case-control design, have identified genetic variants 
that have small to moderate effects on the odds of developing CRC. These variants include 
Variable Number Tandem Repeat (VNTR) alleles in the Harvey Rat Sarcoma Virus 1 (HRAS1) 
and a rapid acetylator phenotype caused by N-acetyltransferase 2 (NAT2) alleles (Kemp et al., 
2004). Other genetic polymorphisms include methionine synthase (MS A2765G) and 
thymidylate synthase (TS 2R/3R promoter).  
 
Investigations into polymorphisms specifically in folate genes started over 20 years ago. In 
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the methyltetrahydrofolate reductase (MTHFR) gene, the C677T and A1298C polymorphisms 
have been of great interest, particularly in terms of their influence on CRC risk, due to their 
involvement in folate metabolism (Chen et al., 1996, Sharp and Little, 2004). A large meta-
analysis concluded that the MTHFR C677T is associated with a reduction in CRC risk (Taioli et 
al., 2009). This is discussed in further detail in Section 1.4.5.  
 
1.3 Molecular biology of colorectal cancer 
The majority (75-80%) of CRCs arise sporadically from environmental and complex gene-
environment interactions, with no obvious links to heredity (Kemp et al., 2004). Twin studies 
estimate that genetic factors (including gene-environment interactions) contribute to 
approximately 35% of all CRCs (Lichtenstein et al., 2000). It has been proposed that most of 
these cases are associated with low-penetrance genetic polymorphisms. Additional risk 
polymorphisms need to be identified to assess an individual’s susceptibility to CRC.  
Sporadic neoplasia in the colon was first characterised by Fearon and Vogelstein in 1990 using 
a multi-step histological model. In this model, mutations in multiple key genes result in the 
activation of oncogenes and the inactivation of tumour suppressor genes. Together, these 
multiple hits accumulate, ultimately leading to the development of cancer. (See Figure 1.1). 
Most sporadic cancers derive from adenomas which are intermediate precursor lesions. 
Adenoma residues are commonly found in colorectal adenocarcinomas (Kinzler and 
Vogelstein, 1996) and have been useful in investigating the mechanisms involved in disease 
progression. Over the past two decades, the Fearon and Vogelstein model has developed to 
include potential epigenetic modifications (accumulative changes in DNA that do not alter the 
base sequence) in several genes which are now believed to contribute to CRC neoplasia via 
the following three pathways: chromosomal instability, microsatellite instability and the CpG 
island methylator phenotype (CIMP). The three pathways are not mutually exclusive, and 








(Strachan and Read, 2004) 
 
Chromosomal instability mainly comprises alterations in chromosomal number, sequence 
changes, chromosomal rearrangements, gene amplification, deletions and loss of 
heterozygosity. Chromosomal instability is a somatic defect that accounts for more than 80% 
of colorectal cancers and is seen in specific genes, including the tumour suppressor genes 
APC, p53 and SMAD. These genes normally oppose malignancy, but when mutated by the loss 
of a wild-type copy, they play a key role in transforming normal colorectal mucosa into 
carcinomas (Markowitz and Bertagnolli, 2009).  
 
Microsatellite instability results from mutations in DNA mismatch repair (DNA MMR) such as 
MLH1, MSH2, PMS2. MSI accounts for approximately 15% of sporadic colorectal cancers 
(Lawes, 2005). DNA MMR normally rectifies spontaneous errors, such as short insertions or 
deletions, which tend to arise during DNA replication. Under normal conditions, a protein 
binds to the mismatch and excises the error, but when there is a defect in DNA MMR, these 
errors accumulate and novel microsatellites (repeated sequences of 1-6 base pairs) are 
formed (Iacopetta et al., 2010). In the majority of such tumours, MLH1 is silenced by DNA 
methylation (Kane et al., 1997) and it has been suggested that many MSI CRCs are initiated 
by the epigenetic silencing of DNA repair mechanisms and alternative genes involved in 
apoptosis (programmed cell death) (Jass, 2007b). 
 
Finally, the CpG island methylator phenotype (CIMP) is increasingly being linked with 
colorectal cancer risk. Aberrations in normal DNA methylation patterns can potentially 
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activate oncogenes, silence tumour suppressor genes and influence rates of mutation. 
Genetic and epigenetic events are now believed to work together to initiate neoplasia and 
hyperproliferation, subsequently resulting in invasive CRC (Das and Singal, 2004). 
 
1.3.1 DNA methylation  
DNA methylation is the addition of methyl groups after DNA replication, typically to CpG 
dinucleotides. DNA methylation restricts transcription and is one of the mechanisms through 
which gene expression is regulated. Additionally, DNA methylation influences mutation rates 
(Jones and Takai, 2001) and is essential to several processes, including genomic imprinting (Li 
et al., 1993) and x-chromosome inactivation. It is also involved in maintaining DNA structure 
(Bird et al., 1995). Altered methylation patterns have consistently been reported to exist in 
cancer cells (Laird, 2005). In early DNA methylation studies, genomic hypomethylation was 
observed in cancer tissue compared with normal tissue of healthy volunteers (Feinberg and 
Vogelstein, 1983). Genomic hypomethylation (in regions that are usually methylated) is often 
found to occur simultaneously with hypermethylation in CpG islands (in regions that are 
usually unmethylated) (Jones and Laird, 1999, Esteller et al., 2000, Herman and Baylin, 2003). 
 
1.3.2 Genomic DNA methylation in Colorectal Cancer  
 
In tumours, genomic hypomethylation is more frequent than gene-specific hypermethylation, 
and an overall loss of 5-methylcytosine is often observed in cancer (Ehrlich et al., 2002, 
Dupont et al., 2004). Genomic hypomethylation has been found in colonic tissue taken from 
early neoplasia, in benign hyperplastic and adenomatous polyps and in malignant carcinomas 
(Goelz et al., 1985, Bariol et al., 2003). DNA hypomethylation does not occur solely in 
neoplastic cells; it is also observed in the normal-appearing colonic mucosa of subjects with 
adenoma and CRC (Pufulete et al., 2003), which suggests that genomic hypomethylation may 
play a role in the early stages of colorectal carcinogenesis. 
 
Methylation events on chromosome 18 have been shown to play a particularly important role 
in the pathogenesis of CRC. In the early stages of the colorectal cancer process, allelic losses 
on chromosome 18 have been shown in up to 70% of primary colorectal tumours (Cardoso et 
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al., 2007), and down-regulation of genes primarily on chromosome 18 is also known to take 
place (Lips et al., 2008). In addition, methylome analysis of colorectal cancer revealed that 
the highest frequency of methylation occurs on genes located on chromosome 18 (Kim et al., 
2011b). Given that genetic alterations, including aberrant DNA methylation (one of the 
earliest molecular alterations in numerous human cancers (Issa, 1999) occur in concert with 
specific stages of the adenoma-carcinoma sequence, it is thought that these combined and 
simultaneous events drive the process of carcinogenesis. For this reason, DNA methylation is 
potentially useful as a biomarker in colorectal cancer prognosis (Grady, 2005). 
 
DNA hypomethylation can also cause loss of imprinting, a major genetic alteration that drives 
cellular proliferation and is frequently observed in a number of human cancers. This 
monoallelic expression ensures that imprinted genes encode proteins for embryonic and 
placental growth and adult metabolism. Imprinting usually refers to the specific expression of 
a parental allele in a set of approximately 50-80 genes. When the precision of this expression 
is altered, loss of imprinting takes place and one of the two alleles is permanently inactivated. 
An example of loss of imprinting is the result of hypomethylation of a differentially 
methylated region in IGF2 and the H19 gene in both colorectal tumours and normal-appearing 
mucosa in the same patient (Cui et al., 1998). Loss of imprinting is also considered an essential 
tool for the diagnosis, prognosis and treatment of human cancers (Jelinic and Shaw, 2007). 
The reason for DNA hypomethylation and the mechanism by which it occurs in cancer are yet 
to be fully elucidated. Dietary factors, including folate status, and common genetic 
polymorphisms in folate-metabolising enzymes with accompanying reduced enzyme 
activities in the methylation pathway, have been suggested as potential causes (Pogribny et 
al., 1997, Stern et al., 2000, Clark and Melki, 2002). 
   
1.3.3 Gene-specific Methylation in Colorectal Cancer 
 
Regional hypermethylation at CpG islands occurs concurrently with genomic 
hypomethylation in cancer cells (Baylin et al., 1998). CpG islands are clusters of CpG 
dinucleotides that are between 0.2 and 3kb in length. DNA hypermethylation at CpG islands 
within the promoter regions of genes is associated with gene silencing. A large amount of 
research has focused on hypermethylation-induced silencing of tumour suppressor genes 
(Wong et al., 2006). Since the retinoblastoma gene (RB1) was identified as being silenced by 
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hypermethylation (Greger et al., 1989), many more tumour suppressor genes, including VHL 
and APC, have been identified as candidates for this mechanism (Feinberg and Tycko, 2004). 
Hypermethylation has been detected in normal-appearing colonic mucosa and has been 
correlated with ageing. It has been suggested that a large proportion of the CpG island 
methylation in CRC is associated with an accumulation of age-related hypermethylation in 
normal colonic tissue (Toyota and Issa, 1999). Genes that undergo this age-related 
methylation include ER, MYOD, N33 and IGF2 (Ahuja et al., 1998). More specifically, in 
colorectal cancer, the tumour suppressor genes shown to be inactivated by hypermethylation 
include the Myf-3 gene, adenomatous polyposis coli (APC) (Esteller et al., 2000), hMLH1 
(Miyakura et al., 2001) and the oestrogen receptor gene (ER) (Issa et al., 1994). In addition to 
hypermethylation-induced tumour suppressor silencing, the hypermethylation of mismatch 
repair genes and cell cycle regulatory genes is also associated with colorectal cancer (Wong 
et al., 2006). 
 
An unusually high increase in promoter hypermethylation of CpG islands, in genes such as 
MINT1, MINT2 and MLH1, defines the CpG-induced methylator phenotype (CIMP) in CRC 
(Issa, 2004). CIMP is associated with microsatellite instability (MSI) (Jass, 2007a) and was first 
described in detail in 1999 when methylation resulting from the ageing process was 
distinguished from methylation resulting from cancer; the authors described CIMP in terms 
of cancer-related methylation. More recently, the role of CIMP has been recognised in CRC, 
with up to 40% of sporadic MSI CRCs being CIMP positive (Toyota and Issa, 1999). CIMP is 
usually associated with proximal colonic tumours, hyperplastic polyps and a poor prognosis 
(Curtin et al., 2007). Two types of CIMP-positive tumours have been postulated: CIMP high 
(associated with BRAF and MLH1) (Shen et al., 2007) and CIMP low (associated with KRAS) 










In addition to DNA methylation, an alternative pathway through which carcinogenesis may 
be influenced is uracil misincorporation into DNA. A key factor in this hypothesis is folate 
deficiency which has been causally linked to strand breakage during replication, hindering the 
transcription of genes involved in carcinogenesis, but the direct cause of strand breakage has 
not been confirmed (Duthie et al., 2000a). Uracil misincorporation into DNA is typically 
quantified by cleaving uracil from DNA and measuring the uracil content in samples (Blount 
and Ames, 1994). DNA synthesis requires folate for the production of purines and the 
pyrimidine nucleoside thymidine. Folate deficiency alters the supply of  5,10-
methylenetetrahydrofolate (THF), a substrate required for donating a methyl group in the 
conversion of deoxyuridine monophosphate (dUMP) to thymidine monophosphate (TMP) by 
thymidylate synthetase (see Figure 1.2). Folate deficiency shifts the balance of DNA 
precursors and subsequently reduces methylation of dUMP, thereby reducing the production 
of TMP. Raised levels of dUMP lead to increases in the misincorporation of uracil instead of 
thymine into DNA (Duthie et al., 2000a). Normally uracil residues are excised from DNA by 
uracil DNA glycosylase. However, if altered deoxyribonucleotide pools (from folate deficiency) 
persist, repeated repair processes are triggered and transient single-strand breaks can arise. 
More critically, double strand breaks can occur during the simultaneous repair of two 
adjacent uracil residues on opposite DNA strands (Choi and Mason, 2000), which can lead to 
more severe levels of DNA damage and instability. 
 
1.4 Dietary folate and biomarkers of neoplasia (DNA methylation and uracil 
misincorporation) 
 
Micronutrients such as folates have increasingly become the focus as ‘chemopreventatives’ 
in CRC due to their involvement in multiple pathways in CRC development and the extent to 
which they may influence biomarkers of neoplasia such as DNA methylation and uracil 
misincorporation (Du et al., 2010). 
 
1.4.1 Folate and diet  
Folates are a group of B vitamin compounds found in dark green vegetables, including 
spinach, broccoli and asparagus; fruits, including oranges and strawberries; and offal, 
particularly liver. Other plant-based sources rich in folate are beans such as kidney, pinto and 
21 
 
chickpeas. Folate compounds are derived from the parent molecule pteroylglutamic acid (also 
known as folic acid), which is added to fortified foods, including breakfast cereals, yeast 
extracts and supplements. Each of the folates possess similar biochemical and nutritional 
properties. Tetrahydrofolate (THF), 5-methylTHF and 5 and 10-formylTHF are the reduced, 
more labile forms found in foods. These compounds possess methyl or formyl groups for one-
carbon substitution. This particular biochemical mechanism, the folate one-carbon 
metabolism (FOCM), is involved in DNA methylation, DNA synthesis and repair, and cellular 
proliferation (Gong et al., 2015). As a result, it plays a key role in modulation of oncogenesis 
including the development of CRC. FOCM is described in detail in Section 1.4.2. 
Bioavailable folate is defined as the amount of folate that is available to be absorbed, 
metabolised and stored. Food folates have a bioavailability of approximately 50% (Sauberlich 
et al., 1987) and in sharp contrast folic acid (the man-made fully oxidised monoglutamate 
form added to foods and supplements) is 100% bioavailable. Absorption of folate from food 
is believed to be affected by a number of factors, including cooking methods, insufficient 
release from the food matrix (cellular structures), inadequate deconjugation of polyglutamate 
chains to monoglutamates, and folate stability (which may be affected by other nutrients) 
food constituents and the environment in the gastrointestinal tract. In contrast to food 
folates, folic acid does not need to be released from the food matrix, and is more stable in 
the intestinal lumen because it already exists in monoglutamate form (McNulty and Pentieva, 
2004).  
Monoglutamyl folates are absorbed by humans in the small intestine, in the proximal and 
distal jejunum as well as in the ileum, where absorption is greatly influenced by pH (Schron, 
1991). They are transported across the brush-border, where conjugases break long folate 
chains into monoglutamates. After absorption, the majority of folates are taken up by the 
liver via the hepatic portal veins and are either retained or released into the bile or blood. A 
portion of folates from the liver, in the form of 5-methylTHF, go back into circulation. 5-
methylTHF is the major folate compound found in plasma; it is therefore assumed to be the 
major circulating folate in humans (Pietrzik et al., 2010). A fraction of folates retained by the 
liver is released into the bile, reabsorbed by the intestine and delivered to the tissue via 
circulating plasma. This process is known as enterohepatic circulation and it is the mechanism 




Adequate folate levels are integral to human health because folate plays an essential role in 
the synthesis of DNA and RNA and in the maintenance of the DNA methylation cycle. Folate 
deficiency affects rapidly dividing tissues, including blood, and can cause megaloblastic 
anaemia. It can also affect the intestinal mucosa, leading to intestinal villous atrophy. Low 
folate levels appear to contribute to the progression of several disorders in humans, including 
neural tube defects, cardiovascular disease, cognitive impairment and various cancers, 
including colorectal cancer (Kim, 2005).  
 
1.4.2 Folate biochemistry  
 
Folate one-carbon metabolism (FOCM) is a complicated system of interrelated reactions that 
provide an adequate supply of methyl groups available for DNA methylation and DNA 
synthesis (Figure 1.2) (Locasale, 2013).  
 
The form of folate required in methylation reactions is 5-methylTHF, the methyl group donor 
for the remethylation of homocysteine. Methionine, in its activated form, S-adenosyl 
methionine (SAM) is the methyl group required in over 100 methylation reactions including 
DNA methylation (Sibani et al., 2002, Kim, 2007a). Folate deficiency is thought to alter 
nucleotide levels and interfere with normal DNA methylation patterns (Choi et al., 2005). The 
essential form of folate in the DNA synthesis cycle is 5,10-methylenetetrahydrofolate (5,10-
methyleneTHF). THF is converted to 5,10-methyleneTHF in a reaction catalysed by serine 
hydroxymethyltransferase. 
 
The activity of the MTHFR enzyme is pivotal in controlling the methyl group supply because it 
catalyses the conversion of 5,10-methyleneTHF to 5-methylTHF. Reduced enzyme activity 
affects the flux of the reaction and alters supplies of both 5-methylTHF and 5,10-
methyleneTHF. Folate in the 5,10 methyleneTHF form is essential to convert deoxyuridylate 
to thymidylate. When folate supplies are limited, uracil is misincorporated into DNA, which 
can lead to breakage of DNA double-strands, chromosomal instability and neoplasia. During 
folate deficiency, MTHFR C677T polymorphism has been associated with thermolability of the 
enzyme which may increase the risk of CRC by disrupting normal patterns of DNA methylation 
23 
 
and synthesis (Sharp and Little, 2004). 
 
Tetrahydrofolate (THF) ‐mediated one‐carbon metabolism is a network of interrelated 
metabolic pathways that take place in the cytoplasm, the mitochondria and also the nucleus. 
Purine and thymidylate synthesis, aswell as remethylation of homocysteine, occurs as a result 
of one‐carbon metabolism in the cytoplasm.  
Catabolism of choline, purines, histidine, serine and glycine interconversion, and cytoplasmic 
metabolism all occur as a result of one‐carbon metabolism in the mitochondria.  
Anomalies which disrupt folate‐mediated one‐carbon metabolism are associated with 
different diseases but the biochemical mechanisms and how they affect the initiation of 
disease is not well understood (Fox/Stover and Marco, Scotti) 
 






THF (tetrahydrofolate), me-THF (5,10-methylene-THF), SHMT (serine hydroxymethyl 
transferase), mTHF (5-methyltetrahydrofolate), MTHFR (methylenetetrahydrofolate 
reductase), F-THF (10-formyltetrahydrofolate), hCYS (homocysteine), MET (methionine), 
MAT (methionine adenyltransferase), SAM (S-adenosylmethionine), SAH (S-
adenosylhomocysteine), SAHH (S-adenosyl homocysteine hydrolase), CBS (cystathionine 
synthase), CGL (cystathionine lyase), Αkb (α-ketobutyrate), BHMT (betaine 
hydroxymethyltransferase), DHFR (dihydrofolate reductase), dimethylglycine (DMG), 
glycine decarboxylase (GLDC) 
thymidylate synthase (TS) 
 
1.4.2.1 The role of homocysteine 
 
An indirect indicator of folate status is homocysteine, a sulphurated, non-protein amino acid. 
Homocysteine intersects the two pathways of remethylation and transulphuration, which 
break the molecule down in the presence of folate, vitamins B6 and B12. During remethylation 
homocysteine takes a methyl group from 5-methylTHF. In transulphuration, homocysteine 
and serine irreversibly form cystathionine. In the absence of sufficient methyl groups from 
the diet (such as B12 and folate) homocysteine can accumulate and lead to 
hyperhomocysteinemia, a risk factor for a number of diseases, particularly cardiovascular 
disease (Cattaneo, 2003).  
 
1.4.2.2 The role of riboflavin  
 
The folate and riboflavin interaction is less well discussed. Riboflavin is a precursor of flavin 
adenine dinucleotide (FAD), a coenzyme required  for 5,10-methylenetetrahydrofolate 
reductase (MTHFR). FAD-dependent MTHFR catalyzes the reaction that generates 5-
methyltetrahydrofolate required to form methionine from homocysteine. 
 
 
In addition to other B-vitamins, increased riboflavin intakes have been associated with a 
reduction in plasma homocysteine concentrations ( Jacques PF, Bostom AG, Wilson PW, Rich 
S, Rosenberg IH, Selhub J, Am J Clin Nutr. 2001). Riboflavin has been shown to be most 
influential in folate metabolism in MTHFR C677T individuals, in particular when low folate 
status is accompanied by increased homocysteine levels, and furthermore riboflavin intake is 
below optimal levels. However, riboflavin has been shown to directly reduce elevated 
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homocysteine concentrations in these individuals, which supports the importance of the 
riboflavin and MTHFR genotype interaction (McNulty H, Dowey le RC, Strain JJ, et al, 
Circulation. 2006;113(1):74-80) 
 
1.4.3  Folate and colorectal cancer  
 
Numerous epidemiological studies have reported that foods containing folate confer 
protection against colorectal cancer. The active compounds found in these foods have not yet 
been isolated. Nevertheless, a considerable amount of research into the mechanisms by 
which this protection may occur has been conducted (Terry et al., 2002). Insufficient folate 
status, leading to DNA strand breaks and impaired DNA methylation, has been proposed as 
one of the mechanisms through which CRC is caused (Kim, 2003).  In seeming contradiction 
to the evidence on folate deficiency, studies have reported that raised folate levels from 
supplementation present an increased risk of CRC, though this risk may only exist in the 
presence of precancerous lesions rather than in disease free individuals (Kim, 2006). This 
phenomenon has been termed the ‘dual modulatory effect’ of folate supplementation. 
Epidemiological studies investigating the link between folate status and CRC risk have 
generally been based on dietary and supplementary intake, folate in serum and red blood 
cells, and plasma homocysteine. However, because neoplastic changes occur at a cellular 
level, there is increasing interest in site-specific folate status and its relation to different 
cancers (Brockton, 2006, Brockton, 2008). When investigating CRC risk, assessing folate status 
in the colon may be more useful than simply assessing folate status in the serum or red blood 
cells. Additionally, lifestyle factors may affect folate levels differently in colonic tissue than in 
serum and red cell folate. 
 
 
1.4.3.1 Folate and colorectal cancer – animal studies 
 
Animal studies have identified an inverse association between folate levels and CRC risk. 
Study designs have included animal models in which chemical carcinogens were administered 
to rodents genetically predisposed to CRC and maintained on a low folate diet (Kim et al., 
1996a). Rats sustained on a moderately folate-deficient diet and injected with 1,2-
dimethylhydrazine, a potent carcinogen that induces mutations primarily in the colon (Newell 
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and Heddle, 2002), were more likely to develop colonic dysplasia and carcinoma (Cravo et al., 
1992). Impaired DNA methylation, including global hypomethylation and regional 
hypermethylation, has been observed in animal colon carcinogenesis where rats developed 
tumours in direct response to being fed a diet deficient in methyl donors such as folate and 
vitamin B12 (Wainfan and Poirier, 1992). 
 
When doses of up to 40 mg folate/kg diet – 20 times the dietary requirement of 2 mg folate/kg 
– were administered to Sprague-Dawley rats, a decrease in macroscopic tumours was 
observed for doses up to 8 mg folate/kg diet (Kim et al., 1996b). This study suggested a dose-
dependent benefit of folate levels up to 4 times the daily dose, beyond which no further 
benefit was observed. Another study showed that low folate levels delayed peripheral nerve 
sheath tumour development in transgenic mice carrying the human-T lymphotrophic virus 
(Bills et al., 1992). Finally, a study of intestinal polyps in a murine model found that dietary 
folate supplementation may suppress polyp growth if administered before genetic alterations 
in the colonic epithelium have occurred, after which folate supplementation was associated 
with increased polyp growth (Song et al., 2000b). Physiological doses of folate 
supplementation in animals have generally been associated with decreased tumour growth 
(Kim et al., 1996b), which also appears to be the case if administered during the early stages 
of neoplasia (Song et al., 2000a, Song et al., 2000b). Conversely, folate administered in 
pharmacological doses after carcinogenesis is established, generally increases tumour growth 
(Kim et al., 1996b, Song et al., 2000b).  
 
1.4.3.2 Folate and colorectal cancer – human studies 
 
Folate status (based on dietary intake, blood folate and colorectal tissue concentration) has 
been shown in numerous prospective and case-control studies to be inversely related to 
colorectal cancer risk in humans (Kim, 2007b).  
 
A 2005 meta-analysis of epidemiological studies that assessed dietary and supplemental 
folate using food frequency questionnaires, diet records and 24-hour recalls found an overall 
protective effect from high consumption of folates (Sanjoaquin et al., 2005). In this study, an 
electronic search of all terms related to folate, colon/rectum and cancer in studies conducted 
since the 1950s was carried out in PubMed, and studies written in English that included 
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dietary or total folate (from both food and supplementation) were included. Seven 
prospective cohort studies showed a 25% lower risk of CRC in subjects with the highest folate 
intake compared with subjects with the lowest folate intake (RR 0.75, 95%CI 0.64-0.89). The 
protective effect was observed more when folate was derived from food rather than 
supplementation. Therefore, potential confounding factors, such as advantage conferred 
collectively from other nutrients in the diet, should be acknowledged. Case-control studies in 
the same meta-analysis showed a similar reduction in risk; however, contrary to the group of 
cohort studies, there was considerable heterogeneity between study designs (Sanjoaquin et 
al., 2005).  
 
Kennedy et al, 2012 performed a meta-analysis and found similar results to those reported in 
the Sanjoaquin 2005 meta-analysis. In this study, MEDLINE, EMBASE and SCOPUS were 
searched for all terms related to folate and colorectal cancer in humans between database 
inception (around the early seventies) and 2009, and studies were only included if at least 
two measures of folate intake were included. Several studies overlapped between this study 
and the Sanjoaquin (2005) meta-analysis. Food frequency was captured either by the Food 
Frequency Questionnaire (FFQ) or the Coronary Artery Risk Development in Young Adults 
(CARDIA) dietary history questionnaire, as well as dietary recording over 24 hours. In 18 case-
control studies, a risk reduction of 13% was observed when high and low folate intake 
participants were compared (Figure 1.3). In the 9 cohort studies, risk was reduced by 18% 
when those in the highest and lowest folate intake categories were compared (Figure 1.4). 
There were more studies in the Kennedy meta-analysis (18 case-control studies and 9 cohort 
studies) than in the Sanjoaquin meta-analysis (9 case-control studies and 7 cohort studies); 
therefore, unsurprisingly, the confidence intervals for the Kennedy meta-analysis for the 
estimate of risk for folate intake were narrower. The subject characteristics in these studies 
are heterogeneous, with a variety of ethnicities and ages included in the study populations, 
however the study still reached statistical significance making this meta-analysis translatable 
across the population (Kennedy et al., 2012).  
 
Figure 1.3 Total folate intake and risk of CRC - meta-analysis of case-control studies 













A very comprehensive and up-to-date meta-analysis performed in 2015 found no evidence of 
a relationship between folic acid supplementation and colorectal cancer risk. Out of a total of 
1229 studies examined, 72 studies were eligible for further analysis and eventually 8 were 
finally included. This meta-analysis used a strict inclusion criteria including RCT study design, 
folic acid dosage, folic acid supplementation and CRC risk and all studies had to be in English. 
Finally, the authors showed lack of significant heterogeneity amongst populations. Larger 













Associations between folate status in humans and colorectal cancer risk have largely been 
investigated with blood biomarkers (serum, red cell folate and plasma homocysteine 
concentrations) (Bird et al., 1995, Kato et al., 1999). In a nested case-control study, 105 
women with colorectal cancer had lower serum folate and higher plasma homocysteine 
concentrations than the 523 controls. After adjustment for potential confounding factors, 
including smoking and alcohol, the risk of colorectal cancer in subjects in the highest serum 
folate quartile was half that of the subjects in the lowest serum folate quartile (OR=0.52, 95% 
CI=0.27-0.97, P=0.04) (Kato et al., 1999). Importantly, in this study the effect of  existing CRC 
on folate cannot be excluded. In a case-control study investigating the correlation of serum 
and red cell folate and homocysteine levels in adenomatous polyps, there was a 24% 
reduction in CRC risk in subjects with red cell folate levels above 160ng/mL. (Bird et al., 1995).  
Folate levels have also been examined in specific tissues in few human and animal studies 
(Kim et al., 1996b, Kim et al., 1998, Kim et al., 2001, Meenan et al., 1996, Ge et al., 2007).  
These studies have provided information on the relationship between systemic levels of 
folate in the body and tissue-specific folate levels in organs such as the colon. This relationship 
is particularly important for future study design with healthy volunteers because systemic 
folate markers can provide useful information where site-specific samples are unobtainable 
(this topic is discussed in more detail in Chapter 5), One study demonstrated variations in 
folate deficiency across different organs. A folate-free diet fed to rats for 25 weeks causes 
lower folate levels in the liver (60%), kidney (59%) and spleen (67%) when compared with 
folate-supplemented controls. This effect was not observed in the brain (Varela-Moreiras and 
Selhub, 1992), suggesting that folate is differentially distributed across different organs. In 
CRC patients, folate levels were found to be lower in neoplastic tissue in the colon than in the 
normal tissue of the same subject (Alonso-Aperte et al., 2008, McGlynn et al., 2013).  
 
A potential correlation between blood biomarkers of folate (serum folate and serum 
homocysteine) and human colonic mucosal folate was assessed as a result of folate 
supplementation in 20 patients with colonic adenomas over the course of one year. Patients 
were randomised to receive either 5mg/d folic acid (n=9) or placebo (n=11). Serum and red 
cell folate, serum homocysteine and colonic mucosal folate concentrations were obtained at 
baseline, 6 months and one year. In individuals who were not supplemented, there was a 
direct correlation between colonic mucosal and serum folate at each time point (r = 0.572–
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0.845; P < 0.015) and a correlation was seen with RBC folate and colonic mucosal folate at 6 
months and 1 year (r = 0.747– 0.771; P < 0.001). In the case of serum homocysteine, an inverse 
correlation was seen with colonic mucosal folate at each time point (r = 20.622– 0.666; P < 
0.008). None of the systemic markers of folate correlated with colonic mucosal folate in 
response to folate supplementation and the authors concluded that at supraphysiological 
folate quantities an effect is not seen (Kim et al., 2001). 
 
The relationship between human colonocyte folate at different sites (duodenum, caecum and 
sigmoid colon) within the gastrointestinal tract was investigated for uniformity, and to 
determine if there was a correlation with serum and red cell folates. An unexpected finding 
led the authors to report a variation across these sites. Caecum folate was lower than that of 
duodenum and sigmoid folate, suggesting a variable mechanism for cellular folate 
transportation and that folate in the colon may not only be derived from blood sources but 
also could be absorbed from the lumen. In subjects with adequate folate status, colonocyte 
folate did not correlate with systemic folate (Meenan et al., 1996).  
 
The same group reported that folate levels were lower in gastrointestinal epithelial tumour 
cells when compared to disease-free cells in the adjacent epithelium (P < 0.02). In agreement 
with their previous study (described above), folate in the normal epithelium of CRC patients 
was not significantly different from that observed in healthy controls. Blood folates and 
vitamin B12 were normal across all groups. Therefore, it was proposed that this observation 
could be due to folate deficiency being localised in the patients with pathologies and that 
neoplastic cells require greater supplies of folate for cell division and proliferation (Meenan 
et al., 1996). 
 
In another study, folate levels were compared between subtypes of polyp patients. Levels 
were 34% lower in the normal mucosa of adenomatous polyp patients than in the normal 
mucosa of hyperplastic polyps patients (P=0.04), suggesting that folate levels may diminish on 
a global level at some stage in the neoplastic process  (Kim et al., 1998). An alternative 
explanation would be that people with low folate levels are more at risk of developing 
adenomatous polyps than hyperplastic polyps. However, in this study, there was no polyp-free 
control group for comparison. The same group concluded that both serum and red blood cell 
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folate accurately reflect folate concentrations in the colonic mucosa and that the strongest 
association exists between serum homocysteine and colorectal folate. This finding is in 
agreement with the proposal that elevated homocysteine levels provide a more sensitive and 
readily available indication of cellular folate deficiency compared to blood folate (Bailey, 
1990).  
 
More recently, the relationship between systemic and colonic folate was examined in 
response to folic acid supplementation over a period of 8 weeks in 106 polyp patients and 98 
healthy volunteers. Increases in plasma folate correlated with colonic tissue folate; however, 
only plasma folate showed a dose-dependent response. Folate supplementation at a dose of 
1,200µg/day did not result in an increase in tissue folate in the colon compared with 400 µg, 
indicating that the response begins to diminish at the upper folate limit. Furthermore, when 
folate levels in the colonic mucosa of the polyp group were compared with those in the 
mucosa of the healthy controls, no differences were detected (Powers et al, 2007). 
 
In conclusion, animal and human studies suggest an inverse association between folate status 
and CRC risk. Folate deficiency appears to increase the risk of colorectal cancer, while folate 
supplementation appears to decrease the risk. This has led to folate being considered a 
potential anti-cancer agent. But for folic acid supplementation to be established as a 
chemopreventive, the appropriate dosage and timing of treatment requires further 
investigation (Kim, 2003). Further studies may be useful in clarifying the relationship between 
localised tissue folate deficiency and systemic folate levels, and whether dietary and 
supplementary folate can influence this relationship. 
 
1.4.4 Folate and colorectal adenoma 
 
It is important to differentiate adenoma risk from CRC risk because evidence suggests that 
folate status influences the different stages of colorectal neoplasia differently.  
 
1.4.4.1 Folate and colorectal adenoma – animal studies 
 
In the APCMin mouse model, mice were assigned to a spectrum of different dietary folate levels 
for three months. After three months, dietary intake and serum folate were both inversely 
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related to the number of small adenomas in the intestine. At the six month time point 
however, fewer distal adenomas were observed in the mice who were fed a folate deficient 
diet when compared with the mice on a folate supplemented diet and serum folate correlated 
positively with the number of distal adenomas (Song et al., 2000a). The authors concluded 
that folate deficiency inhibited growth of neoplasms which were already established. It is 
difficult to directly extrapolate findings from animal models to human adenoma because of 
differences in clinical presentation, histology and molecular biology. In APCMin model flat foci 
of dysplasia develop rather than adenoma and these lesions do not go on to develop into 
adenocarcinoma because the animals die of intestinal obstruction first . 
 
1.4.4.2  Folate and colorectal adenoma – human studies 
 
Mixed results have been observed for the relationship between folate status and the risk of 
colorectal adenoma incidence and recurrence in humans.  
 
In the prospective Nurse’s Health Study, the role of folate intake in CRC was investigated, 
particularly with respect to timing, concentration, and the influence on colorectal cancer and 
adenoma. Long term (12-16 years) and short term (4-8 years) total folate intake, measured 
by FFQ prior to diagnosis, was associated with a reduced risk of colorectal adenoma. Adenoma 
risk was strongly inversely associated with folate intake at 4-8 years prior to diagnosis (RR: 
0.68 [95% CI: 0.60, 0.78], at doses of ≥800 compared with <250μg folate/d). This study 
concluded that folate intake reduces the risk of adenoma but not CRC and that folate intake 
is therefore only protective in the early stages of neoplasia (Lee et al., 2011). 
 
A recent study investigated the role of folate in the chemoprevention of the primary 
occurrence of adenoma. The study was carried out over three years in 791 subjects over the 
age of 50 years who had no history of previous adenomas and who were randomised to 
receive 1mg/d folic acid or treatment without folic acid. There were 64 adenomas in the folic 
acid group and 132 adenomas in the control group (unadjusted risk ratio (RR), 0.49; 95% 
confidence interval (CI), 0.37-0.63; P < 0.01), indicating that prevention with 1 mg/d folic acid 
supplementation could reduce the incidence of colorectal adenomas but this was shown only 




As part of a randomised trial with a cardiovascular primary endpoint, it was found that a 
combination of folic acid, vitamin B6 and vitamin B12 did not significantly affect the risk of 
colorectal adenoma among women with adequate folate status and at high risk of 
cardiovascular disease (Song et al., 2012). 
 
Regarding adenoma recurrence, a study by Cole et al demonstrated that 1mg/day of folic acid 
supplementation for up to 6 years did not reduce risk. However, in this population, folate 
levels were adequate because of mandatory folate fortification in the US, thus the effect of 
the supplementation may have been difficult to quantify. A subgroup analysis was carried out 
for 508 patients who participated in the complete duration of the study. Three or more 
adenomas were observed in 11 (4.3%) participants in the placebo group versus 27 (10.9%) 
participants in the folic acid group (RR, 2.52; 95% CI, 1.28-4.98; P=0.008), suggesting an 
increased adenoma risk for folate-replete patients with previously removed adenomas (Cole 
et al., 2007). In contrast another group supplemented patients for only 3 years, but at a much 
higher dose (5 mg/day) and showed that folate prevents adenoma recurrence. A double-
blind, placebo-controlled trial of 94 patients with colorectal adenomatous polyps, where all 
polyps were removed prior to supplementation, one arm was treated with folic acid (n=49) 
and one arm with placebo (n=45). Subjects were checked for adenoma recurrence at three 
years, the mean number of polyps observed in the folic acid group was 0.36 polyps (SD 0.69) 
and the mean number of polyps in the placebo group was 0.82 (SD 1.17), suggesting a greater 
than two-fold protective effect of folate in preventing adenoma recurrence (Jaszewski et al., 
2008).  
 
In a large, double-blind study, patients were randomised to receive 1mg/day folic acid (n=338) 
or placebo (n=334), and baseline plasma folate levels were recorded. The primary endpoint 
was the appearance of new adenomas during the study (1996-2004). The secondary 
endpoints were the total number of recurrent adenomas, the staging and the specific sites of 
the lesions. Folic acid supplementation failed to protect against the recurrence of at least one 
adenoma (relative risk RR: 0.82; 95% CI: 0.59,1.13; P=0.22), but an increased risk of neoplasia 
was not observed. In patients who had low plasma folate concentrations at baseline (<7.5 
ng/mL) in combination with high alcohol intake, a significant decrease in recurrent adenomas 
was observed, suggesting a dose response relationship between folate levels and adenomas. 
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This study benefited from large numbers, but a key limitation was the lack of endoscopy at 
baseline to assess current pathology. Additionally, adenomas were not reviewed by a central 
pathologist for unbiased staging and disease outcome. Similar to the Cole study described 
above, participants here were subject to mandatory folic acid fortification of food during the 
course of the study, resulting in a population with an adequate folate status (Wu et al., 2009).  
 
Finally, folate supplementation was not beneficial in protecting against the recurrence of 
adenomas in a large, double-blind, 2-factorial design trial of 0.5mg/day folic acid or placebo 
and 300 mg/day aspirin or placebo. However, aspirin was found to reduce adenoma 
recurrence (Logan et al., 2008). 
 
1.4.5 Genetic polymorphisms involved in folate metabolism 
 
Functional polymorphisms in genes encoding enzymes in folate metabolism is a further 
consideration in the relationship between folate and CRC risk.  
 
1.4.5.1 The MTHFR enzyme  
 
The MTHFR enzyme maintains the balance between DNA methylation and DNA synthesis. The 
DNA methylation and DNA synthesis pathways are both dependent on the availability of 
methyl groups. 
 
1.4.5.2 The MTHFR C677T genotype and colorectal cancer 
 
The MTHFR C677T polymorphism, a common mutation in the 5,10-
methylenetetrahydrofolate (5,10-methyleneTHF) reductase gene, has been linked to a 
reduced risk of colorectal cancer risk (Taioli et al., 2009). 
 
The MTHFR gene is located on chromosome 1 (1p 36.3), and MTHFR C677T is one of several 
polymorphisms which encode the enzymes involved in folate metabolism that have been 
extensively investigated in colorectal cancer. The transition from C (cytosine) to T (thymine) 
is a point mutation occurring at nucleotide 677 in exon 4, and it results in a change from amino 
acid alanine to valine. The prevalence of this mutation differs with ethnicity. Between 10-12% 
of Caucasian and Asian populations are homozygous for the T allele, and 50% are 
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heterozygotes (Frosst et al., 1995, Brattstrom et al., 1998). However, among individuals of 
African descent, approximately 1-10% of the population carries the TT mutation (Le Marchand 
et al., 2005). 
 
An inverse association between the MTHFR C677T genotype and colorectal cancer has been 
repeatedly reported, but the precise biological mechanism of this relationship has yet to be 
established. The MTHFR enzyme catalyses the conversion of 5,10-methyleneTHF to 5-
methylTHF. The TT genotype increases the thermolability and reduces the activity of the 
MTHFR enzyme, decreasing 5-methylTHF supplies and thus elevating plasma homocysteine 
levels (Frosst et al., 1995). Limited supplies of 5-methylTHF alter the capacity of methyl group 
donation and can therefore impair the methylation cycle. Mutations that alter the activity of 
the MTHFR enzyme have been proposed to affect cancer risk through two mechanisms: DNA 
methylation and uracil misincorporation (Blount et al., 1997, Jia and Guo, 2013).  
 
The CC genotype is referred to as wild-type, and the CT and TT genotypes are referred to 
respectively as the heterozygous and homozygous variants. Lower levels of enzyme activity 
relative to the CC genotype are generally observed in the CT and the TT genotypes (30% and 
65%, respectively) (Brockton, 2006). In lymphocyte extracts, complementary DNA (cDNA) 
expression showed that the MTHFR C677T mutation is associated with a reduction in enzyme 
activity and an increase in thermolability (Frosst et al., 1995). It has been proposed that when 
folate status is sufficient, the methyl group supply is adequate and the reduction in enzyme 
activity is not enough to have a substantially negative effect on DNA methylation. The reduced 
MTHFR enzyme activity in a folate-adequate environment is thought to increase the pool of 
5,10-methyleneTHF (a cofactor in nucleotide synthesis) and improve the efficiency of DNA 
synthesis and repair. However, when folate status is not sufficient, both DNA methylation and 
DNA synthesis are thought to be compromised, subsequently increasing the CRC risk (Das and 
Singal, 2004). A recent literature search performed during the preparation of this thesis did 
not reveal any studies that have explored the relationship between the MTHFR C667T 
polymorphism and colorectal cancer risk specifically in animals. Apcmin/+ mice are used as an 
animal model to emulate the MTHFR TT mutation because of a characteristic decrease in 
MTHFR activity in comparison to wild-types (Chen et al., 2001). This mouse model has been 
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explored for adenoma rates in animals with existing tumours or a predisposition to 
adenomas. This study is described in more detail below Section 1.4.5.3. 
The MTHFR polymorphism and colorectal cancer risk was assessed by a large meta-analysis 
of over 30,000 subjects stratified by ethnicity (approximately one-third cases and two-thirds 
controls) and a pooled analysis (approximately 5,000 cases and 8,000 controls), both 
performed by the same authors (Taioli et al., 2009). The meta-analysis odds ratio reported 
that the TT genotype was associated with an overall CRC risk of [OR 0.83 (95% CI: 0.77, 0.90)] 
when compared with the CC genotype (Figure 1.5). No overall association was observed 
between the CT genotype and CRC risk. Of the 27 studies examined, approximately half 
showed a positive association and half showed negative association with CT and CRC risk. 
Upon stratification by ethnic group, white and Asian individuals with the TT genotype were 
both reported to have a lower risk of CRC, but this protective effect was not seen in Latino or 
black individuals. Smoking and BMI did not influence this interaction in individuals with the 
TT genotype, but regular consumption of alcohol did have a detrimental effect. Of the 29 
studies included in the meta-analysis, 14 were included in the pooled analysis for which data 
for individuals was extracted from the Genetic Susceptibility to Environmental Carcinogens 
(GSEC) database (www.gsec.net). The odds ratio for CRC risk with the TT genotypes was 
similar to the meta-analysis across the three ethnicities (Taioli et al., 2009). 
 
The TT genotype was associated with an overall reduction in the risk of CRC in two earlier 
meta-analyses (Hubner et al., 2006, Huang et al., 2007). Further analyses that separated 
patients with cancer of the colon from those with cancer of the rectum determined that this 
risk reduction was primarily for cancer of the colon. When smoking status was examined, it 
was noted that those who had smoked more than 14.2 pack years and possessed the TT 
genotype were at a significantly higher risk of developing CRC than the CC genotype. In 
addition, alcohol drinkers had a 22% lower risk of developing colorectal cancer if they had the 
TT genotype compared with the CC genotype. However, in the non-drinker group, no 






1.4.5.3 The MTHFR C677T genotype and colorectal adenoma   
 
The extent to which the MTHFR genotype influences adenoma risk has also been extensively 
studied and some key studies are described in Table 1.5.  
 
In humans, a case-control study showed no association between the MTHFR C677T genotype 
and adenoma risk; furthermore, there was no evidence of an interaction between folate 
status and alcohol habits. This study included 296 cases and 317 controls aged 50-74 years 
using data from the faecal occult blood test screening program in the UK. None of the 
participants had any previous malignancies. Dietary folate was assessed by FFQ, which 
includes information about folate supplementation. The authors suggested that varying folate 
status in UK studies, in contrast to other studies globally, was the result of mandatory folate 
supplementation outside of the UK (Lightfoot et al., 2008).  
 
To conclude regarding the role of the MTHFR C677T in CRC risk, the TT mutation has 
consistently been observed to reduce risk, and this reduction is modified by folate status. In 
contrast, colorectal adenoma risk does not appear to be mediated by the MTHFR 677TT 





















Authors Study design Folate status 
Association between MTHFR 
C677T and risk of adenoma 
Lightfoot et al., 
2008) 
296 cases, 317 
controls  
FFQ No association 
Chen et al., 
1998 
379 cases, 726 
controls 
FFQ No association 
Hirose et al., 
2005 






No association  
Marugame et 
al., 2000 
205 cases, 220 
controls 
FFQ and plasma 
folate 
No association  





FFQ, red cell and 
plasma folate 
Increased adenoma risk in TT 
subjects in lowest quartile for RBC 
(OR, 2.04 and 95% CI, 0.6 –7.0). 
Increased adenoma risk in TT 
subjects in lowest quartile for 
plasma folate (OR, 1.84 and 95% CI, 
0.6 –7.0)  
Marugame et 
al., 2003 
177 cases, 192 
controls 
Plasma folate 
Decreased adenoma risk in TT 
subjects with high folate compared 
with CC subjects 




Red blood cell 
MTHFR 677T and low folate status 
‘strongly’ linked to high-risk 
adenomas in smokers 





No association between MTHFR 
C677T and adenoma, only with 
CRC. 
Boyapati et al., 
2004 
177 cases, 228 
controls 
FFQ No association 
Levine et al., 
2011 
665 cases, 695 
healthy controls  
FFQ and plasma 
folate 
No association  
Mitrou et al., 
2006 
894 cases, 946 
controls 
FFQ No association  
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1.4.6 Genomic DNA methylation and folate in colorectal cancer  
 
1.4.6.1 Animal studies 
 
Animal studies of methyl group (methionine, folate and B12) depletion have repeatedly shown 
genome-wide DNA hypomethylation in animal tissues (Kim, 2004). In several animal studies 
(Table 1.2), the effects of folate depletion on DNA methylation in the colon (during timespans 
ranging from 10 to 26 weeks, with or without exposure to carcinogen) were investigated. The 
majority of these studies showed no effect of folate depletion on genomic DNA methylation 
in rodent tissue. 
 
Table 1.2 The influence of folate deficiency on genomic DNA methylation in rodent tissue 
 




Change in genomic DNA 
methylation   
Kim et al, 1995 Mild 15 No change observed 
Kim et al, 1996a Mild plus 
carcinogen 
20 No change observed 
Duthie et al, 2000c Mild 10 No change observed 
Le Leu et al, 2000 Mild plus 
carcinogen 
13/26 No change observed 




13 No change observed 
Choi et al, 2003 Mild 8 No change observed 
Sohn et al, 2003 Severe 5 Increased by 30% after week 3 
(P=0.02) 
Keyes et al, 2007  Depletion/repletion 
with folic acid 
20 Incremental increase from, depletion 
to repletion to supplementation 
(P<0.023) 
Liu et al, 2007  Mild 10 No change observed 
Uthus et al., 2006 Mild 10 No change observed 
Duthie et al, 2010  Mild 24 No change observed 









1.4.6.2 Human studies  
 
Human studies investigating the associations between folate status and genomic DNA 
methylation in leucocytes, lymphocytes and colonic mucosa have produced varying results. 
In vitro studies have shown that folate deficiency can cause modifications of DNA methylation 
in the colonic epithelium, but this effect is dependent on the cell line (Stempak et al., 2005). 
Human colon cancer cells cultured in a folate-free medium and analysed by the Comet assay 
(Quantifies strand breakage caused by enzymatic digestion of hypomethylated DNA) showed 
an increase in global DNA hypomethylation compared with cells grown in medium containing 
3mM/L folic acid after 14 days. This effect was not observed at 7 days and it was reversed 
when folic acid was reintroduced into the medium (Wasson et al., 2006).  
 
Folate depletion-repletion studies in lymphocytes showed a slight decrease in DNA 
methylation in response to a low folate diet in healthy post-menopausal women (49 to 63 
years). This effect was subsequently reversed by a folate-sufficient diet (Jacob et al., 1998). In 
a similar study, folate depletion caused marginal DNA hypomethylation, but this was not 
reversed by folate repletion; however, subjects were older (60-85 years) and age-related 
methylation factors might have had an effect (Rampersaud et al., 2000). In a study where 
folate depletion levels and duration were similar to those in the Rampersaud study, 
hypomethylation was not observed, but in this population subjects were young females (20-














Table 1.3 The influence of folate depletion on genomic DNA methylation in humans 
 
Authors Study population Level of folate 
depletion 




Jacob et al., 1998 Post-menopausal 
women (n=8) 





Rampersaud et al., 
2000 
Post-menopausal 
women (n=33)  
118 mg/d (7 weeks) Leucocytes 10% 
reduction 
(P=0.0012) 






In observational studies, both case-control and cohort, have consistently shown genomic DNA 
hypomethylation (in blood and/or tumour tissue) to be associated with CRC, but studies 
investigating the influence of folate status (intake, dietary or supplementary, or systemic) on 


















Table 1.4 Association between folate status and DNA methylation 
 
Authors Study design Tissue  Association with genomic DNA 
methylation 
Fenech et al., 
1998 
Cross-sectional young 
male/female (n=106)  
Leucocytes No correlation with Red cell 







(n=35),  healthy 
volunteers (n=76) 
Colon Correlated negatively with 
serum  and red cell folate and 






volunteers (n=68)  
Colon Correlated negatively with 
serum folate (r=-0.311, P=0.01), 
red cell folate (r=-0.356, P=0.03) 
and positively with plasma tHcy 
(r=0.256, P=0.04) 




Leucocyte Correlated negatively (P=0.03) 
but no association after 







Colon No association with dietary 






hyperplastic polyps (16) 
and adenomatous 
polyps (40) 





Furthermore, folate supplementation studies have shown mixed results (Table 1.5), with 
many reporting no change in DNA methylation in response to folate supplementation. Studies 
that have detected an increase in genomic DNA methylation following folic acid 
supplementation have generally administered folic acid at pharmacological doses (1-10 
mg/day), a dosage 5-50 times that of the UK Reference Nutrient Intake (RNI) of 200µg/day. 
An increase in genomic DNA methylation in the rectal mucosa of patients receiving 10mg/day  
folic acid for 6 months was observed but only after the removal of colorectal adenomas (Cravo 
et al., 1994). Another study by the same group showed increases in DNA methylation in the 
rectal mucosa after 3 months of folate supplementation at a dose  of 5mg/day. However, this 
increase was only observed in patients possessing a single polyp (Cravo et al., 1998). A study 
performed by the second supervisor of this PhD project (Dr Maria Pufulete) reported an 
increase in genomic DNA methylation in leucocytes and colonic mucosa of subjects with 
adenomas after folic acid supplementation of 400µg/day for 10 weeks and a non-significant 
increase in genomic DNA methylation in CRC subjects. However, all subjects had neoplasia 
and this may have influenced DNA methylation (Pufulete et al., 2005a). In two other studies 
of neoplasia-free volunteers without other colonic pathologies, no changes in DNA 
methylation were found after supplementation with folic acid at supraphysiological doses of 
2mg/day. However, both studies had small populations (63 and 61) and both employed the 
methyl acceptance assay. The latter has been shown to be less accurate than other 
methodologies because it estimates genomic DNA methylation from all methylated purified 
and intact genomic DNA, but this does not include DNA damaged upon sample collection or 
during preparation (Fenech et al., 1998, Basten et al., 2006). Two larger studies of 216 and 
195 healthy volunteers examined DNA methylation in uncoagulated blood, and leucocytes 
respectively, both employed the LC-ESI-MS/MS method which is described in Chapter 2. (Jung 
et al., 2011, Crider et al., 2011). Neither study showed any association of DNA methylation 
with supplementation, but in the study by Crider et al., subjects on 4mg/day folic acid for 6 
months showed a reduction in methylation when coagulated blood samples were used. One 
strength of this study was that results in both coagulated and uncoagulated samples were 
verified using both the methyl acceptance assay and LC-ES MS/MS. Jung’s study was the first 
of its kind to recruit a sample of 216 healthy volunteers for an extended period of time. The 
participants were given 800µg/day of folic acid for 3 years. However, in this study volunteers 




Long interspersed nucleotide element (Line-1) methylation pyrosequencing analysis has 
shown that DNA methylation may be reduced in precursor neoplastic lesions compared with 
normal colonic mucosa, particularly on the right side of the colon when compared with the 
left side (Chalitchagorn et al., 2004) (Estecio et al., 2007). Line-1 was used to analyse non-
tumour colonic samples in a large study of 388 colorectal adenoma patients in a randomised 
controlled trial of folic acid at a dose of 1mg/day for 3 years. DNA methylation in the colonic 
mucosa on the right side was significantly less than on the left side (P<0.001) but no difference 
was observed as a direct result of supplementation, nor did the results change when adjusted 






Table 1.5 Effect of folate supplementation on DNA methylation in humans 
 
Authors Design Subjects recruited Duration  Dosage Assays Effect on DNA 
methylation  
Cravo et al., 1994 RCT Adenoma (n=12), 
CRC (n=12), healthy 
volunteers (n=8) 
6 months 10 
mg/d   
Rectal tissue, [3H] 
methyl acceptance 
Increase 
Cravo et al ., 1998 RCT Adenoma (n=20) 3 months 5mg/d Rectal tissue, [3H] 
methyl acceptance 
No effect 
Kim et al ., 2001 RCT Adenoma (n=20) 1 year 5mg/d Rectal tissue, [3H] 
methyl acceptance 
Increase 
Pufulete et al ., 
2005a 
RCT Adenoma (n=31) 10 weeks 400 
µg/d 
Leucocytes Rectal 
tissue [3H] methyl 
acceptance 
Increase: 31% (leucocytes) 
25% (rectal tissue)  
Figueiredo et al ., 
2009 
RCT Adenoma (n=388) 3 years 1mg/d Rectal tissue LINE-1 
analysis, 
pyrosequencing 
No effect  
Fenech et al ., 
1998 
RCT Healthy volunteers 
(n=63) 
12 weeks 2mg/d Lymphocytes [[3H] 
methyl acceptance 
No effect 
Basten et al ., 2004 RCT Healthy volunteers 
(n=61) 





Axume et al ., 
2007a 
Depletion/repletion Healthy females 
(n=43) 
14 weeks 800 
µg/d 
Cytosine extension  No effect 
Jung et al ., 2011 RCT Healthy volunteers 
with (n=216) 
elevated tHcy 









6 months 4mg/d Coagulated and 
uncoagulated blood 
No effect in uncoagulated 





The studies summarized above show considerable variability in the results reported for the 
relationship between folate status and genomic DNA methylation. This may be due to a 
number of factors including study populations, a range of study designs and sample sizes, the 
types of tissue and tumours analysed and inconsistent assay types. Earlier studies of DNA 
methylation employed the methyl acceptance assay, which works by enzyme mediated 
genomic DNA methylation. This is an imprecise technique because DNA may not remain intact 
during handling, which could lead to irreproducible results (Nephew et al., 2009). Other 
techniques for investigating genomic DNA methylation have included assessing repetitive 
element methylation and various restriction sites across the genome. Both techniques have 
shown inconsistent results (Wu et al., 2011). Furthermore, different regions of the genome 
have been measured using different assays, which may detect varying levels of upregulation 
(Nephew et al., 2009). 
 
 
1.4.6.3 The MTHFR C677T genotype 
 
Data on the interaction between folate (intake and status) and the MTHFR C677T genotype 
and their influence on DNA methylation are limited (see Table 1.6 below). Further studies 
could help to clarify the mechanism by which folate supplies and the C677T polymorphism 
interact to affect DNA methylation.  
 
In humans, one study reported that DNA was hypomethylated in the peripheral leucocytes of 
TT individuals compared with CC individuals (P<0.05) and that DNA methylation was positively 
associated with systemic folate in red blood cells (Stern et al., 2000). Another study found 
leucocyte DNA was hypomethylated in TT subjects with inadequate folate status (Friso et al., 
2002b).  
 
A folate depletion-repletion study was employed to investigate the influence of folate status 
on genomic DNA methylation in the leucocytes of young women according to the MTHFR 
C677T genotype. Overall genomic DNA methylation was decreased in all subjects during 
depletion but, once repleted, women homozygous for the MTHFR C677T mutation had a 
greater increase in DNA methylation than women with the CC genotype. This confirmed a 
protective effect of the TT mutation (Shelnutt et al., 2004). Another study investigating this 
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relationship showed that a folate-restricted diet followed by a high folate diet in 18-45-year-
old Mexican women for a period of 14 weeks resulted in lower DNA methylation in the TT 
group than in the CC and CT groups, suggesting an interaction between the mutation, folate 
metabolism and genomic DNA methylation. The same investigators examined genomic DNA 
methylation changes in leucocytes in African American women in response to a folate-
restricted and a folate-rich diet, but only individuals who possessed the CC genotype were 
used in this study. During folate treatment, DNA methylation was not modified by differential 
folate intake and the authors concluded that the 14 week duration of folate supplementation 
may have been too short a timeframe in which to observe changes in such a young population 
(Axume et al., 2007a, Axume et al., 2007b). These studies investigated the effects of the 
MTHFR C677T genotype on DNA methylation in leucocytes to determine whether the 
interactions depended on folate status. A previous pilot study by this group did not show 
differences in genomic DNA methylation in the colonic mucosa between CC and TT 
individuals, but sample numbers were small (CC, n=38, CT=24, TT, n=6) (Pufulete et al., 
2005b). Larger sample sizes are needed to increase statistical power and detect differences 
in methylation between individuals with and without the MTHFR C677T mutation and to 



















Table 1.6 The influence of MTHFR C677T genotype on DNA methylation in Neoplasia free volunteers 
Authors MTHFR 
C677T  
Design and folate 
measured 
Tissue for analysis of 
DNA methylation 
Assocation with DNA methylation 
Stern et al., 2000 9CC, 
10TT 
Red cell folate  Leucocytes Methylation reduced in TT 
compared to CC (P<0.05) 
Friso et al., 2002 187 CC, 
105 TT 
Red cell folate Leucocytes 50% Reduction in TT compared 
with CC (P<0.001) 
Shelnutt et al., 2004 22CC, 
19TT 
Depletion 115 µg/dDFE 
*7 weeks, 400 µg/dDFE 
7 weeks repletion 
Leucocytes Increased in TT subjects compared 
with CC during repletion (P=0.03) 
Pufulete et al., 2005b 38CC, 
6TT 
Serum, red cell folate, 
plasma tHcy 
Rectal No effect demonstrated 
Axume et al., 2007b 14CC, 
17TT 
Depletion 135 µg/dDFE 
*7 weeks, 400/800 
µg/dDFE 7 weeks 
repletion 
Leucocytes Reduced in TT subjects only at 
week 14 when compared with CC 




400 µg for 12 weeks 
Leucocytes No effect on depletion or 
repletion 
Jung et al., 2011 76CC, 
70CT, 
70TT 
0.8 mg/day for 3 years Leucocytes No effect 
Friso et al., 2013 116CC, 
29TT 
Plasma folate Peripheral blood 
mononuclear cells 
(PBMCs) 
Reduced in TT subjects with low 
folate compared with CC (OR 7.04, 




1.4.7 Uracil misincorporation and folate in colorectal cancer  
 
1.4.7.1 In-vitro studies 
 
In-vitro studies have generally shown that folate deficiency increases strand breaks and uracil 
misincorporation in DNA. In Chinese hamster ovary cells, folate deficiency exacerbated 
irradiation-induced strand breaks (Branda and Blickensderfer, 1993). In colonocytes, folate 
deficiency was reported to increase strand breaks and uracil misincorporation, and these 
changes were concentration-dependent (1-10ng/mL), corresponding to folate concentrations 
found in human plasma (Duthie et al., 2000b). Increased uracil misincorporation was also 
observed in both human myeloid cells (Wickramasinghe and Fida, 1994) and lymphocytes 
grown in folate-depleted media (Duthie and McMillan, 1997). 
 
1.4.7.2 Animal studies 
 
Animal studies have previously demonstrated that folate deficiency increases uracil 
misincorporation into DNA in a dose-dependent manner in vivo. A surprising finding was that 
folate supplementation in young mice increased uracil misincorporation (Kim et al., 2011b). 
However, uracil misincorporation, DNA strand breaks and DNA fragmentation were all 
observed in hepatocytes of weanling male rats deprived of folate over a 9-week period when 
compared with controls on a folate-supplemented diet (James et al., 1997).  
   
Folate depletion studies in animal models have shown that uracil misincorporation increases 
as a result of a folate depleted diet. A folate depletion-repletion and supplementation study 
investigated the relationship between ageing, folate status, and uracil misincorporation in a 
rat model. Weanling (n=44) and one-year-old rats (n=44) were given either a folate-free, 
folate-replete or folate-supplemented diet. The rats were euthanised at 0, 8 or 20 weeks, and 
folate levels and the amount of uracil that was misincorporated into DNA was measured in 
the colon. Uracil misincorporation in the colon increased by 50% in the older rats that 
received the folate-free and folate-replete diets compared with the corresponding younger 
rats (P=0.05). Furthermore, in the older rats, uracil misincorporation increased stepwise from 
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the folate-free to the folate-supplemented group (P=0.05 for the trend) suggesting a non-
favourable effect from folate when combined with the aging process. In younger rats, uracil 
misincorporation into the DNA was not significantly affected (Choi et al., 2003). Another 
folate deficiency study was carried out in mice lacking in uracil DNA glycosylase (Ung-/-), 
which excises uracil residues from DNA. Animals were given either a folate-deficient diet or a 
control diet for 32 weeks. The folate-deficient diet produced a significant increase in plasma 
homocysteine and a simultaneous increase in uracil misincorporation; however, these 
changes were not sufficient to initiate tumour growth (Linhart et al., 2009). 
 
A more recent study was specifically designed to examine the effects of ageing and dietary 
folate on uracil misincorporation into DNA in the colonic and hepatic tissues of mice (42 male 
C57BL/6 mice in each arm of the study). Young mice (4 months) in one arm were compared 
with older mice in the other arm (18 months). For 20 weeks, the mice were given one of four 
different diets: (1) folate-depleted (2) folate-replete (3) folate-supplemented (8 mg/kg diet) 
and (4) folate-depleted (0 mg/kg diet) with thymidine supplementation (1.8 mg/kg diet). 
Unexpectedly, the younger group of folate-supplemented mice at a dose four times the basal 
requirement showed an increase in uracil misincorporation in the colon when compared with 
the folate-depleted and folate-replete groups (P<0.05). There was no change observed in the 
older group. In the liver, the opposite effect was observed; in older mice, uracil 
misincorporation decreased in response to increasing dietary folate, although this effect was 
not significant. In both old and young mice, uracil misincorporation did not differ between 
the folate-depleted group and the folate-depleted with thymidine supplementation. The 
overall effect of age led the authors to speculate that high dose folic acid supplementation 
can cause uracil misincorporation into colonic DNA and increase CRC risk from a young age. 
The results of this study are opposed to those of both the Linhart and the Choi study, leading 
the authors of the Kim study to conclude that mandatory folate fortification and voluntary 
folate supplementation should be carefully considered in relation to mechanisms for 




1.4.7.3 Human studies 
 
Folate supplementation studies in humans have shown varying effects on uracil 
misincorporation across different subpopulations. Supplementing the diet of healthy subjects 
with folic acid (1.2 mg/day) for 12 weeks caused a 22% reduction in uracil misincorporation 
(p<0.05) in lymphocyte DNA without reducing other biomarkers of genomic stability, 
including DNA strand breakage. When these results were split by folate quartiles at baseline, 
the reduction in uracil misincorporation from supplementation was even more apparent for 
subjects in the lowest folate quartile (Basten et al., 2006). In a pilot study of 14 individuals, 
the dietary intake of healthy volunteers was monitored with food diaries for two months. 
Folate (400µg/day) was administered from the beginning of the second month. The results 
showed that adequate folate status (from diet or supplementation) decreased uracil 
misincorporation in leucocytes, but this effect was observed only in individuals with plasma 
vitamin B12 concentrations above 400pg/mL (Kapiszewska et al., 2005). Conversely, a six-
month period of high dose folic acid (5mg/day; 25 times the RNI) administered to patients 
with a history of colorectal adenoma, caused uracil misincorporation in the rectal mucosa 
when compared with baseline (P=0.02) but no change was observed when compared with 
the placebo group (P=0.42). Changes in uracil misincorporation between groups were not 
significantly different. This study does not support the case for folic acid supplementation as 
a chemopreventative agent to reduce uracil misincorporation in the colon of subjects with 
previous history of adenoma (van den Donk et al., 2007a). A more recent study investigated 
uracil misincorporation in relation to folate status in patients with either hyperplastic (n=16) 
or adenomatous polyps (n=40) and in disease-free controls (n=53). No association was found 
between systemic biomarkers of folate status and uracil misincorporation in any group. The 
relationship between tissue folate and uracil misincorporation in the disease-free group was 
not reported, but in patients with hyperplastic or adenomatous polyps, tissue folate was 
lower and the uracil misincorporation higher in the polyp tissue compared with normal-
appearing tissue adjacent to the polyp and normal-appearing tissue distal to the polyp 




As part of the Aspirin/Folate Polyp Prevention Study, Hazra et al. (2010) evaluated the effect 
of 3 years of a placebo or folate supplementation (1 mg/day) on uracil misincorporation in 
both human rectal mucosa (n=92) and white blood cells (n=60) in patients with previous 
adenomas. Differences between the placebo and the treated groups with regard to measures 
of plasma and red cell folate, as well as homocysteine, were all in the expected direction after 
supplementation. However, uracil misincorporation in rectal mucosa after 3 years of 
supplementation was not significantly associated with red blood cell folate (Spearman’s 
correlation = -0.18, P=0.09) or plasma folate (Spearman correlation = -0.15, P=0.14). 
Additionally, uracil misincorporation in white blood cells (WBCs) was not significantly 
associated with red cell folate (Spearman’s correlation = 0.003, P=0.97) or plasma folate 
(Spearman’s correlation = 0.006, P=0.97). Folic acid supplementation did not influence either 
rectal mucosal or WBC uracil misincorporation levels (Hazra et al., 2010). 
 
1.4.7.4 The MTHFR C677T genotype 
 
Very few studies have investigated the relationship between the MTHFR C677T genotype, 
folate and uracil misincorporation. 
 
The human HCT116 colonic cancer cell line, a well-established in vitro model of the MTHFR 
C677T genotype in humans, was utilised to look at the effect of the mutation on uracil 
misincorporation. The MTHFR C677T mutation was associated with changes in folate 
cofactors, including decreased MTHFR activity, decreased intracellular 5-methylTHF and 
increased intracellular 5,10-methyleneTHF, increased cellular growth and increased activity 
of thymidylate synthetase. The MTHFR C677T mutation caused a 31% reduction in uracil 
misincorporation, but this effect did not reach statistical significance (P=0.07) (Sohn et al., 
2009). 
 
The effect of 4 weeks of folic acid supplementation on uracil misincorporation into DNA was 
examined in the leucocytes of young, healthy volunteers. No correlation was observed 
between plasma folate levels and uracil misincorporation, and when separated out by 
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genotype, the MTHFR C677T polymorphism did not influence uracil misincorporation. This 
population was small (n=14) and mildly folate deficient; the baseline plasma folate levels were 
not measured, but the folate intake assessment showed a mean folate dietary intake of 52% 
RDA. Only one subject consumed 100% of the RDA (Kapiszewska et al., 2005). The relationship 
between the MTHFR C677T genotype, blood folate levels and DNA stability was studied in 
human lymphocytes from healthy volunteers. Lower plasma folate and higher plasma 
homocysteine levels were observed in TT individuals, but no significant differences were 
observed between the CC and TT groups in lymphocyte DNA strand breaks or uracil 
misincorporation (Narayanan et al., 2004).  
 
In a randomised, double-blind, placebo-controlled trial, the effects of 12 weeks of daily folic 
acid supplementation (1.2 mg) in a healthy, folate-replete cohort of 15 men and 15 women 
with a mean age of 42 years was investigated. A significant inverse association was observed 
between red cell folate and uracil misincorporation into the DNA of lymphocytes, both prior 
to and after supplementation (P<0.005), whereas DNA strand breakage and global DNA 
methylation were not influenced by the 3-month intervention with folic acid. The MTHFR 
genotype did not influence uracil misincorporation, but the numbers in the TT group were 
very small and were not adequate to detect significance (Basten et al., 2006). 
 
Biomarkers of genomic stability need to be investigated in larger populations of healthy 
subjects in association with the MTHFR genotype. Research groups investigating the influence 
of folate status and supplementation on misincorporation of uracil into DNA report varying 
results. There have been no large studies looking at the influence of folate status and the 
MTHFR C677T genotype on uracil misincorporation into the DNA in colon cells of volunteers 








1.5 Rationale for proposed research in normal neoplasia-free volunteers 
 
There are several gaps in the existing knowledge of folate status and DNA methylation and 
uracil misincorporation and these are described below (1-5). 
 
1. A limitation of the studies described is that the relationship between folate status 
and DNA methylation and uracil misincorporation has mostly been reported in 
subjects with disease and confounding factors of the disease may have affected 
biomarker measurement. Further investigation is required to determine the extent 
to which the MTHFR C677T genotype folate status influences DNA methylation and 
uracil misincorporation in normal colonic mucosa of disease free volunteers. Larger 
samples of subjects free of confounding factors (such as inflammation, early disease 
or lifestyle factors such as alcoholism) are also needed to shed light on the 
relationship between these biomarkers of damage and folate status in disease free 
humans to provide a better understanding of colorectal cancer risk and preventative 
measures which may be taken to reduce risk.  
 
2. The studies described have assessed CRC risk and folate status and DNA methylation 
and uracil misincorporation in cell lines, animal models, and human leucocytes and 
lymphocytes but less so in human colons. Further work is needed to clarify the extent 
to which mechanisms involving folate status and DNA methylation and uracil 
misincorporation are affected by site and tissue specificity. Therefore, studies in 
which these markers are measured in both blood and specific tissues may clarify site-
specific risk and also reveal the usefulness of systemic biomarkers as surrogates 
when it is not possible to obtain tissue samples from the colon. 
 
3. Additionally, many of the studies conducted to date have measured genomic DNA 
methylation by the [3H]-methyl acceptance assay, which is non-specific and prone to 
a large degree of variation. More sensitive assays, including LC-MS/MS for genomic 
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Folate status and the MTHFR C677T polymorphism influence intermediary biomarkers of 
neoplasia (DNA methylation and uracil misincorporation) in the colonic epithelium of human 
subjects without colorectal adenomas or cancer. 
 
1.6.1 Aims (Study 1) 
 
To investigate the association between MTHFR genotype, systemic and colonic folate status, 
DNA methylation and uracil misincorporation in the colon of subjects without colorectal 
adenomas or cancer. 
 
1.6.2  Aims (Study 2) 
 
To determine whether increasing folate intake in subjects without colorectal neoplasia 





• To investigate the influence of systemic and colonic folate biomarkers on DNA 
methylation. 
• To investigate the influence of systemic and colonic folate biomarkers on uracil 
misincorporation. 
• To investigate the influence of MTHFR genotype on DNA methylation in the colon. 
• To investigate the influence of MTHFR genotype on uracil misincorporation in the 
colon.  




• To investigate whether systemic folate biomarkers can predict colonic tissue folate. 
• To investigate the influence of demographic and lifestyle characteristics on DNA 
methylation, uracil misincorporation and colonic mucosal folate level in the colon. 
• To determine whether folate supplementation modifies DNA methylation, and 
systemic and colonic folate levels, and whether the response differs according to the 

























2.1 Study Background 
 
The FOLGEN Study was a continuation of work undertaken in 2000–2002, by the second 
supervisor of this PhD, where a case-control study investigated genomic DNA methylation in 
the colonic mucosa of subjects with colorectal cancer or adenoma, and also subjects without 
neoplasia. Genomic DNA hypomethylation in normal-appearing colonic mucosa was 
associated with low folate status and a risk of neoplasia (Pufulete et al., 2003). Additionally, 
an intervention study in subjects with colorectal adenoma suggested that short-term folate 
supplementation (400 g/day) increased genomic DNA methylation in leucocytes and 
colorectal mucosa when compared with controls (Pufulete et al., 2005b). During this study a 
questionnaire was developed and validated to assess dietary folate intake (Pufulete et al., 
2002). These two studies supported a link between folate status and genomic DNA 
methylation in the colon, but the sample size was small, which limited detection of the 
influence of specific genetic polymorphisms on colonic DNA methylation. The current project 
followed on from this work and aimed to assess the impact of folate status (systemic and 
colonic) and the MTHFR C677T mutation on DNA methylation and uracil misincorporation in 
the colon of volunteers without colorectal adenoma or cancer. 
 
2.1.1 Funding and Ethical Approval 
 
This project was funded by the Biotechnology and Biological Sciences Research Council 
(BBSRC). All aspects of the study were approved by the Research Ethics Committees (REC) at 







2.1.2 FOLGEN subject population and study overview 
 
Subjects for this study were recruited sequentially from a series of subjects attending the 
Endoscopy Department at King’s College Hospital NHS Trust. A referral for a clinically 
indicated colonoscopy was made in response to complaints such as persistent diarrhea or 
constipation, bloating, abdominal pain or repeated bleeding on opening of the bowel. 
Subjects were usually referred by their GP or by a clinician on the ward.  
 
2.2 Study design  
 
FOLGEN Study 1 was a cross-sectional study designed with the aim of recruiting approximately 
400 subjects with no abnormal findings on colonoscopy. Primary endpoints were differences 
in MTHFR C677T genotypes (CC, CT and TT) for both genomic methylation and uracil 
misincorporation in the colon. At the time of study design there was no data available on 
differences in uracil misincorporation for these genotypes. However, it was possible to 
calculate sample size from an observational study in which leucocyte DNA methylation was 
measured in healthy subjects (Friso et al., 2002b). This showed that 32 TT individuals and 128 
CC individuals would be sufficient to detect a 50% difference (0.5SD, 30ng mCyt/μg DNA) in 
genomic DNA methylation between CC and TT individuals (5% significance level, two tailed) 
for the MTHFR C677T mutation. In order to recruit approximately 40 TT subjects an upper 
limit of 400 was proposed because the frequency of the TT genotype in the general population 
is approximately 10% (Frosst et al., 1995). 
 
FOLGEN Study 2 was a randomised, double-blind, placebo-controlled parallel-design 
intervention study to investigate the effect of folic acid supplementation on DNA methylation 
and uracil misincorporation. Sample size was calculated from a previous folate intervention 
study in which genomic DNA methylation in colonic mucosa was an endpoint. Subjects were 
assigned to receive either a 400 g folic acid supplement or placebo for 3 months. Blood and 
colorectal tissue samples were obtained at baseline (at the end of colonoscopy) and at post 
intervention (using sigmoidoscopy). 
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2.2.1 Subject recruitment methods – Folgen 1   
 
Medical records of all subjects referred to the Endoscopy Departments at King’s College 
Hospital and Guy’s and St Thomas’ Hospital NHS Foundation Trusts between December 2006 
and February 2009 were screened according to study criteria (described below) and subjects 
who satisfied the inclusion criteria were approached to take part in the study. Prior to any 
study-specific procedures taking place, an Informed Consent Form (ICF) was signed by each 
subject who had agreed to participate (See Appendix 1).  
 
2.2.1.1 Inclusion criteria:  
 
At colonoscopy: 
• Subjects who had a normal colonoscopy (to the ileocaecal valve).  
• Subjects with no macroscopic evidence of malignancy, adenomatous or hyperplastic polyps, 
or inflammation. 
 
2.2.1.2 Exclusion criteria: 
 
At Screening: 
• Subjects with a previous history of colorectal cancer/polyps. 
• Subjects with a strong family history of colorectal cancer or adenomatous polyposis coli 
(according to the Amsterdam Criteria: one first degree relative under age 40 or two first 
degree relatives of any age diagnosed with colorectal cancer). 
• Subjects with inflammatory bowel disease or current/past history of gluten-sensitive 
enteropathy. 
• Family history of endometrial cancer. 
• Documented renal or liver disease. 
• Pregnancy, epilepsy, alcoholism or pernicious anaemia.  





• Evidence of tumours/polyps/inflammation at colonoscopy. 
Figure 2.1 depicts the flow of sequential events in Study 1. After consent and prior to 
colonoscopy, newly recruited subjects were questioned further to check for exclusions that 
may not have been detailed in the hospital notes. If the subject consented, they were taken 
through the study Health Questionnaire (see Appendix 2) for the collection of demographic 
data on height and weight (for calculation of BMI), ethnicity, smoking habits, alcohol intake, 
Marmite consumption, current medication (including confirmation of no folate antagonists), 
folic acid supplement usage in the past three months, allergies, medical problems, and 
physical activity levels. A cannula was then put into the arm of the subject for sedation, pain 
relief and bowel relaxant to make the procedure more comfortable. At the point of 
cannulation, five blood samples were taken for the study. The subject then entered the 
procedure room for colonoscopy. The procedure was monitored closely throughout the 
colonoscopy, and subsequent enrolment into the study only happened if the 
inclusion/exclusion criteria was satisfied. Under no circumstances were subjects enrolled if 
there were any signs of redness or inflammation observed in the large bowel. Additionally, if 
the colonoscopy had to be terminated early for any reason, such as pain or lack of compliance 
with bowel preparation (colonic lavage solution – KleanPrep, Norgine, Harefield, UK), 
subjects were immediately excluded because pathology or inflammation could not be ruled 
out in parts of the colon that had not been visible, including the ileocaecal valve. If there was 
no evidence of pathology or inflammation to explain the subject’s symptoms, and if the 
colonoscopy was successfully completed to the ileocaecal valve, six tissue biopsies were taken 
on withdrawal of the colonoscope, and the subject was included in the study. Blood samples 
were sent to the Departments of Clinical Biochemistry and Haematology for systemic folate 
biomarker analysis and tissues samples were transported and stored (according to the Human 
Tissues Act) for primary and secondary endpoint analysis. All of these methods are described 
in more detail below (Sections 2.4-2.7). A previously validated FFQ was given to each subject 
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2.2.2 Subject recruitment – Study 2 
 
Study 2 was conducted in a subgroup of subjects who were recruited into Study 1. After 
participation in Study 1 and determination of the MTHFR C677T genotype using restriction 
fragment length polymorphism (RFLP) analysis (see section 2.4.5), subjects with CC and TT 
genotypes and who met the inclusion criteria (described below) were approached by 
telephone call and asked if they would be willing to take part in the 12-week study. The 
consent was signed and the FFQ was completed if it had not been returned through the post. 
 
2.2.2.1 Inclusion criteria:  
 
• Subjects with a normal colonoscopy (to the ileocaecal valve)  
• Subjects with no adenomas or polyps (apart from very small polyps sent to histology and no 
neoplasia confirmed) 
• Subjects with no macroscopic evidence of malignancy, adenomatous or hyperplastic polyps, 
or inflammation 
• Subjects from Study 1 with either the MHTFR CC or TT genotype 
• Subjects who agreed to attend the hospital for a repeat biopsy by rigid sigmoidoscopy 
 
2.2.2.2 Exclusion criteria: 
 
• Use of anti-folate (e.g., methotrexate) medication or other folate antagonists 
• Subjects whose biopsies results showed inflammation or any sign of neoplasia 
• Subjects from Study 1 with the MHTFR CT genotype 
 
Figure 2.2 depicts the flow of sequential events in Study 2. The aim of the study was for 
patients to be randomised to either folic acid (400 g/day) or an identically matched placebo 
(30 subjects in each arm) and stratified according to the MTHFR C677T genotype for a three-
month intervention period. After several months, recruitment remained extremely slow and 
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it became evident that final recruitment would be far lower than expected. The decision was 
made to remove the blind. At this point folic acid or placebo was deliberately assigned to 
subjects with the MTHFR CC and TT genotypes in as balanced a way as possible to try and 
enable a meaningful comparison in the analysis.  
 
During this time, progress and compliance was monitored by telephone every 2 weeks. At the 
end of the intervention, subjects attended the Outpatient Department for post-intervention 
follow-up. Unused tablets were returned and counted (so that compliance could be verified), 
post-intervention fasting venous blood samples were drawn and rectal biopsies were 
collected with rigid sigmoidoscopy. Blood and tissue samples from Study 2 were compared 
with matching baseline samples from Study 1 for primary and secondary endpoint analysis. 
The study aimed to recruit 60 subjects in total – 30 subjects in the folic acid arm and 30 
subjects in the placebo arm. This number was based on a previous folate intervention study 
carried out by this group, which also assessed genomic DNA methylation in colonic mucosa 
as an endpoint. This trial suggested that 23 subjects in each arm (folic acid and placebo) would 
be adequate to detect a 136Bq/g/DNA (0.8SD) change in genomic DNA methylation as a 
result of supplementing with folic acid with P0.05 (80% power). The decision to recruit 30 
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2.3 Demographic and dietary data, and biomarker sample collection 
 
2.3.1 Health Questionnaire (HQ) 
 
As described above, the Health Questionnaire (see Appendix 2) was used to collect 
demographic and lifestyle data as well as medication, supplementation usage and activity 
levels. Data for ethnicity were recorded into four ethnic subgroups (white, black, Asian and 
other) but for the purpose of the analysis Asian and other were combined and reported as 
‘other’ due to small numbers in both of these groups. 
2.3.2  Food Frequency Questionnaire 
 
On leaving the hospital, all subjects were given a Food Frequency Questionnaire to complete 
in order to be able to assess dietary folate intake (previously validated in healthy volunteers 
recruited from the public) (Pufulete et al., 2002). Subjects were invited to a non-compulsory 
research follow-up and they were also given a stamped addressed envelope and asked if they 
would mind posting their questionnaires should they be unable to attend their study follow-
up appointment. 
 
2.3.3 Blood sample collection 
 
Prior to colonoscopy, fasting venous blood samples were collected from the cannula using 
the vacutainer technique. Blood was collected into EDTA vacutainers for full blood count, 
plasma homocysteine, red cell folate and leucocyte DNA extraction, and into vacutainers 
containing no anticoagulant for determination of serum folate and vitamin B12. The blood 
samples for plasma homocysteine and DNA extraction were immediately chilled on ice. The 
plasma homocysteine sample was centrifuged and the plasma was collected within 2 hours, 




2.3.4 Tissue biopsy sample collection 
 
If there were no macroscopic abnormalities (inflammation) found at the end of colonoscopy, 
up to six biopsies (5-64mg) were removed from the rectum. Each tissue sample was placed 
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into a sterile, DNAse-, RNAse-free cryovial (Greiner Labortechnik) and instantly snap frozen in 
liquid nitrogen before storage at -70C for analysis of three endpoints: tissue folate 
concentration, genomic DNA methylation and uracil misincorporation. 
 
2.4 Blood Biomarker analysis 
 
2.4.1 Determination of blood folates, serum B12 and plasma homocysteine 
 
Folate status (serum and red cell folate and plasma homocysteine), serum vitamin B12 and 
liver function were all analysed in the Departments of Clinical Biochemistry and Haematology 
at King’s College Hospital NHS Trust London. 
 
Serum and red cell folate, serum vitamin B12 and homocysteine were all determined using the 
Bayer Advia Centaur® assay (Siemens Healthcare Diagnostics, US), a competitive 
immunoassay which utilizes direct, chemiluminescent technology. Within batch CV was 
<2.2%, and between batch CV was <5.2% for serum and red cell folate, as well as the 
homocysteine assay. 
 
2.4.1.1 Serum Folate Assay – A brief Description   
 
The serum sample was pretreated to release the folate from endogenous binding proteins in 
the sample. Folate in the sample competes with acridinium ester-labelled folate in the Lite 
Reagent (Siemens Healthcare Diagnostics Ltd) for biotin-labelled folate binding protein; this 
binds to avidin, which is covalently bound to paramagnetic particles in the Solid Phase. The 
amount of folate present is inverse to the amount of relative light units (RLUs) detected by 
the system. 
2.4.1.2 Red Cell Folate Assay – A brief Description 
 
Folate in the sample competes with acridinium ester-labelled folate in the Lite Reagent for a 
biotin-labelled folate binding protein. This is bound to avidin, which is covalently coupled to 
paramagnetic particles in the Solid Phase. The Advia Centaur folate assay requires the sample 
to be pre-treated to release folate from endogenous binding proteins. The amount of folate 
present is inverse to the number of relative light units (RLUs) detected by the system. 
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2.4.1.3 Vitamin B12 Assay – A brief Description 
 
Vitamin B12 in the sample competes with acridinium ester-labelled vitamin for purified 
intrinsic factor; this is covalently coupled to paramagnetic particles in the Solid Phase. A 
sodium hydroxide releasing agent and dithiothreitol DTT release the vitamin B12 from the 
endogenous binding proteins in the sample. Vitamin B12 levels are inversely related to the 
amount of relative light units (RLUs) detected by the system. 
 
2.4.1.4 Homocysteine Assay – A brief Description 
 
Homocysteine in the sample was reduced using a reducing agent to free homocysteine and 
converted to S-adenosylhomocysteine (SAH) with a homocysteine enzyme reagent (supplied 
by Siemens Healthcare Diagnostics Ltd). SAH covalently linked to paramagnetic particles in 
the solid phase competes with converted SAH from the subject sample for acridinium ester-
labelled anti-SAH in the lite reagent. An inverse relationship exists between the amount of 
homocysteine present in the sample and the amount of relative light units (RLUs) detected 
by the system. 
 
2.5 Determination of folates in colorectal mucosa - method development 
 
Tissue folate concentration for the 336 subjects was determined in 1-2 colorectal biopsies by 
the microbiological assay (MBA) using Lactobacillus Rhamnosus (ATCC 7469): The method was 
refined from a well-established assay that had been used in the department for some years. 
The assay was first established from a method kindly supplied by Anthony Wright from the 
Institute of Food Research. The assay was originally developed by the current author for a 
MSc project investigating folate bioavailability in food (Kennedy, 2004). The standard 
microbiological assay is routinely employed for folate quantification in food such as broccoli 
and in human samples – usually whole blood. The assay was particularly suitable for this study 
because it measures the total content of the different folate molecules rather than the 
individual folate values as measured using other methods. The bacterium Lactobacillus 
Rhamnosus is highly sensitive to the presence of folate which was ideal in this study because 




2.5.1 Assay Development 
 
In any folate quantification method, folate must first be extracted from the sample by careful 
disruption and homogenisation of the samples in extraction buffer to release the folate from 
the cells (Gregory, 1989). 
 
Next, the folate must be deconjugated into shorter chains (mono- and diglutamates) as the 
molecule exists in tissue as polyglutamate chains. Lactobacillus Rhamnosus produces a signal 
far more reliably in response to smaller mono and diglutamate folate units. This conversion 
requires a deconjugase such as chicken pancreas or rat plasma (Shrestha et al., 2000). 
 
Biopsies in this study were small. Large tissue samples were not available as biopsies were 
collected from healthy volunteers who had not undergone resection for previous disease. To 
quantify tissue folate from small colonic biopsies of 5–64mg, the food protocol described 
above required considerable method development to adapt the previous microbiological 
assay (MBA) protocol for much smaller samples (Kim et al., 1998, Kim et al., 2001). Where 
extraction of folates in the food protocol was straightforward using an Ultra Turrax probe, it 
was much more challenging to physically disrupt the cells in very small pieces of mucosa while 
optimising and preserving the total folate released. An Ultra Turrax probe, sonication (bath 
and probe) and a reusable Teflon pestle in a 1.5mL Eppendorf tube with liquid nitrogen were 
three methods that were all tested in an attempt to pulverise the biopsies. 
 
It became apparent that homogenising the tissue with the Ultra Turrax was not possible 
because the tissue was so small that it ended up lodged on the blade and there was a risk of 
losing the tissue altogether. In the same vein, sonication was difficult to achieve and cells 
were left largely intact. Ultimately, after testing all techniques and measuring folate released 
from similar sized biopsies, the pestle technique resulted in superior mechanical disruption 
of the cells. The Teflon pestle fitted tightly into the 1.5mL Eppendorf tube, which enabled 
samples to be forcibly crushed and sheared against the wall of the Eppendorf tube until there 
was nothing visible. Additionally, this option prevented samples from thawing prior to the 




2.5.1 Extraction and deconjugation of folate from Colonic tissue 
 
1M KPO4 Stock Buffer was made up by dissolving 68.045g KH2PO4 and 87.087g K2HPO4 in 1L 
AR water and storing at 2-8C. 
 
Reagents: 
Potassium Dihydrogen Orthophosphate (KH2PO4) (Sigma Aldrich) 
Dipotassium Hydrogen Orthophosphate (K2HPO4) (Sigma Aldrich) 
β-mercaptoethanol (Sigma Aldrich) 
Bis (2-hydroxyethyl)imino-tris(hydroxymethyl)methane (Bis-triz) 
Sodium Ascorbate (Sigma Aldrich) 
Analytical Reagent (AR) grade water (Thermoscientific) 
Desiccated Chicken Pancreas (BD Biosciences Codified Cat. No. 245910) 
 
2.5.1.1 Extraction of folate from 5-64mg samples of colorectal mucosa 
 
After removal from the -70C freezer, colonic biopsies were weighed and placed back on ice 
to ensure that the folates remained intact until extraction. Each biopsy sample was then 
crushed and sheared against a 1.5mL Eppendorf tube with a Teflon pestle over dry ice until 
only minute pieces of sample remained. However, the texture of the tissue was very tough 
and, therefore, difficult to completely eliminate in some cases.  
 
200µL freshly prepared folate extraction buffer [5 mmol -mercaptoethanol/L and 0.1mol 
sodium ascorbate/L in 0.1mol bis (2-hydroxyethyl)imino tris(hydroxymethyl)methane/L, pH 
7.85] were added to each sample, and the pestle was rinsed in it to remove all of the 
homogenate. Eppendorf tubes were placed in a hot water bath at >90C for 20 minutes before 
cooling in an iced water bath for 10 minutes. Samples were then centrifuged at 13,500 rpm 
for 30 minutes, and the supernatant was pipetted off and stored in an Eppendorf tube at -
70C. At the end of each extraction, pestles were sterilised for the next use. 
2.5.1.2 Deconjugation of folate previously removed from colorectal tissue samples  
 
A 5mg/mL stock chicken pancreas solution was prepared by adding 60mg chicken pancreas 
to 12mL AR water in a Falcon tube. The solution was carefully and gently mixed for 10 minutes 
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and centrifuged for a further 10 minutes at 1250 x g, 2000 rpm at 15C. A working buffer 0.1M 
KPO4 containing 10mg/mL sodium ascorbate solution – was also prepared. The following 
deconjugation systems were constructed: 
 
• 100µL folate sample (biopsy extract described above) 
• 10µL chicken pancreas supernatant  
• 90µL 0.1 M NaPO4 buffer pH 7 
 
Ten blanks were constructed by replacing the folate extracts with KPO4 buffer to obtain a total 
buffer volume of 190µL and combining with 10µL chicken pancreas solution. The tubes were 
incubated at 37C for 2 hours, after which the process was halted by freezing. Samples were 
stored at -70C prior to assay.  
2.5.2 Quality Control Stock Sample 
 
One large colonic mucosal sample (left over from a resection in a previous study) was weighed 
(662.5mg) and placed into a sterile 100mL Duran Bottle with freshly prepared folate 
extraction buffer (66.3mL). The mixture was homogenised with a Turrax probe to 
mechanically disrupt the tissue cells (this method worked well with a much larger piece of 
tissue). The mixture was then split between two sterile 50mL Falcon tubes, which were placed 
in a water bath at 90C for 20 minutes. After heating, the tubes were cooled in an iced water 
bath for 10 minutes. The Falcon tubes were then centrifuged at 13,500 rpm for 30 minutes. 
The quality control samples were incubated at 37C for 2 hours. Incubation was halted by 
freezing at -70C prior to analysis. 
 
The QC deconjugation system comprised 100µL of tissue sample extract, 10µL of chicken 
pancreas solution and 90µL of 0.1 M KPO4 containing 10mg/mL of sodium ascorbate solution. 
The tubes were incubated at 37C for 2 hours, after which the process was halted by freezing. 
Samples were stored at -70C prior to analysis.  
 




2.5.3 Assay Plate Preparation 
 
The subject sample, the blank and the QC were diluted 25-fold in two steps: 
1 100µL of the subject sample was diluted with 400µL of 0.5% sodium ascorbate 
solution. 
2 200µL of the above sample was diluted with 800µL of 0.5% sodium ascorbate 
solution. 
 
Dilutions were made according to previous concentrations described in the literature (Kim et 
al., 1998).  
 
2.5.4 Preparation of Folic acid standards 
 
Reagents 
• Folic acid (Sigma Aldrich) 
• Sodium hydroxide (NaOH) (Sigma Aldrich) 
• Sodium ascorbate (Sigma Aldrich) 
 
Solution A: Folic acid stock solution (200 μg/mL) 
Folic acid (20mg) was weighed and added to a volumetric flask with 0.1 M NaOH (4mL) 
solution and made up to 100mL with AR water to obtain a 200 μg/mL solution.  
 
Solution B: Folic acid intermediate solution (10 μg/mL) 
Solution A (10mL) was added to 200mL 0.1 M NaPO4 buffer (20mL stock buffer 1 M NaPO4 
diluted by 180mL AR water) to obtain a 10 μg/mL intermediate folic acid solution. Adjustment 
to pH 7 was obtained with dropwise addition of concentrated NaOH and monitored with a 
spectrophotometer (Emax 1 cm 1% 10 μg/mL at 282 nm=0.625).  
Solution C: Folic acid working standard (100 ng/mL) 
Solution B (2.5mL) was diluted with 250mL 0.5% sodium ascorbate solution (1.25g sodium 
ascorbate in 250mL AR water) in a volumetric flask. Aliquots of 1mL were dispensed into Nunc 




Solution D: Folic acid calibration curve standard (1 ng/mL) 
Solution D was made up on the day of the assay with the addition of 0.5mL of Solution C 
made up to 50mL with freshly prepared 0.5% sodium ascorbate solution in a volumetric 
flask to obtain a 1 ng/mL concentration.  
 
2.5.5 Preparation of Folic Acid Casei Medium (FACM)  
 
Reagents: 
- Folic acid casei medium (FACM) (Biosciences Cat. No. 282210) 
- Chloramphenicol (Fisher Scientific) 
- Manganese sulphate (MnSO4H2O) (Sigma Aldrich) 
- Ethanol 
- Analytical Reagent (AR) grade water  
 
The assay medium was prepared by weighing out 4 x 11.75 g FACM and placing each in a 
250mL Duran bottle to be made up to 200mL with AR water. Each solution was shaken 
vigorously to dissolve the FACM thoroughly. 40mg chloramphenicol was dissolved in 400μL 
ethanol and made up to 20mL with AR water. 3.75mL of the chloramphenicol solution was 
added to each bottle of medium. Manganese sulphate (878.4mg) was dissolved in 40mL AR 
water, and 5mL was added to each bottle before the 4 bottles were brought to the boil for 1 
to 2 minutes, cooled down and made up to 250mL with AR water. The media were decanted 
into 50mL Duran bottles, and each bottle was autoclaved at 121C for 5 minutes before being 





2.5.6 Preparation of calibration dilutions 
Nunc tubes containing Solution D were taken from the -70C freezer on the day of assay and 
further diluted into 9 calibration series with 0.5% sodium ascorbate solution as shown below.  
 




Tube Solution D  
(mL) 
0.5% sodium ascorbate 
solution  
(mL) 
Folic acid concentration 
(pg/mL) 
1 0 2.0 0 
2 0.05 1.95 2.5 
3 0.1 1.9 5.0 
4 0.15 1.85 7.5 
5 0.2 1.8 10.0 
6 0.3 1.7 15.0 
7 0.4 1.6 20.0 
8 0.5 1.5 25.0 
9 0.6 1.4 30.0 
 
 
2.5.7 Preparation of calibration and assay plates 
 
Lactobacillus Rhamnosus aliquots were prepared previously during an Msc project from 
freeze dried organisms by the current author (Kennedy, 2004). Briefly 3ng folic acid (30 l) 
was added to 20mL growth and 20mg ascorbic acid. This was incubated at 37°C until the 
organism was growing freely, a process which took approximately 5 or 6 days to achieve. 
Following this, the log phase could be pre-determined. At the beginning of the day, 4 x 20mL 
growth medium (with added folic acid + ascorbic acid) and different concentrations of 
subculture (100 l, 500 l and 2mL) were incubated at 37 °C. The absorbance of the three 
cultures were followed hourly at 600nm and plotted against time for up to 48h to find an 
optimum time and concentration in which to use the culture for the assay. 
 
On the day of the assay, the cryopreserved organism was removed from the freezer and 
defrosted. Each 50mL Duran bottle of assay medium was inoculated with 200μL of the 
organism, and 50mg of ascorbic acid was also added. The FACM was carefully shaken to 




Aliquots of 200μL of inoculated medium were then added to every well (using a multi-channel 
pipette) in both the calibration plate and the assay plate. 
 
2.5.7.1 Calibration Plate 
 
The nine calibration series described above were added to the calibration plate; 8 wells in 
each column were filled with one dilution standard (i.e.100μL of each standard in a full 
column of 8 wells across 9 columns) as shown in Figure 2.3. 
 
2.5.7.2 Assay plate 
 
There were 8 wells (one column per subject) in the assay plate. 100μL diluted folate extract 
was added to the 200μL inoculated medium in each well for each of the 336 subjects. The 
assay plate blanks and the deconjugation blanks each made up one column of the plate. See 
Figure 2.4 
 
Plates were firmly sealed using a Mylar acetate plate sealer and roller (ICN pharmaceuticals); 
the plates were then carefully vortexed to ensure homogenous mixtures. They were then 
incubated at 37C for 42 hours.  
 
After incubation, the plates were inverted to mix the liquid, and the optical density in each 
well was determined on a microplate reader (Anthos 2001) at 620nm in order to calculate the 





Figure 2.3 Calibration Plate Layout 
 
  A B C D E F G H I J 
1 200µL AM 
100µL Dil 1 
(0 pg FA) 
200µL AM 
100µL Dil 2  
(2.5 pg FA) 
200µL AM 
100µL Dil 3 
(5.0 pg FA)  
200µL AM 
100µL Dil 4 
(7.5 pg FA) 
200µL AM 
100µL Dil 5 
(10 pg FA)  
200µL AM 
100µL Dil 6 
(15 pg FA) 
200µL AM 
100µL Dil 7 
(20 pg FA)  
200µL AM 
100µL Dil 8 
(25 pg FA)  
200µL AM 
100µL Dil 9 




2 200µL AM 
100µL Dil 1 
(0 pg FA) 
200µL AM 
100µL Dil 2  
(2.5 pg FA) 
200µL AM 
100µL Dil 3 
(5.0 pg FA)  
200µL AM 
100µL Dil 4 
(7.5 pg FA) 
200µL AM 
100µL Dil 5 
(10 pg FA)  
200µL AM 
100µL Dil 6 
(15 pg FA) 
200µL AM 
100µL Dil 7 
(20 pg FA)  
200µL AM 
100µL Dil 8 
(25 pg FA)  
200µL AM 
100µL Dil 9 




3 200µL AM 
100µL Dil 1 
(0 pg FA) 
200µL AM 
100µL Dil 2  
(2.5 pg FA) 
200µL AM 
100µL Dil 3 
(5.0 pg FA)  
200µL AM 
100µL Dil 4 
(7.5 pg FA) 
200µL AM 
100µL Dil 5 
(10 pg FA)  
200µL AM 
100µL Dil 6 
(15 pg FA) 
200µL AM 
100µL Dil 7 
(20 pg FA)  
200µL AM 
100µL Dil 8 
(25 pg FA)  
200µL AM 
100µL Dil 9 




4 200µL AM 
100µL Dil 1 
(0 pg FA) 
200µL AM 
100µL Dil 2  
(2.5 pg FA) 
200µL AM 
100µL Dil 3 
(5.0 pg FA)  
200µL AM 
100µL Dil 4 
(7.5 pg FA) 
200µL AM 
100µL Dil 5 
(10 pg FA)  
200µL AM 
100µL Dil 6 
(15 pg FA) 
200µL AM 
100µL Dil 7 
(20 pg FA)  
200µL AM 
100µL Dil 8 
(25 pg FA)  
200µL AM 
100µL Dil 9 




5 200µL AM 
100µL Dil 1 
(0 pg FA) 
200µL AM 
100µL Dil 2  
(2.5 pg FA) 
200µL AM 
100µL Dil 3 
(5.0 pg FA)  
200µL AM 
100µL Dil 4 
(7.5 pg FA) 
200µL AM 
100µL Dil 5 
(10 pg FA)  
200µL AM 
100µL Dil 6 
(15 pg FA) 
200µL AM 
100µL Dil 7 
(20 pg FA)  
200µL AM 
100µL Dil 8 
(25 pg FA)  
200µL AM 
100µL Dil 9 




6 200µL AM 
100µL Dil 1 
(0 pg FA) 
200µL AM 
100µL Dil 2  
(2.5 pg FA) 
200µL AM 
100µL Dil 3 
(5.0 pg FA)  
200µL AM 
100µL Dil 4 
(7.5 pg FA) 
200µL AM 
100µL Dil 5 
(10 pg FA)  
200µL AM 
100µL Dil 6 
(15 pg FA) 
200µL AM 
100µL Dil 7 
(20 pg FA)  
200µL AM 
100µL Dil 8 
(25 pg FA)  
200µL AM 
100µL Dil 9 




7 200µL AM 
100µL Dil 1 
(0 pg FA) 
200µL AM 
100µL Dil 2  
(2.5 pg FA) 
200µL AM 
100µL Dil 3 
(5.0 pg FA)  
200µL AM 
100µL Dil 4 
(7.5 pg FA) 
200µL AM 
100µL Dil 5 
(10 pg FA)  
200µL AM 
100µL Dil 6 
(15 pg FA) 
200µL AM 
100µL Dil 7 
(20 pg FA)  
200µL AM 
100µL Dil 8 
(25 pg FA)  
200µL AM 
100µL Dil 9 




8 200µL AM 
100µL Dil 1 
(0 pg FA) 
200µL AM 
100µL Dil 2  
(2.5 pg FA) 
200µL AM 
100µL Dil 3 
(5.0 pg FA)  
200µL AM 
100µL Dil 4 
(7.5 pg FA) 
200µL AM 
100µL Dil 5 
(10 pg FA)  
200µL AM 
100µL Dil 6 
(15 pg FA) 
200µL AM 
100µL Dil 7 
(20 pg FA)  
200µL AM 
100µL Dil 8 
(25 pg FA)  
200µL AM 
100µL Dil 9 









Figure 2.4 Folate Sample Plate Layout 
 
  A B C D E F G H I J 













































































































































































































































2.6 The MTHFR C677T genotype 
2.6.1 Genomic DNA extraction 
 
DNA was extracted from leucocytes in the blood samples using the GenElute TM Blood 
Genomic DNA Kit (Sigma). 
 
Laboratory Equipment required: 
Water bath @ 55°C 
Filter barrier pipette tips 
Microcentrifuge tubes (1.5mL) 
Microcentrifuge (Micro Centaur MSE)  
 
GenElute TM Blood Genomic DNA Kit components (product code NA 2010, Sigma): 
Resuspension Solution  
Lysis Solution  
Column Preparation Solution  
Wash Solution Concentrate  
Elution Solution (10mM Tris-HCl, 0.5mM EDTA, pH 9.0) 
Proteinase K  
RNase A Solution  
GenElute Miniprep Binding Columns  
Collection Tubes, 2.0mL  
Molecular biology grade ethanol (product coder E 7148, Sigma) 





The Prewash Solution Concentrate was diluted with 27.5mL molecular biology grade 
ethanol (100%).  
 
Wash Solution: 




Proteinase K:  




• 200μL room temperature-equilibrated whole blood was added to a 1.5mL Eppendorf 
tube containing 20μL Proteinase K solution. This was vortexed to thoroughly mix the 
enzyme. 
• 20μL RNase A Solution was added to the sample before vortexing again for 15 seconds 
and then incubated for 2 minutes at room temperature. This step was carried out to 
obtain RNA-free genomic DNA. 
• 200μL Lysis Solution C, a chaotropic salt-containing solution, was added to the sample 
before vortexing for 15 seconds before being incubated at 55C in a water-bath for 
10 minutes. 
• 200μL 100% ethanol was added to the lysate and vortexed for 5-10 seconds to obtain 
a homogeneous solution. 
• To maximise consistent binding of DNA to the silica membrane, 500μL column 
preparation solution was added to each pre-assembled GenElute Miniprep Binding 
Column and centrifuged at high speed (12,000 × g) for 1 minute. The flow-through 
liquid was discarded. 
• The lysate was carefully loaded into the pre-treated GenElute Miniprep Binding 
Column and centrifuged at low speed (≥6,500 × g) for 1 minute. The collection tube 
containing the flow-through liquid was discarded, and the column was placed into a 
new 2mL collection tube. 
• To remove potential contaminants, 500μL Prewash Solution was added to the 
column, which was centrifuged at low speed (≥6,500 × g) for 1 minute. The collection 
tube containing the flow-through liquid was discarded, and the column was placed 
into a new 2mL collection tube.  
• To ensure the column was free of ethanol (known to interfere with the Polymerase 
Chain Reaction (PCR)), 500μL Wash Solution was added to the column and centrifuged 
at high speed (12,000× g) for 3 minutes until the column was dry. The flow-through 
liquid was discarded, and the collection tube was used to collect further flow-through 
liquid during an additional centrifugation step at high speed (12,000 × g) for 1 minute. 
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The collection tube containing the flow-through liquid was discarded, and the column 
was placed into a new 2mL collection tube.  
• 100μL Elution Solution was added directly into the centre of the column, and after 
incubation for 5 minutes at room temperature, it was centrifuged at low speed 
(≥6,500 × g) for 1 min. This step was repeated, and both eluates were collected into a 
1.5mL Eppendorf tube. 
• The combined eluate containing pure genomic DNA was stored at 4C on a short-term 
basis.  
 
2.6.2 DNA Quantitation 
 
DNA concentration was quantified by a Nano Drop® ND-1000 UV spectrophotometer, and 
agarose gel electrophoresis (Figure 2.5 below) was used to confirm the presence of a pure 




Nano Drop® ND-1000 UV spectrophotometer 
Pipette and pipette tips with filter barrier 
Molecular biology reagent water (nuclease free water, Ambion) 
The Nano Drop spectrophotometer was switched on, the software was set to ‘measure 
DNA’, and initialisation was achieved by blanking with 1.5μL nuclease-free water pipetted 
onto the measurement surface. The surface was carefully cleaned and dried before 1.5μL 
DNA solution was added and the measurement was made. Each sample was measured in 
duplicate to optimise accuracy. The Nano Drop® output provided the concentration in 
ng/μL (the peak should be at 260nm for DNA with a 280/260nm ratio ideally between 1.7 
and 2.0; below 1.7 suggested high concentrations of protein were still present, and above 
2.0 indicated poor quality DNA product). If the ratios were outside of these limits the 
dilutions were repeated and samples were rerun. 
 
 2.6.3 Gel Electrophoresis 
 
Laboratory Equipment required: 
Horizontal electrophoresis tank  
Horizontal electrophoresis gel tray 
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 Power supply (Apelex, PS 3002) 
 UV transilluminator (Alpha Imager, Alpha Innotech Corporation 2000) 
 Gel combs (16 well) 
 Eppendorf tubes (0.5mL) 




Routine use agarose (product code A9539) 
Ethidium bromide (product code E-7637, Sigma) 
Trizma base (product code T-6066, Sigma) 
Boric Acid (product code B-6768, Sigma) 
EDTA (product code E-5134, Sigma) 
DNA ladder (Hyperladder V and VI, Bioline) 
Deionized water 
Loading buffer (50mg BB, 3mL 10×TBE, 7mL glycerol) 
Molecular biology reagent water (nuclease free water, Ambion) 
 
10 × TBE buffer (1 L) 
108g Trizma base, 55g boric, acid and 7.45g EDTA were dissolved in deionised water and 
diluted by a factor of 10. 
 
Agarose gel preparation (0.7, 1.5, 3.0% w/v) 
• 0.7, 1.5, or 3.0g of agarose powder was dissolved in 100mL 1 × TBE buffer in a 
conical flask and heated in a microwave. 
• The gel was left to cool, and 10μL ethidium bromide (5mg/mL) was added. 
• The mixture was swirled for homogeneity and poured into the gel tray with the 




• Genomic DNA: 7 μL molecular biology grade water, 2μL loading buffer, and 1 μL 
pure genomic DNA were added to a 0.5mL Eppendorf tube, and a 0.7% w/v 
agarose gel was used.  
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• PCR product: 2μL loading buffer and 15μL PCR product were added to a 0.5mL 
Eppendorf tube, and a 1.5% w/v agarose gel was used. 
• Digested PCR product: 2μL loading buffer and 20μL digested PCR product were 




• Approximately 500mL 1 × TBE buffer was poured into the electrophoresis tank. 
• The autoclave tape and comb were removed from the set gel, and the gel tray 
was inserted into the tank. 
For a 0.7% w/v agarose gel, 2 μL Hyperladder VI was loaded into one of the outside 
wells, and 10μL of the DNA solution was added to the remaining wells (Figure 2.5). 
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To confirm the presence of genomic DNA from blood samples in 351 subjects in order to be 
able to ascertain MTHFR genotype for Study 1 analysis, and also to screen for Study 2  
 
Lanes 1-11:  10μL genomic DNA solution (1μL DNA) 
Lane 12:  10μL control sample (pooled DNA taken from student blood samples) 
Lane 13:  Buffer (control) 







Figure 2.6: 1.5% Electrophoresis gel   
 
For a 1.5% w/v agarose gel, 3 μL DNA Hyperladder V (Size Range 25 to 500bp) was loaded 
into one of the outside wells, and 17 μL PCR product was loaded into the remaining 
wells.  
 
Electrophoresis run on a 1.5% agarose gel to confirm presence of PCR products of the 
MTHFR gene in 351 subjects to ascertain MTHFR genotype for Study 1 analysis and also 
screen for Study 2  
Lanes 1-7: 15 μL MTHFR gene PCR product 
Lane 8: 15 μL control sample - pooled DNA taken from student blood samples  
Lane 9: Buffer (control  
Lane 10: 3 μL DNA Hyperladder V (Size Range 25 to 500bp)  
 
      1         2          3         4         5          6        7         8          9        10 
 
 










2.6.4 Determination of the MTHFR mutation 
 
Genotype: 
MTHFR C677T genotype was determined by Restriction Fragment Length Polymorphism 
(RFLP) analysis using a previously developed protocol (Frosst et al., 1995) that comprised 
PCR followed by Hinf I digestion. 
Reagents: 
  MTHFR primers (MWG-Biotech AG) 
HotStar Taq polymerase (Biotage) 
dNTPs (Amersham Pharmacia Biotech) 
Amplitaq Gold (Perkin-Elmer) 
Restriction enzymes Hinf I (Invitrogen) 
Hinf I H Buffer (Invitrogen) 
Molecular biology reagent grade water (nuclease free water, Ambion) 
Hyperladder V (Bioline) 
TrackIt ladder 100bp (Invitrogen) 
 
PCR for the MTHFR gene: 
Forward and reverse primer sequences for the methylenetetrahydrofolate reductase 









A G G A C G G T G C G G T G A G A G T G    
    
Both forward and reverse primers were supplied at a concentration of 100M and diluted 




• 25L of all four individual 100 mM dNTP stocks were mixed together to yield a 
100 L solution of 25 mM mixed dNTPs. The mixed dNTPs were then diluted in a 
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1:5 ratio (100 L dNTPs in 400 L water) to obtain a 5mM solution and were 
aliquoted into 3 tubes.  
• 2L dNTP mix was used per 50L PCR reaction volume to reach a concentration 
of 200M for each dNTP. 
 
Reaction mix     
10  PCR buffer    2.5   1.5 mMmgCl2 
dNTPs     1.0   200 M 
Forward primer    0.5   0.1 M 
Reverse primer    0.5   0.1 M 
Water     19.375  
HotStar Taq polymerase  0.125  1.25 U  
  
Total     24.0 L 
 
• 1.0μL purified genomic DNA solution was added to 24L reaction mix, giving a 
final volume of 25L in each well. 
 
• PCR reaction programme: 
 
95C 15 min  
95C 1 min, 55C 1 min, 72C 1 min; for 35 cycles 
72C 10 min 
4C ∞ 
 
• After PCR, purity was investigated on a 1.5% agarose gel (Figure 2.6), and the 
success of the amplification process was confirmed with regard to the MTHFR 









Restriction Fragment Length Polymorphism (RFLP) 
 
The restriction enzyme Hinf I recognises the G*ANTC sequence and cleaves after G. After 
Hinf I digestion, an individual homozygous for the wild-type MTHFR C677 polymorphism 
possesses one 198 bp fragment; an individual heterozygous for the MTHFR C677T 
polymorphism possesses 3 fragments of 198 bp, 175 bp and 23 bp; and an individual 
homozygous for the mutant MTHFR C677T polymorphism has 2 fragments of 175 bp and 
23 bp as follows: 
 
Genotype   After Digestion 
CC    198 bp 
TT    175 bp + 23 bp  
CT    198 bp + 175 bp + 23 bp 
 
10 L restriction digest was prepared as follows and scaled up accordingly: 
 
Reaction Mix       × 1 
10  buffer (H buffer)      2.0 
Water       7.5 
Restriction enzyme (Hinf I)    0.5 
 












• 10L PCR product was added to the reaction mix. 
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• Samples were incubated overnight at 37C on a thermal cycler. 
• The digested PCR products were then analysed on a 3.0% agarose gel (Figure 2.7), 
and the genotype for the MTHFR C677T polymorphism was determined. 
• The power was set to 150V for 45 minutes for a 0.7 and 1.5% w/v agarose gel and 
100V for 1 hour 30 minutes for a 3.0% w/v agarose gel. 
• After the gel was run, it was removed from the electrophoresis tank and 
photographed under a UV illuminator. 
 
For a 3.0% w/v agarose gel, 3 μL DNA HyperladderV and 4 μL 10 bp TrackIt ladder were 
loaded into one of the outside wells and 2 μL sample DNA was loaded into the remaining 
wells.  
 
In Figure 2.7, homozygous wild-type (CC) samples are seen in lanes 2, 4, 7, 12, and 13; 
heterozygous (CT) samples are in lanes 3, 5, and 8-11; and a homozygous mutant for the 
MTHFR C677T polymorphism sample can be seen in lane 6. 
 
Hinf I digested PCR product of the MTHFR gene run on a 3.0% agarose gel from samples 
of 351 subjects to ascertain MTHFR genotype for Study 1 analysis and also screen for Study 
2. 
Lane 1: 4 μL Track It 10 bp DNA Ladder 
Lanes 2-12: Digested PCR product 
Lane 13: control sample 
Lane 14: Buffer (control) 


















Figure 2.7 3.0% electrophoresis gel  
 




2.7 Genomic DNA Methylation  
 
Genomic DNA methylation in colorectal mucosa was quantitatively determined by liquid 
chromatography/electrospray ionisation mass spectrometry (LC-ESI-MS/MS). The 
method, which was selected for precision, sensitivity, selectivity, and speed was adapted 
from a previously reported protocol using the LC-ESI-MS/MS method (Friso et al., 2002b). 
 
Genomic methylation was assessed firstly by heating to denature the DNA and adding the 
stable isotope [13C,15N2] 2′-deoxycytidine. Then enzymatic hydrolysis was carried out by 
sequential digestion,and the whole solution was injected onto an analytical column. The 
four DNA bases were separated and 5-methylcytosine was identified using LCMS in the 
Multiple Reaction Monitoring (MRM) mode.  
 
The precursor/product ion pair of m/z 228/112 was monitored for 2′-deoxycytidine and 
m/z 242/126 for 5-methyl-2′-deoxycytidine, with a dwell time of 500ms for each pair. The 
chromatographic peaks for 2′-deoxycytidine and 5-methyl-2′-deoxycytidine eluted at 5.0 
and 6.5 minutes, respectively. Quantification was achieved by comparison to known  
 
 
concentrations of internal standard. Chromatograms were analysed using the Quanlynx v 




Cytosine and 5-methylcytosine content in DNA was calculated from calibration curves 
where the area ratios of 2′-deoxycytidine or 5-methyl-2′-deoxycytidine to the internal 




S1 nuclease (deoxyribonuclease P1, endonuclease P1) Sigma N8630 
Shrimp alkaline phosphatase GE Healthcare e70092Y 
Snake Venom Phosphodiesterase (SVP) USB Europe 20240Y 







Filter barrier pipette tips 
Microcentrifuge tubes (0.5mL) 
Microcentrifuge (Micro Centaur MSE) 
Phenomenex Synergi Polar RP column  
 
2.7.3. Solution preparation: 
 
S1 nuclease (deoxyribonuclease P1, endonuclease P1) (2 units/µL) 
 
The certificate of analysis was consulted for the S1 nuclease (deoxyribonuclease P1, 
endonuclease P1) vials, which contained 205 units/vial. As instructed, 152.5µL 0.05M 
ammonium acetate, pH 5.3 was added to obtain a final concentration of 2 units/µL (Crain, 
PF methods in enzymology vol 193, 1990). The diluted solution was divided into aliquots 
and stored at -20C until use. 
 
SV Phosphodiesterase (0.002 units/µL) 
 
The SVP vial containing 100 units was re-suspended in 500µL re-suspension buffer 
provided to produce a solution of 0.2 units/µL. This was divided into 50 aliquots of 10µL 
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each. To each aliquot, 90µL re-suspension buffer was added to make a concentration of 
0.02 units/µL. This was stored at -20C until use. Before use, a further dilution was carried 
out by transferring 10µL of the 0.02 units/µL solution into another 0.5mL and adding 90µL 
re-suspension buffer to make a final concentration of 0.002 units/µL.  
2.7.4 Shrimp alkaline phosphatase 1 unit/µL 
 
A 500µL vial had was divided into aliquots and stored at -20C until used.  
 
2.7.5 DNA Digestion 
 
For each subject, 20µL of DNA was aliquoted into a 0.5mL Eppendorf tube and placed in 
a heating block at 100C to denature it. After exactly 5 minutes, each tube was 
immediately chilled on ice, and 10µL labeled deoxycytidine was added to each Eppendorf 
tube along with 3µL 0.1M ammonium acetate pH 5.3 and 2µL Nuclease S1 (4 units). The 
Eppendorf tubes were placed back on the heating block for two hours at 45C. At the end 
of the two hours, 3.5mL 1M ammonium bicarbonate + 2µL SVP (0.004 units) were added, 
and the Eppendorf tubes were heated for a further two hours at 37C. Finally, in the third 
stage of the trienzymatic digestion, 4.05mL SAP reaction buffer + 1µL SAP (1 unit) was 
added before heating again at 37C for one hour. At the end of the hour, the heat was 
increased to 65C for a further 15 minutes. Next 200µL of the mobile phase was added, 
and the digested DNA solution was added to a glass vial prior to LC/ESI/MS analysis. 
2.7.6 Genomic DNA methylation analysis   
 
For quantitation of genomic DNA methylation by LC-ESI-MS/MS, chromatography was 
performed by injecting 40µL of the digested DNA/isocratic mobile phase consisting of 
10mM ammonium formate solution + 0.1 % formic acid:methanol (95:5) onto a 
Phenomenex Synergi Polar RP column, 250 × 2 mm, 4 µm particle size, 80 Å pore size 
(Cheshire, UK), coupled to a Column tandem mass spectrometer (Micromass Quattro 
Ultima) operating in the electrospray ionisation (ESI positive) mode.  
 
For mass spectrometry, the experimental conditions were as follows: column 
temperature, 30C; sample rack temperature, 4C; source block temperature, 120C; 
desolvation temperature, 450C; cone gas (N2) flow, ~100 L/h; desolvation gas (N2) flow; 
~650 L/h; collision gas (Ar) pressure; ~2.7 x 10-3 mbar; capillary voltage, 2.5 KV; and cone 




Unit mass resolution (LM & HM) 1&2 was set to 13, and collision energy voltage and 
multiplier voltages were 12V and 650V, respectively.  
 
2′-deoxycytidine and 5-methyl-2′-deoxycytidine (Sigma-Aldrich, USA) were used as 
external standards, and the chromatographic peaks were eluted at 5.0 and 6.5 minutes, 
respectively (Figure 2.8).   
 
As described above, quantification was carried out in the multiple reaction monitoring 
(MRM) mode by monitoring the precursor/product ion pair of m/z 228/112 for 2′-
deoxycytidine and m/z 242/126 for 5-methyl-2′-deoxycytidine, with a dwell time of 500ms 
for each pair.   
 
The Quanlynx v 4.1 software package (Manchester, UK) was used to analyse the 
chromatograms. DNA methylation status was calculated from the area ratios of 2′-
deoxycytidine or 5-methyl-2′-deoxycytidine to internal standard (labelled [13C,15N2] 2′-
deoxycytidine) under the curve, which were plotted against known concentrations of 2′-
deoxycytidine or 5-methyl-2′-deoxycytidine. Genomic DNA methylation status was 
expressed as the relative amount of 5-methyl-2′-deoxycytidine compared to total 
deoxycytidine residues. 
 
Pooled DNA extracts from study subjects were assayed for the control samples. The within-
assay and between-assay coefficients of variations were 3.9% and 10.0%, respectively.  
 
 






2.8 Quantification of Uracil content in DNA 
 
Uracil Misincorporation was determined by measuring uracil content in DNA samples 
using an adaptation of a previously described method (Blount et al., 1994) using gas 
chromatography and negative chemical ionization-MS.  
2.8.1 Reagents  
 
Uracil (Sigma Aldrich)  
Uracil internal standard (U-13C4, 99%; U-15N2, 98%) (Cambridge Isotope Laboratories, 
Inc.)  
Uracil DNA glycosylase (UDG) (Invitrogen) 
1µL 3,5-bis(trifluoromethyl)benzyl bromide (BTFMBzBR) (SigmaAldrich) 
EDTA Na salt (EDTA (product code E-5134, Sigma) 
Trizma base (product code T-6066, Sigma) 
Acetonitrile (271004 Sigma-Aldrich) 
DNA methylation QC1 050509
Time
2.00 4.00 6.00 8.00
%
0
2.00 4.00 6.00 8.00
%
0
2.00 4.00 6.00 8.00
%
0






















Triethylamine (T0886 Sigma-Aldrich) 




G24 incubator shaker  
Agilent Technologies 6890N network Gas Chromatograph system  
Agilent Enhanced MSD Chem Station running on Windows XP Professional. 
SpeedVac container  
Eppendorf tube  
Milli-Q purification system water  
 
2.8.3  Solution preparation 
 
Stock 1 M Tris HCL pH8 
Trizma base (12.1 g) was added to 100mL AR water and mixed until dissolved; pH was 
adjusted to 8 with concentrated HCl. The solution was then autoclaved. 
Stock 0.2 M EDTA Na salt pH8 
EDTA Na salt (14.888 g) was dissolved into 200mL AR water, and the pH was adjusted to 
8 with NaOH, after which the solution was autoclaved. 
TE Buffer 
TE buffer was prepared by combining Tris HCL, pH 8 and stock EDTA Na Salt (1 M Tris HCl, 
pH 8 was prepared from 12.1 g Trizma base added to 100mL AR water in a volumetric 
flask, and the pH was adjusted to 8 with concentrated HCl before autoclaving. Stock EDTA 
Na Salt 0.2 M, pH 8 was made by adding 14.888 g EDTA Na salt to 200mL AR water, and 
the pH was adjusted to 8 with NaOH before autoclaving at 120°C). 
 
Uracil standards  
Uracil (Sigma Aldrich) and the uracil internal standard (U-13C4, 99%; U-15N2, 98%) 
(Cambridge Isotope Laboratories, Inc.) were both weighed out (10mg) and made up to 
100mL with Milli-Q purification system water in a volumetric flask to give a 100 pg/µl stock 





Uracil Standard and Uracil Internal standard Solutions 
 
100ng/µl - Master Standard or Master Internal Standard: 
10mg uracil or uracil internal standard (U-13C4, 99%; U-15N2, 98%) was weighed out and 
made up to 100mL with Milli-Q purification system water in a volumetric flask. 
 
100 pg/µl - Stock Standard or Stock Internal Standard:  
10µL Master Stock Solution above was made up to 100mL with Milli-Q purification system 
water. 
 
0.2 pg/µl Working Standard: 
200µL Stock Solution was made up to 100mL with Milli-Q purification system water. 
 
2.5 pg/µl Internal Working Standard: 
 






A dilution series were constructed in 2.0mL tubes (Table 2.2)  
 
Table 2.2 Uracil calibration series 
   
 
Tube Weight uracil in 
each vial (pg)  
Volume of working 
solution  (µl) 
Weight of 




1 0 O 0 0 
2 0 0 50 20 
3 50 250 50 20 
4 0.6 3 50 20 
5 1.3 6.5 50 20 
6 2.5 12.5 50 20 
7 5 25 50 20 
8 10 50 50 20 
9 30 150 50 20 
10 50 250 50 20 
11 100 500 50 20 
12 150 750 50 20 
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Next 50µL TE buffer and 2 units uracil DNA glycosylase (UDG) (Invitrogen) were added to 
each DNA sample (1-100µL) of known individual concentration before incubation at 37C 
for 1 hour to remove the uracil, after which 20µL (50pg) (U-13C4, 99%; U-15N2, 98%) 
uracil internal standard was added. Solutions of standards and DNA samples were then 
dried for 4 hours in a SpeedVac container. The residue in each Eppendorf tube was re-
suspended in the following: 50µL acetonitrile, 10µL triethylamine, 1µL 3,5-
bis(trifluoromethyl)benzyl bromide (BTFMBzBR) (SigmaAldrich). Samples were shaken at 
500 rpm in a G24 incubator shaker at 30C to form N1N3-(3,5-
bis[trifluoromethly]benzyl)uracil (ura-diBTFMBZ), and 50µL water was added to improve 
extractability of ura-diBTFMBZ. The derivatised uracil was extracted into 100µL isooctane 
by vortexing for 30s and then minicentrifuged at full speed for 30s. The top phase 
(isooctane) was collected and analysed by GCMS. 
 
2.8.4 Determination of uracil content in DNA 
 
Uracil content was measured using the Agilent Technologies 6890N network Gas 
Chromatograph system equipped with a 7683 series autoinjector, a PTV (Gerstel) Inlet 
and a 5673 inert mass selective detector with a chemical ionization module, and the 
software was Agilent Enhanced MSD Chem Station running on Windows XP Professional. 
Samples were introduced onto the column via a Programmable Temperature Vaporisation 
(PTV) inlet in solvent mode with carrier gas: helium (BOC products GC grade), and the 
operating parameters were optimised using Agilent technologies PTV flow calculator 
















GCMS operating parameters 
 
Parameter Specification  
Column type Agilent technologies HP-5 MS capillary 
Column dimensions 30 m length x 250 mm internal diameter x 0.25 mm film 
thickness 
Injection liner Agilent technologies open baffle swirl hole design 
Column flow 1.5mL/min (constant flow mode) 
Injection mode solvent vent, inlet temperature program 
Pneumatics control vent pressure 1.3 psi, vent flow 100mL/min, vent end 
time 0.9 min. purge time 1.5 min. 
Injection volume 6 ml total as 3x 2 ml, 1 s delay time. 
Oven program initial temp. 100°C, holding for 1 min and ramping to 
240°C by 25°C/min, then to 280°C, hold 2 min, then  
40°C/min to 320, hold 2 min. 
Run time 13.6 min. Interface/Source/Quad Temperatures: 
250°C/106°C/150°C. EM Offset: 400 above autotune. 
Solvent Delay 6 min. Tune file: ncich4.u 
Acquisition mode negative chemical ionization with selected ion 
monitoring 
Resolution low 
Dwell time per ion 120 ms 
Ion masses 337, 343 corresponding to amidic anion (M-227) via a 
dissociative electron capture mechanism in a 
thermalised electronic methanic environment. 
 
 
Calculation of uracil in DNA 
 
Selected ion chromatograms were extracted, and the peak areas (integrated detector 
responses) were tabulated in Excel. A calibration curve was constructed for uracil by 
plotting the ratio of the 337 ion signal (native uracil) to that of the 343 ion (internal 
standard) against the molecular mass of uracil. Uracil concentrations were derived using 
the equation from the calibration curve.  




2.9 Statistical analysis 
 
All data were analysed using the Statistical Package for Social Sciences (SPSS) version 
21.0. 
 













































3  The association between the MTHFR C677T genotype and folate status and 





Disruptions in DNA methylation patterns can occur both on a genomic and gene-specific 
level in colorectal carcinogenesis (Issa et al., 2004). Reduction in genomic DNA 
methylation (hypomethylation) normally occurs with an increase in gene-specific DNA 
methylation (hypermethylation). Genomic DNA methylation in blood cells has been 
associated with serum folate and red cell folate in CRC patients and healthy volunteers 
(Pufulete et al., 2003, Pufulete et al., 2005b). The MTHFR C677T genotype is an additional 
factor which may influence the interaction between DNA methylation and folate status in 
leukocytes (Friso et al., 2002b, Axume et al., 2007b). This relationship has not been fully 
elucidated in the colon and at the time the current study was carried out, there were no 
reports of this relationship in subjects without colorectal cancer. 
 
The aim of this study was to investigate the association of biomarkers of folate status and 
the MTHFR C677T polymorphism on genomic DNA methylation in the colon of human 




Folate status and the MTHFR C677T mutation are associated with DNA methylation in the 




1. To investigate the association between MTHFR C667T genotype and genomic DNA 
methylation in the colon of subjects without colorectal adenoma or cancer. 
 
2. To investigate the association between folate status and genomic DNA 









1. To determine the MTHFR genotype using restriction fragment length 
polymorphism (RFLP) analysis in blood cells of all study subjects  
2. To determine serum and red cell folate, vitamin B12 and homocysteine status in 
blood using the competitive immunoassay and folate status in colonic mucosa 
using a microbiological assay. 
3. To quantitatively determine genomic DNA methylation in colonic mucosa by liquid 
chromatography/electrospray ionisation tandem mass spectrometry (LC-ESI-
MS/MS) and investigate associations with the MTHFR C677T genotype and with 
these folate biomarkers. 
 
3.2 Methods  
 
3.2.1 Subject recruitment  
 
Subject recruitment, inclusion and exclusion criteria, demographic data collection and 
tissue sample collection are all described in Chapter 2, Sections 2.1-2.3. All subjects 
provided blood samples for determination of the MTHFR C677T genotype, serum and red 
cell folate, colon tissue folate, serum vitamin B12 and plasma homocysteine, as well as 
mucosal biopsies for the determination of genomic DNA methylation.  
 
3.2.2 Laboratory Methods 
 
Methods for the extraction of DNA, and for the determination of genomic DNA 
methylation and biomarkers of folate and vitamin B12 status are described in detail in 
Chapter 2, Sections 2.4-2.7.1. 
 
3.2.3 Statistical analysis 
 
The primary endpoint of this current study was to look for differences in genomic DNA 
methylation between the MTHFR 677 CC and TT genotypic subgroups. Target sample size 
(n=400) was calculated using data from an observational study which measured DNA 
methylation in the leukocytes of healthy volunteers with the CC and TT genotypes (Friso 
et al., 2002a). The study was powered to detect a 50% difference (0.5 SD, 30 ng mCyt/mg 
DNA) in genomic DNA methylation between the CC and TT genotypes (5% signiﬁcance 
level, 2 tailed, and 80% power; with a ratio of CC to TT as 4:1). 
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Subject characteristics and dietary and lifestyle data are displayed as mean (SD) and 
frequency (%) apart from daily alcohol consumption and smoking, which are displayed as 
median (IQR) due to being very skewed. Differences in subject characteristics between 
genotypes were tested using ANOVA for continuous variables (age, BMI, folate intake), 
Chi-squared tests for categorical variables (gender, ethnicity and nutritional supplement 
use). The Kruskal-Wallis test was used for alcohol intake and smoking, this was because 
variables were not normally distributed and did not meet the assumptions of ANOVA. 
 
Biomarkers are displayed as median and inter-quartile Range (IQR) (the range between 
the first and the third quartile) because they were not normally distributed. Differences 
in single continuous variables (serum and red cell folate, colonic tissue folate, serum 
vitamin B12, plasma homocysteine and genomic DNA methylation) between genotypes 
were compared using the Kruskal-Wallis test because they were not normally distributed 
and did not meet the assumptions of ANOVA. 
 
Spearman’s rank correlation coefficients were used to investigate associations between 
DNA methylation and folate biomarkers because data were not normally distributed. 
 
Spearman’s rank correlation coefficients were also used to investigate associations 
between DNA methylation and continuous demographic variables age, BMI, dietary folate 
intake, total folate intake, number of cigarettes smoked and amount of alcohol consumed. 
 
Differences in genomic DNA methylation between demographic and lifestyle factor sub-
groups were assessed using the Mann-Whitney test (gender, smoking status, drinking 
status and nutritional and folic acid supplementation) and the Kruskal-Wallis test 
(ethnicity) as these variables were not normally distributed and did not meet the 
assumptions of ANOVA. 
 
Multiple linear regression was used to assess whether DNA methylation could be 
predicted from any of the independent variables. Forced Entry, or ‘Enter’ in SPSS, was 
selected as the method of Multiple Linear Regression. All predictors are entered into the 
model at the same time and in no particular order. Ranked variable DNA methylation was 
added to the model as the dependent variable. The MTHFR C677T genotype and ranked 
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variables (tissue folate, serum and red cell folate, plasma homocysteine) were all added 
as predictors.  
 
In a second model, additional variables were added to the model, these were age 
(continuous), gender (male or female), ethnic group (white, black, other), nutritional 
supplement use (user or non-user) and serum vitamin B12 (continuous). This method relies 
on theoretical justification for the selection of predictor variables. Adjustments were 
made for age, gender and ethnicity because there is evidence that DNA methylation 
differs by these variables (Jones et al., 2015, Zhang et al., 2011).  
 
3.3 Results  
 
3.3.1 Study recruitment 
 
A total of the 3112 subjects were screened for the current study, 2466 did not meet the 
inclusion criteria and 295 declined to participate. A total of 351 subjects were included 
and screened. Of those, 4 subjects were excluded because their biochemistry results were 
reported to be missing by the laboratory and 11 were excluded due to abnormal liver 
function tests (an exclusion criterion). Overall 336 (96%) patients were included in the 
main analysis.  
 
3.3.2 Subject characteristics and dietary and lifestyle data  
 
Table 3.1 shows the subject characteristics in this study. The average age of the subjects 
was 57 years. Overall, there were more women (62%) than men, the majority of subjects 
were Caucasian (67%), and there was a large proportion of African Caribbean Black 
subjects (21%), 5% of the study were Asian and the remaining 3% were classified as other. 
Mean BMI was 26.9 kg/m2. Approximately 23% of the population were smokers with a 
median consumption of 12 cigarettes per day. Approximately 56% of the subjects 
reported drinking alcohol with a median consumption of 11g per day. 31% were 
nutritional supplement users (sources were variable and data was not available on 
micronutrient content across the study), and 14% consumed folic acid containing 
supplements (sources were variable, the majority of which contained 400 µg) on a daily 
basis. Of the 60 subjects who provided data on dietary folate intake, the average daily 
intake was 348 µg/day, and when combined with folate from supplementation, the mean 
total daily intake was 373 µg/day. It was not possible to complete health questionnaires 
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for 28 subjects due to time pressure when subjects were required to go in for their 




























































results not returned 
(n=4) 
 
Subjects  included 
(n=351) 
 
Refused to participate (295) 
 
Included for analysis 
(n=336) 
Serum folate 
Red cell folate 
Plasma homocysteine 
Colonic tissue folate 
MTHFR genotype 
Genomic DNA methylation 
by LCMSMS 
 









Table 3.1 Subject characteristics and dietary and lifestyle data  
  n     
Age  (Years) 336 
 
57 (16) 
Gender [n (%)]            336 Male 128 (38) 
                                      
 
Female  208 (62) 
Ethnic group [n (%)]      324 Caucasian 226 (67) 
    
 
African Caribbean  69 (21) 
  
Asian 18 (5) 
  
Other 11 (3) 
BMI (kg/m2) 308 
 
26.9 (6) 
Nutritional supplement use [n (%)] 309 Non-user 214 (69) 
  
User 95 (31) 
Folate containing supplement use [n (%)] 308 Non-user 264 (86) 
 
 
User 44 (14) 
Dietary folate intake (µg/day) 60 
 
348 (115) 
Total folate intake (µg/day)  
(diet + supplements)  
60 
 
373 (140)  
Drinking [n (%)] 308 Non-drinker 136(44) 
  
Drinker 172(56) 
Alcohol Intake (g/day) 172 
 
11.0 (4-22) 
Smoking [n (%)]       314 Non-smoker 243 (77)  
  
Smoker 71 (23) 
 
Cigarettes/day 
71   12 (5-20) 
Data are mean (SD) or frequency (%) 









3.3.3 Subject characteristics by genotype 
 
Table 3.2 shows subject characteristics by MTHFR C677T genotype for the 336 subjects 
included in the final analysis, 55% were homozygous for the wild-type allele (CC), 35% 
carried one mutant allele (CT) and 10% were homozygous for the mutant allele (TT). There 
were no significant differences between genotypes in age, gender, BMI, smoking status, 
drinking status, nutritional supplement use, or folic acid supplement use. However, there 
was an association between genotype and ethnicity. In order to test for differences 
between the distributions of genotypes between ethnic groups it was necessary to 
combine the Asian and other ethnic sub-groups. The Chi-squared test showed that there 




































Age (yr)  336 
 
57 (15) 57 (16) 54 (17) 0.58 
Gender [n (% 
within gender)] 
336 Male 67 (52) 51 (40) 10 (8) 0.36 
  
Female 118 (57) 68 (32) 22 (11) 
 
Ethnic group  
n (% within 
ethnic group) 
324 White 114 (50) 87 (38) 25 (12) 0.03 
  
Black 50 (72) 16 (23) 3 (4) 
 
  
Other  16 (55) 10 (34) 3 (10) 
 
BMI (kg/m2) 308 
 
26.9 (6.7) 26.7 (5.2) 25.6 ( 6.3) 0.8 
Nutritional 
supplement use  




114 (53) 78 (36) 22 (10) 0.8 
  









145 (55) 94 (35) 26 (10) 0.92 
  
User 23 (52) 17 (38) 4 (9) 
 
Dietary folate 
intake (µg/day)  
60 
 












10.6 (3.2-21.7) 12.0 (4.1-24.0) 9.6 (6.2-22.3) 0.55 
Cigarettes/day 71   15 (5-20) 11 (5.8-20) 10 (5.3-18.8) 0.88 
Date are mean (SD) (Age, BMI and folate intake), median (IQR) (alcohol intake and cigarettes smoked) and 
frequency (%) (gender, ethnicity and nutritional supplement use)   
Differences between genotypes were assessed using Chi squared tests (gender, ethnic group, nutritional 
supplement use, and folic acid supplement use) and ANOVA (age, BMI, folate intake) and the Kruskal-Wallis 




3.3.4 Biomarkers of folate status, vitamin B12 and genomic DNA methylation by 
MTHFR C667T genotype  
 
None of the biomarkers of folate status, serum vitamin B12, or DNA methylation differed 
by MTHFR C677T genotype (Table 3.3). 
 
Table 3.3 DNA methylation, tissue folate, systemic folate biomarkers and vitamin B12 
by the MTHFR genotype 
   
CC (n=185) CT (n=119) TT (n=32) 
 
  





335 4.30   3.90-4.78 4.23 3.80-4.60 4.22 3.65-4.70 0.54 
Serum folate 
(nmol/l) 
332 26.1 17.9-38.5 24.5 16.4-38.3 25.4 15.7-33.5 0.40 
Red cell folate 
(nmol/l)  




335 0.89 0.59-1.26 0.88 0.56-1.21 0.90 0.52-1.36 0.91 
Serum vitamin 
B12 (pmol/l)  




330 15.6  12.3-
21.0 
16.2 13.5-16.2 17.8 9.80-11.6 0.30 
Data are median (IQR). The Kruskal-Wallis test was used to test for differences between genotypes 
 
3.3.5 Association between demographic variables and biomarkers of folate status, 
and genomic DNA methylation  
 
There were no significant relationships between genomic DNA methylation and colonic 
tissue folate, serum or red cell folate, serum vitamin B12 and plasma homocysteine. Red 
cell folate was tending towards significance but weakly and non-significantly (Table 3.4 















335 0.03 0.61 
Serum folate 332 -0.001 0.98 
Red cell folate  330 -0.10 0.08 
Serum vitamin B12  332 -0.03 0.57 
Plasma 
homocysteine 
330 0.04 0.49 
Data are Spearman’s Rank correlation coefficient  
 
Figure 3.2 Genomic DNA methylation versus red cell folate (ρ= - 0.10, P=0.08, n=329) 
 
  
There were no associations between genomic DNA methylation and any of the continuous 













335 -0.01 0.84 
BMI  307 -0.05 0.37 
Alcohol intake  172 -0.02 0.78 
Cigarettes smoked 71 0.01 0.93 
Dietary folate  60 0.10 0.45 
Total folate intake  60 0.20 0.13 
Data are Spearman's rank correlation coefficient  
Correlations with cigarettes and alcohol intake were tested in drinkers and smokers only 
 
3.3.6 DNA methylation by demographic and lifestyle subgroups  
 
There were no differences in DNA methylation in the colon between men and women or 




















(% methylcytosine)  
  n   Median  IQR P 
Gender 128 Male 4.30 3.90-4.80 0.35 
 
207 Female 4.20 3.80-4.70 
Ethnicity 225 White 4.20 3.80-4.70 0.48 
 69 Black 4.30 3.90-4.80 
  29 Other  4.30 3.90-4.70 
Data are median (IQR). The Mann-Whitney test was used to assess differences 
between males and females and the Kruskal-Wallis test was used to assess 
differences in ethnic groups. 
 
 Additionally, there were no differences in DNA methylation between smokers and non-



























Table 3.7 Genomic DNA methylation by smoking, drinking and supplement use 
 
 
DNA Methylation  
(% methylcytosine)  
  n   Median IQR P 
Smoking 243 Non smoker 4.30 3.90-4.70 0.65 
 
71 Smoker 4.30 3.80-4.70 
 
    
 
Drinking 136 Non drinker 4.30 3.90-4.70 0.64 
 
172 Drinker 4.20 3.80-4.70 




214 Non-user 4.20 3.90-4.70 0.94 
 
95 User 4.30 3.90-4.70 
Folic acid 
supplement use 
264 Non user 4.40 3.90-4.90 0.49 
 
44 User 4.30 3.80-4.70 
Data are median (IQR). The Mann-Whitney test was used to assess differences in genomic DNA 




3.3.7 Multiple linear regression 
 
Multiple linear regression was used to assess the relationship between DNA methylation 
in the colonic mucosa (which was added as the dependent variable) and the predictor 
variables MTHFR C677T genotype (CT or TT with CC as the reference variable), and 
biomarkers of folate status which were ranked (Table 3.8a). DNA methylation was not 
associated with any of the predictor variables apart from red cell folate where there was 











Table 3.8a ANCOVA model with genomic DNA methylation as the dependent variable 
and the MTHFR C677T genotype, biomarkers of folate status and serum B12 as the 
predictors (n=336) 
 








CT -0.03 0.79 
TT -0.12 0.43 
Serum folate  0.001 0.44 
Red cell folate  -0.001 0.08 
Tissue folate  0.0002 0.83 
Plasma homocysteine  0.0003 0.66 
Multiple linear regression model (Forced Entry). 
All folate biomarkers are ranked variables. 
Model summary: Adjusted R square = -0.007, F= 0.75, P=0.61 
 
 
The same relationship was investigated with additional adjustments made for age, 
gender, ethnicity (black or other, with white as a reference), supplement use (user or non-
user), and serum vitamin B12 (Table 3.8b). The relationship between DNA methylation and 
red cell folate described in the above model was no longer observed after adjustment 














Table 3.8b ANCOVA model with genomic DNA methylation in colonic mucosa as the 
dependent variable and the MTHFR C677T genotype, biomarkers of folate status and 
serum B12 as the predictors (n=336)  





CC (reference)   
CT -0.04 0.68 
TT -0.18 0.27 
Serum folate 0.001 0.52 
Red cell folate 0.00 0.43 
Tissue folate  0.001 0.47 
Plasma homocysteine  0.001 0.44 
Age -0.01 0.12 
Gender 0.03 0.80 
White ethnic  group (reference) 
  
Black ethnic group 0.01 0.89 
Other ethnic group -0.02 0.87 
Supplement user -0.05 0.63 
Multiple linear regression model (Forced Entry). 
All folate biomarkers are ranked variables. 
Model summary: Adjusted R square = -0.02, F= 0.59, P=0.84 
 
3.4 Discussion 
The aim of this cross-sectional study was to investigate the influence of folate and the 
MTHFR C677T polymorphism on genomic DNA methylation in the colon. Volunteers 
without neoplasia were selected for inclusion with the aim of excluding potentially 
confounding effects of cancer on DNA methylation in the colon. DNA methylation was 
quantified using a sensitive LC-ESI-MS/MS approach and both colonic tissue and systemic 
folate were measured for comprehensive characterization of folate status.  
 
There were three main findings in the present study which are described below (1-3): 
1. DNA methylation, an intermediate marker of colorectal cancer, did not differ by 
MTHFR C677T genotype.  
2. There were no significant associations observed between DNA methylation and 
any of the biomarkers of folate status (in blood or colonic mucosa), or dietary 
intake or folate supplementation. DNA methylation in colonic tissue was non-
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significantly and inversely associated with red cell folate (DNA hypomethylation 
was associated with increases in red cell folate). 
3. DNA methylation in the colon was not associated with demographic variables and 
lifestyle variables (age, BMI, cigarettes smoked, alcohol intake, dietary and total 
folate intake).  
 
The only association observed with DNA methylation in the current study was an inverse 
relationship with red blood cell folate. This is contradictory to previous work in this group 
where a non-significant weak, positive association was seen with DNA methylation and 
both serum and red cell folate (P = 0.07 and P = 0.08, respectively) in subjects without 
neoplasia (Pufulete et al., 2005b). The important difference between the two studies is 
the assay that was utilised. The previous study used the methyl acceptance assay to 
measure DNA methylation, while the current study used LC-ESI-MS/MS. A parallel study 
led by another student demonstrated that gene-specific DNA methylation was also 
unaffected by the MTHFR C667T genotype in the same population (Hanks et al., 2013). 
Similar findings have also been reported in patients with resected colorectal adenomas 
(Figueiredo et al., 2009b). 
 
Associations between folate status and DNA methylation have been observed with the 
methyl acceptance assay (Cravo et al., 1994, Cravo et al., 1998, Pufulete et al., 2005a) but 
these findings have not been replicated using other global DNA methylation  
 
The influence of the MTHFR C677T genotype and folate on DNA methylation in the colonic 
mucosa has previously been examined in subjects with a history of neoplasia. Figueiredo 
et al., (2009) studied 388 subjects participating in a trial testing the efficacy of aspirin and 
folic acid in the prevention of colorectal adenomas. They measured DNA methylation by 
pyrosequencing for LINE-1 repetitive elements (surrogate measure of global DNA 
methylation) on normal-appearing colonoscopy specimens from the left and right colon. 
In agreement with findings in this chapter, global DNA methylation was not influenced by 
the MTHFR genotype and showed no association with demographic or lifestyle 
characteristics, plasma B6 and dietary folate. Interestingly, DNA methylation differed 
significantly between the left and right side of the colon which suggested site-specific 
differences in DNA methylation of the colonic mucosa. It is important to note that though 
normal colonic tissue was collected in the Figueiredo study, these subjects had previously 
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resected adenomas and neoplasia could have had a significant effect on the DNA 
methylation status of the remaining normal colonic tissue (Esteller et al., 2000). 
 
In another study, methylation of LINE-1 repetitive elements was investigated in paired 
samples of tumour tissue and normal mucosa in a cohort of 178 subjects. Lower levels of 
LINE-1 DNA methylation were observed in patients with the MTHFR C677T and A1298C 
polymorphism haplotype (low activity genotype) than in the wild types (~5%; P=0.033)  
(Iacopetta et al., 2007). 
 
A lack of association between the MTHFR TT genotype and DNA methylation in healthy 
subjects has been previously reported by our group (described above) in a much smaller 
cross-sectional study of folate-replete subjects (n=68) without colorectal polyps or cancer 
(Pufulete et al., 2005b) in this study a non-significant, weak positive association was found 
between genomic DNA methylation and and the MTHFR C677T genotype. In contrast, a 
non-significant negative correlation (P=0.08) between red cell folate and genomic DNA 
methylation was observed in the present study (Table 3.8a), suggesting that DNA might 
be hypomethylated as red cell folate concentration increases. In the present study, 
genomic DNA methylation was quantified by LC-ESI-MS/MS, a method which has 
demonstrated superior sensitivity, precision and reproducibility (Kok et al., 2007, Friso et 
al., 2002a) over the methyl acceptance assay (Nephew et al., 2009) and the LINE-1 
approach which quantifies repetitive element DNA methylation (Figueiredo et al., 2009b, 
Wallace et al., 2010). 
 
In general, it has been reported that there is no association between the MTHFR C677T 
genotype and DNA methylation but the influence of folate on this relationship has 
produced conflicting results.  
In the present study, biomarkers of folate status were not found to influence genomic 
DNA methylation. Additionally, neither folate intake from diet or supplementation 
affected DNA methylation. However, availability of data on folate intake was 
disappointingly low due to FFQ completion by only 60 subjects (18%). The reason for this 
was that on the day of colonoscopy it was inappropriate to expect subjects to complete a 
long questionnaire prior to their procedure as they were often nervous and anxious, while 
after their procedure many patients were still affected by sedation from the procedure. 
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Patients who had not been sedated were asked to complete the questionnaire before 
leaving the hospital. If this was not possible it was difficult to find an opportunity where 
patients could complete the questionnaires at a later date because most did not have to 
return to the hospital for further follow-up.  
 
A possible limitation of the present study is that although these patients were deemed 
neoplasia free, they had all been referred for colonoscopy because of gastrointestinal 
problems and colonic symptoms such as bloating, bleeding or change in bowel habit 
(usually diarrhea or constipation). Though there were no obvious signs of clinical 
pathology on colonoscopy or histology, inflammatory bowel diseases are a known risk 
factor for CRC (World Cancer Report, 2014). Therefore it cannot be ruled out that the 
underlying causes of these symptoms did not in some way affect DNA methylation in the 
colon, nor that these causes could be associated with folate status. Additionally, in 
Chapter 2, an overview of colorectal mucosal biopsy collection and a range of biopsy 
sizes is described (5-64mg) and this considerable heterogeneity in sample size is likely 
to have influenced the proportion of cell types contained in each sample which may 
have in turn affected molecular measurements made on these biopsies due to different 
cell types having different levels of DNA methylation and uracil misincorporation. As 
described in Chapter 1, the range of methodology in the literature  indicates variation in 
these endpoints depending on the tissue assayed i.e  between lymphocytes, leucocytes, 
and colonic biopsies so it is assumed that this wide variability in size range would add to 
the variability of the readings and potentially introduce less reliability. 
As discussed above, findings on the influence of the MTHFR C677T genotype and 
biomarkers of folate status on global DNA methylation have been inconsistent. This is not 
surprising given the variation in study designs and the populations studied. Neoplasia free 
and cancer patients have been studied with vastly different sample sizes and demographic 
variables while different methodologies have been used to quantify DNA methylation. In 
addition, colonic samples have been collected from variable anatomical sites and different 
peripheral or tissue-derived cell types have been analysed. More work is needed to 
explain the relationship between folate and DNA methylation when other polymorphisms 
are considered (in addition to MTHFR C677T) and with contributions from other 1-carbon 
sources such as choline and betaine, in the methylation reaction which make this 
interaction complex. These complexities may be addressed in part by genome-wide 
analysis of DNA methylation which enables analysis of multiple polymorphisms and 
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mutations in candidate genes, and by taking into account the potential effects of other 
vitamins to obtain a more comprehensive picture (Crider et al., 2012, Cheng et al., 2015).  
In summary, this study found that the MTHFR C667T genotype and folate status did not 
influence genomic DNA methylation in the colon of this cohort. Inclusion of well-matched 
neoplasia-free subjects was important for minimizing the potential effects of cancer on 
DNA methylation in the colon. The subjects included in this study all possessed normal or 
high folate levels and folate biomarkers did not differ between genotypes. Further work 
is needed to verify the protective mechanism of the MTHFR C667T genotype on DNA 









































4  The association between the MTHFR C677T genotype and folate status with 
uracil misincorporation in DNA in the colon of subjects without colorectal 




Folate is essential for the conversion of deoxyuridylate to thymidylate but when folate 
supply is limited, thymidylate levels are depleted. As a result, uracil can be 
misincorporated into the DNA. Uracil misincorporation may cause DNA double-strands 
breaks, chromosomal instability and eventually neoplasia (Sharp and Little, 2004).  
 
There have been no large studies looking at the influence of folate status and the MTHFR 
C677T genotype on uracil misincorporation into DNA in colonic cells of humans without 
previous or current colorectal adenomas or cancer. Uracil misincorporation can be 
measured by simply measuring the uracil content of DNA since DNA should not normally 
contain uracil. 
 
4.1.1 Hypothesis  
 
Folate status and the MTHFR C677T mutation are associated with uracil misincorporation 
in the colon of subjects without colorectal adenoma or cancer.  
4.1.2 Aims 
 
1. To investigate the association between the MTHFR C667T genotype and uracil 
content of DNA in the colon of subjects without colorectal adenoma or cancer. 
2. To investigate the association between folate status and uracil content of DNA in 
the colon of subjects without colorectal adenoma or cancer. 
 
 
4.1.3 Objectives  
 
1. To determine the MTHFR genotype using restriction fragment length 
polymorphism (RFLP) analysis in blood cells of all study subjects.  
2. To determine serum and red cell folate, vitamin  B12 and homocysteine status in 
blood using competitive immunoassay status and folate status in colonic mucosa 





3. To quantitatively determine uracil content of DNA in colorectal mucosa by gas 
chromatography mass spectrometry (GCMS) and investigate associations with the 




4.2.1  Subject recruitment  
 
A total of 336 study participants were included, all of whom provided blood samples for 
the analysis of systemic folate biomarkers and mucosal biopsies for analysis of tissue 
folate levels and DNA uracil content. Due to time constraints, it was only possible to 
determine uracil content in the DNA of 236 subjects. Subject recruitment, inclusion and 
exclusion criteria, demographic data collection, and dietary folate data, blood and tissue 
sample collection are described in detail in Chapter 2, Sections 2.1-2.5.  
 
4.2.2 Laboratory Methods 
 
In brief, uracil content in DNA was determined by extraction of DNA followed by gas 
chromatography mass spectrometry (GCMS). Details on blood assays, MTHFR genotyping 
and the determination of tissue folate and uracil content in DNA can be found in methods 
detailed in Chapter 2, Section 2.7.  
 
4.2.3 Statistical analysis 
 
All data were analysed by using IBM® SPSS® version 21. Subject characteristics and dietary 
and lifestyle data are displayed as mean (SD) and frequency (%). 
 
Systemic folate biomarkers, vitamin B12 and colonic folate in the uracil analysis group 
(n=236) were compared with the group for whom uracil was not analysed (n=100). This 
was to investigate whether the uracil sub-group was representative of the whole sample. 
 
Balance between the group who had uracil content results (n=236) and the group for 
whom uracil could not be analysed (n=100) was compared using the unpaired t-test for 
subject characteristics and dietary and lifestyle variables. Biomarkers are displayed as 
median (interquartile range) as they were not normally distributed and differences 
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between the groups with and without uracil results were tested using the Mann Whitney 
test.  
 
Differences in uracil content between genotypes were compared using the Kruskal-Wallis 
test. Spearman’s rank correlation coefficients were used to look for associations between 
uracil misincorporation and folate biomarkers because data were not normally 
distributed. 
 
Spearman’s rank correlation coefficients were also used to test for associations between 
uracil content and demographic variables (age, BMI, dietary folate intake, total folate 
intake, number of cigarettes smoked and amount of alcohol consumed). 
 
Differences in uracil content between groups were assessed using the Mann Whitney test 
(gender, smoking status, drinking status and nutritional and folic acid supplementation) 
and the Kruskal Wallis test (ethnicity). 
 
Multiple linear regression was used to assess whether uracil content could be predicted 
from any of the independent variables. Forced Entry, or ‘Enter’ in SPSS, was selected as 
the method of Multiple Linear Regression. This method relies on theoretical justification 
for the selection of predictor variables. All predictors are entered into the model at the 
same time and in no particular order. Uracil content (ranked) was added to the model as 
the dependent variable and the following variables were added to the model as the 
independent predictor variables: MTHFR C677T genotype, tissue folate, serum and red 
cell folate, plasma homocysteine and serum vitamin B12 (ranked). In a second model, 
adjustments were made for demographic variables (age, sex, ethnic group, BMI, smoking, 
nutritional supplement use, and alcohol intake). For the categorical predictor variables, 
MTHFR C677T, CT and TT were tested against CC as the reference group and for ethnicity 







4.3 Results  
 
4.3.1 Characteristics and habitual dietary and lifestyle data  
 
General demographic and folate characteristics of the 236 subjects in the uracil test group 
are shown next to the group for whom there were no uracil results (Table 4.1). Statistical 
analysis showed that there were no differences in demographic variables between 
subjects in the two groups. The majority of subjects were white (67%) followed by black 
subjects (21%) reflecting the local population in South East London. Approximately 75% 
of the population were non-smokers and 45% were non-drinkers. Only 27% of subjects 
took nutritional supplements (multivitamins from various companies) and 14% took daily 
folic acid supplements. Data on dietary folate intake was only available for 33 subjects 


























Table 4.1 Subject characteristics, dietary and lifestyle characteristics in subjects with 
uracil results and those without uracil results 
   
n 










Age  (Years) 236 
 
56 (16) 100 57 (16) 0.62 
Gender [n (%)]            236 Male 98 (42) 100 30 (30) 0.06 
                                      
 




Ethnic group [n (%)]                228 White 159 (70) 95 66 (69) 0.90 
                    
 




Other 19 (8) 
 
10 (11) 
BMI (kg/m2) 236 
 
27.2 (6) 100 26.3 (6) 0.23 
Supplement use [n 
%)]     
219 Non-user  159 (73) 89 55 (61) 0.07 
                                                  
 




Folic acid supplement 
use [n (%)]  
219 Non-user  189 (86) 89 76 (85) 0.90 
  
User 30 (14) 
 
13  (15) 
 









Total folate intake 









Drinking  [n (%)]     222 Non-
drinker 
99 (45) 93 44 (47) 0.13 
  
Drinker 123 (55) 
 
49 (53) 
Smoking [n (%)]       221 Non-
smoker 
171 (77) 93 72 (77) 0.38 
  
Smoker 50 (23) 
 
21 (23) 
MTHFR genotype 236 CC 130 (55) 100 55 (55) 0.17 
  
CT 80 (34) 
 
39 (39) 
    TT 26 (11)   6 (6) 
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Date are mean (SD) (Age, BMI and folate intake), median (IQR) (alcohol intake and number of 
cigarettes smoked) and frequency (%) (gender, ethnicity and nutritional supplement use). 
Differences between the two groups were assessed using t-tests for continuous variables (age, 
BMI, folate intake, cigarettes smoked) and Chi Squared tests for categorical data (gender, 
ethnicity, supplement use, drinking, smoking and MTHFR genotype) and the Mann-Whitney 
test for cigarettes smoked and alcohol intake.  
 
4.3.2 Biomarkers of folate status and serum B12  
 
Systemic and colonic folate biomarkers in the uracil analysis group (n=236) were 
compared with the group for whom uracil was not analysed (n=100) (Table 4.2). 
Biomarkers in the group for whom uracil was reported were broadly representative of the 
group where uracil content was not analysed, except plasma homocysteine which was 
significantly higher in the uracil-tested group (P=0.02). 
 
Table 4.2 Folate biomarkers: a comparison of subjects with uracil results and 




















































4.3.3 Uracil content by MTHFR C677T Genotype  
 
Median uracil content in DNA (taken from colonic mucosa) for the cohort was 5.1pg/µg 
(IQR 3.2-8.5) Uracil content by genotype is displayed in Table 4.3 where it can be seen that 
there were no differences between the three MTHFR C677T genotypes. 
 
Table 4.3 Uracil content according to MTHFR C677T Genotype 
 
  
Uracil  (pg/µg)   
MTHFR 
C677T 
n Median IQR P value 
CC 130 5.00 3.35-8.35 0.99 
CT 80 5.05 2.73-8.80 
TT 26 5.30 3.63-8.05 
Data are median (IQR). Differences between the MTHFR C677T genotypes were 
tested using the Kruskal-Wallis test 
 
4.3.4 Association between uracil content and DNA methylation and biomarkers of 
folate status and vitamin B12 in the colon  
 
Next, uracil content in DNA was tested for associations with DNA methylation, and then 
for associations with folate biomarkers. No association was observed with uracil content 
and DNA methylation, or with colonic tissue folate, homocysteine, serum vitamin B12 
(Table 4.4). The exception was with serum folate which showed a positive association with 
uracil content in DNA (ρ =0.20; P=0.02), this relationship is also depicted in Figure 4.1 and 














Table 4.4 Association between uracil content in DNA and genomic DNA methylation 





DNA Methylation (% methylcytosine)  236 -0.03 0.70 
Colonic tissue folate (nmol/g) 235 0.08 0.20 
Serum folate (nmol/l) 233 0.20 0.02 
Red cell folate (nmol/l) 230 0.13 0.06 
Serum vitamin B12 (pmol/l) 232 0.04 0.56 
Plasma homocysteine (mmol/l) 233 -0.004 0.95 
Data are Spearman's Rank correlation coefficient 
 
 

















4.3.5 Differences in uracil content in the colon between demographic and lifestyle 
subgroups  
 
There were no differences in uracil content between men and women, or between 
ethnic groups (Table 4.5).  
 





n   Median IQR P 
Gender 98 Male 5.00 3.50-9.45 0.37 
 138 Female 5.10 2.95-7.85 
Ethnicity 159 White 5.05 3.00-8.80 0.66 
 
50 Black 4.80 3.20-7.13 
  
19 Other  5.50 3.80-9.30 
Data are median (IQR). Differences in uracil content in DNA were assessed using 
the Mann-Whitney test for gender and the Kruskal-Wallis test for ethnic groups 
 
Uracil content was significantly higher (6.10 pg/µg) in the DNA of nutritional 
supplementation users than in non-users (4.80 pg/µg) (P=0.01) (Table 4.6, Figure 4.3). 
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Additionally, there were no differences in uracil content between smokers and non-
smokers or drinkers and non-drinkers.   
 
Table 4.6 Uracil content in DNA by smoking, drinking and supplement use subgroups 
 
   Uracil (pg/µg) 
  n   Median IQR P 
Drinking 123 Non-
drinker 
5.50 3.40-8.80 0.27 
 99 Drinker 4.85 2.98-7.80 
Smoking 171 Non-
smoker 
5.05 3.30-8.80 0.72 
 50 Smoker 5.25 3.13-7.35 
Nutritional 
supplement use 
158 Non-user 4.80 2.98-7.20 0.01 
 60 User 6.10 3.90-9.88  
Folic acid supplement 
use 
188 Non-user 4.90 3.20-7.68 0.06 
 30 User 6.70 3.20-10.9  
Uracil content is displayed as median and IQR. The Mann-Whitney test was used to assess 
differences in uracil content between groups. 
 
The significant difference in uracil content in DNA between nutritional supplement users 
and non-users is also depicted below in a boxplot. Circles represent outliers and stars 



















4.3.6 Associations between uracil content in DNA in the colon and demographic and 
lifestyle characteristics 
Spearman’s Rank correlation showed no associations observed between uracil content 
in DNA and age, BMI, dietary or total folate intake, alcohol quantity consumed, or 




















Age  236 -0.02 0.72 
BMI  236 0.07 0.28 
Dietary folate intake 33 0.001 1.0 
Total folate intake  33 0.08 0.68 
Alcohol intake   123 -0.02 0.82 
Cigarettes smoked  50 -0.04 0.53 
Data are Spearman's rank correlation coefficient  

































4.3.7 Multiple linear regression 
 
Multiple linear regression (Forced Entry method) was used to assess the relationship 
between ranked variable uracil content as the dependent variable, the MTHFR C677T 
genotype (CT or TT with CC as the reference variable) and each of the biomarkers of folate 
status and vitamin B12 which were all ranked. The weak association with red cell folate 
disappeared. As seen with Spearman’s correlation, serum folate was positively associated 
with uracil content (β=0.19, P=0.03) however the overall model was not significant (Table 
4.8a).  
 
Table 4.8a ANCOVA model with uracil content in DNA as the dependent variable and 







MTHFR C677T   
CC (reference)   
CT 0.60 0.95 
TT -6.16 0.69 
Serum folate (nmol/l) 0.19 0.03 
Red cell folate (nmol/l) 0.05 0.55 
Colonic tissue folate (nmol/g 
tissue) 
0.01 0.93 
Serum vitamin B12 (pmol/l) 0.005 0.95 
Plasma homocysteine (µmol/l) 0.06 0.44 
Multiple linear regression model (Forced Entry). 
All folate biomarkers are ranked variables. 














In a second model, further adjustment was made for DNA methylation, age, gender, 
ethnicity (black or other, with white as a reference) and supplement use (user or non-user) 
whilst excluding each of the folate biomarkers to see if it affected the model. With 
additional adjustment for these demographic and lifestyle variables and with plasma 
homocysteine removed, the positive association between uracil content and serum folate 
became more significant (β=0.22, P=0.02). A positive association with supplement use was 
observed (β =27.3 P=0.01) and the overall model was significant (P=0.09) (Table 4.8b).  
 
 
Table 4.8b ANCOVA model with uracil content in DNA as the dependent variable and 
the MTHFR C677T genotype, biomarkers of folate status, demographic and lifestyle 








MTHFR C677T   
CC (reference)   
CT 1.08 0.92 
TT -4.57 0.77 
Genomic DNA methylation  
(% methylcytosine) 
-0.02 0.82 
Serum folate (nmol/l) 0.22 0.02 
Red cell folate (nmol/l) 0.05 0.61 
Tissue folate (nmol/g tissue) 0.03 0.73 
Serum vitamin B12 (pmol/l) -0.05 0.57 
Plasma homocysteine (µmol/l) 0.09 0.31 
Age (years) -0.39 0.27 
Gender -15.0 0.14 
Ethnicity White (reference)   
Black ethnic group 1.34 0.89 
Other' ethnic group -5.20 0.63 
Supplement user 27.3 0.01 
Multiple linear regression model (Forced Entry). 
All folate biomarkers are ranked variables. 








The aim of this chapter was to examine whether folate status and the MTHFR C667T 
polymorphism influenced uracil DNA misincorporation in the colonic mucosa and to 
examine possible associations between uracil content and demographic and lifestyle 
variables. Uracil content in DNA was determined using gas chromatography mass 
spectrometry (GCMS) and both colonic tissue and systemic folate were measured for 
comprehensive characterisation of folate status.  
 
There were four main findings in the present study which are described below (1-4): 
1. Uracil content did not differ by MTHFR C677T genotype.  
2. Uracil content in colonic tissue was positively associated with serum folate and 
red cell folate (non-significantly) but there were no associations with the other 
folate biomarkers or serum B12. 
3. Uracil content in colonic mucosa was higher in nutritional supplement users than 
in non-users. 
4. There were no associations between uracil content and all other demographic 
variables (age, BMI, cigarettes smoked, alcohol intake, and dietary and total folate 
intake).  
 
Uracil analysis was performed on 236 subjects from the original cohort of 336 healthy 
participants. Colonic DNA was previously used for quantitation of DNA methylation, 
genotyping and for the determination of tissue folate. 100 individuals could not be 
included due to lack of sufficient DNA remaining for uracil analysis. Nevertheless, the 
uracil cohort was broadly representative of the larger cohort with no differences observed 
between demographic and lifestyle characteristics or biomarkers apart from plasma 
homocysteine which was significantly higher in the uracil-tested group. 
 
Median uracil content in DNA from colonic mucosa for the entire cohort was 5.1 pg/µg 
(IQR 3.2-8.5). When tested by the MTHFR C667T genotype there was no effect, suggesting 
that the MTHFR C667T polymorphism conferred no significant protective effect on uracil 
misincorporation in pathology-free subjects with adequate folate status (Table 4.3). A 
similar observation was previously reported by Narayanan et al. (2004), who examined 
lymphocytes and showed that markers of DNA stability (including strand breaks, 
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misincorporated uracil and global DNA methylation) did not differ between the three 
MTHFR C667T variants (Narayanan et al., 2004). In line with these findings, there was no 
relationship observed between the two primary endpoints, genomic DNA methylation 
(tested as genomic DNA hypomethylation) and uracil misincorporation (tested as uracil 
content), in the colonic mucosa of this cohort.  
 
In this chapter a significant positive correlation was found between serum folate and 
uracil content in DNA). Uracil content in the colon was higher in nutritional supplement 
users than in non-users  but no differences were seen between folic acid users and non-
users and no associations were seen with dietary folate alone or total folate intake 
(dietary plus supplements). Thus, the data suggests that in this cohort of subjects with 
adequate folate status, who were free of colorectal neoplasia or other obvious colonic 
pathologies, uracil misincorporation into DNA in the colon is positively associated with 
systemic folate and increased in subjects who take folate containing daily nutritional 
supplements. Whether this increase in uracil content in nutritional supplement users 
reflects confounding effects of other micronutrients (such as vitamin B12 which also plays 
a prominent role in 1-carbon metabolism) contained in the nutritional supplements is not 
known and would require further investigation. These findings are intriguing given that 
folate deficiency is generally associated with DNA hypomethylation and increased uracil 
misincorporation into DNA. ((Choi and Mason, 2000, Linhart et al., 2009). 
 
More specifically, older in vitro studies using different cell types have indicated an inverse 
relationship between folate levels and uracil misincorporation (Libbus et al., 1990, Branda 
et al., 1997, James et al., 1994, Wickramasinghe SN, 2009, Melnyk S1, 1999) and animal 
studies have reported elevated uracil misincorporation following depletion of dietary 
folate (James and Yin, 1989, Duthie et al., 2000a, Linhart et al., 2009). In humans, McGlynn 
et al. (2013) compared folate levels and uracil misincorporation in cultured colonocytes 
isolated from biopsy specimens from specific regions of the colon in patients with either 
adenomatous or hyperplastic polyps (n=56) and disease-free controls (n=53). They 
reported a significant inverse relationship between folate levels and uracil 
misincorporation in polyps but this was not observed in cells derived from normal mucosa. 
They also found that folate levels in the normal mucosa of subjects with adenoma were 
significantly lower than those in anatomically matching colonic segments taken from 
healthy individuals. The authors proposed that localised folate deficiency in specific 
regions of the colon might be carcinogenic due to elevated uracil misincorporation and 
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DNA hypomethylation. Folate deficiency could promote carcinogenesis while tumours 
might also deplete folate from the surrounding tissue (McGlynn et al., 2013).  
 
In a very recent study of patients with adenomatous polyps, who were assigned to receive 
600µg/day folic acid or placebo for six months, an increase in colonic mucosal folate was 
observed with a decrease in uracil misincorporation in the mucosa adjacent to the polyp 
(P=0.05). These results led the authors to conclude that site specific folate depletion 
(adjacent to the adenomatous polyp) may have become replete in response to 
supplementation (O'Reilly et al., 2016). 
 
Hazra et al. (2010) found that folic acid supplementation for 3 years (1 mg/day) combined 
with aspirin, conferred no influence on uracil misincorporation in the rectal mucosa or in 
white blood cells in subjects who were replete in folate and with a history of colorectal 
adenoma (Hazra et al., 2010). Importantly, these authors suggested that additional large-
scale studies are needed to clarify if uracil misincorporation is an important risk factor in 
CRC.  
Moreover, previous studies in animal models have suggested that folate can promote 
carcinogenesis once a neoplasm has been established (Kim et al., 1996b, Song et al., 
2000b). Kim et al. (2011) suggested that uracil misincorporation might be influenced by 
age and found that young mice showed an increase in uracil misincorporation into DNA 
when folate intake was increased (P=0.03) but, in contrast, this positive association was 
not seen in older mice at the upper limit of age (22 months) (Kim et al., 2011a). 
 
In human subjects with a history of colorectal adenomas, high dose folic acid (5mg/d) 
administered for six months together with vitamin B12 (1.25mg/day) induced an increase 
in uracil misincorporation in the rectal mucosa as a result of folic acid supplementation 
though this was not significant when compared with increases seen in the placebo group 
(van den Donk, 2007). This appears to be the only study in humans which is in agreement 
with the results of the current study. 
It is important to note that, although neoplasia-free, subjects were admitted to hospital 
as day patients because they had experienced symptoms of colonic pathology and 
underwent diagnostic sigmoidoscopy. Thus, other underlying pathology of the colonic 
mucosa which might influence uracil misincorporation cannot be completely excluded.  
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In summary, uracil misincorporation into DNA in the colonic mucosa of healthy subjects 
with adequate folate levels was influenced by serum and red cell folate (marginally) aswell 
as nutritional supplementation but was not influenced by the MTHFR C667T 
polymorphism or demographic and lifestyle characteristics. To the best of the author’s 
knowledge, this is the first time a positive correlation between folate levels and uracil 
misincorporation in the colonic mucosal DNA of neoplasia-free subjects with adequate 
folate status has been observed. This unexpected observation may reflect localised 










































5  Colonic tissue folate measurements and whether they are predicted by systemic 





Folate has long been associated with colorectal cancer risk. Low folate status and dietary 
folate intake has generally been associated with an increased risk of colorectal cancer in 
meta-analyses (Sanjoaquin et al., 2005, Kennedy et al., 2012). Reports on the relationship 
between systemic folate levels and colorectal cancer risk have been less consistent. This 
might be due to the sensitivity and precision of the assays because small changes in folate 
levels may not be detected in routine blood analysis (Kim et al., 1998). Thus, the precise 
relationship between folate and cancer risk may not have been fully assessed. It has also 
long been established that vulnerability to folate depletion is tissue specific (Varela-
Moreiras and Selhub, 1992) and it is not clear whether a relationship exists between 
systemic folate concentrations and folate levels in the colonic mucosa, the site where 
colonic carcinogenesis is initiated. Additionally, folate in the colonic mucosa is not 
exclusively derived from the blood and may also come from intestinal luminal folates in 
the colorectum (Camilo et al., 1996).  
 
In a study of women taking pharmacological doses of folate depleting contraceptive pill, 
subjects were observed to have megaloblastosis in the cervico-vaginal cells whereas the 
controls were not seen to have this change. This is an abnormality caused by impaired 
DNA synthesis, often arising from folate and vitamin B12 deficiencies. Perhaps surprisingly, 
these cellular changes did not correlate with serum folate and vitamin B12 depletion, and 
they returned to normal once the contraception was ceased. The authors of this study 
concluded that folate metabolism is organ specific (Whitehead et al., 1973).  
 
The issue of whether systemic folate status may predict folate levels in human colonic 
mucosa has been much debated. Folate status has been significantly and positively 
associated with dietary intake and systemic folate markers (serum, red cell folate, plasma 
homocysteine) (Kim et al., 1998, Kim et al., 1996b, Kim et al., 2000) whereas in other 
studies no correlation was observed (Meenan et al., 1996). 
 
 Reports on folate status specifically in the colon have largely been derived from studies 
of subjects with CRC, including polyps and adenoma, which may confound results due to 
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complicated mechanisms involved in cancer development and progression, and the 
involvement of folic acid in 1-carbon metabolism (Kim et al., 2011b). 
 
There were two aims in this chapter. Firstly to investigate whether systemic markers of 
folate status (serum, red cell folate, plasma homocysteine) and serum vitamin B12 reflect 
colonic mucosal folate levels. A microbiological assay already present in this laboratory 
from a previous experiment carried out by the current investigator for an MSc project (Kim 
et al., 1998, Kim et al., 2001) was modified. The concentration of folate in small biopsies 
of colonic mucosa obtained from neoplasia-free subjects was measured and compared 
with folate in their blood samples. The second aim was to investigate whether the MTHFR 





1. Folate status in the colon is influenced by the MTHFR C677T genotype, 
demographic and lifestyle factors. 





1. To determine whether systemic markers of folate status reflect colonic folate 
status. 
2. To determine the influence of the MTHFR C677T genotype, demographic and 
lifestyle factors on colonic folate levels.  
5.1.3 Objectives 
 
1. To quantify folate levels in colonic mucosal biopsies using a microbiological assay 
(MBA). 
2. To compare colonic folate levels with systemic markers of folate status. 
3. To investigate the influence of MTHFR C677T genotype, demographic and lifestyle 





5.2.1 Subject recruitment 
 
Folate analysis in this chapter was performed on the same cohort of 336 healthy subjects 
participating in the cross-sectional Study 1 (detailed in Chapter 3). All patients provided 
blood samples for determination of systemic markers of folate status and vitamin B12, and 
mucosal biopsies for determination of colonic mucosal folate. Subject recruitment, 
inclusion and exclusion criteria, demographic data collection, blood and tissue sample 
collection for measurement of colonic and systemic folate and the MTHFR C677T 
genotype are fully described in Chapter 2.  
 
5.2.2 Laboratory Methods 
 
Methodology for determination of colonic tissue folate and systemic markers of folate 
status and vitamin B12 are described in Chapter 2, Section 2.4 and 2.5, pages 77-87. Serum 
and red cell folate, serum vitamin B12 and homocysteine were all determined using the 
Bayer Advia Centaur® assay (Siemens Healthcare Diagnostics, US). Tissue folate was 
determined using an in-house microbiological assay which was developed for a previous 
study on folate bioavailability in food. The assay was modified to measure total folate in 
small tissue biopsies (5-64mg) using a method developed by Kim. This method is described 
previously in Section 2.5.1 (Kim et al., 1998, Kim et al., 2001) 
 
5.2.3  Statistical Analysis 
 
A power calculation was originally performed for Study 1 (see Statistical Analysis, Chapter 
3) and the same cohort of 336 healthy subjects were included in this study. 
 
All data were analysed using IBM® SPSS® version 21.  
 
Folate biomarkers were not normally distributed and therefore displayed as median (IQR), 
the range between the first and the third quartile.  
 
Differences in colonic tissue folate between two groups (gender, smoking status, drinking 
status and nutritional and folic acid supplementation) were assessed using the Mann 




Data were not normally distributed, so Spearman’s rank correlation coefficient was used 
to test for associations between colonic tissue folate and systemic markers of folate 
status. Spearman’s rank correlation coefficient was also used to test the relationship 
between colonic tissue folate and the continuous demographic variables age, BMI, dietary 
folate intake, total folate intake, number of cigarettes smoked and amount of alcohol 
consumed. Where correlations were seen with tissue folate, additional analyses were 
performed to investigate a possible relationship with the systemic markers of folate status 
and serum B12.  
 
Multiple linear regression was used to assess whether tissue folate could be predicted 
from any of the independent variables. Forced Entry, or ‘Enter’ in SPSS, was selected as 
the method of Multiple Linear Regression. All predictors are entered into the model at 
the same time and in no particular order. Tissue folate (ranked) was added to the model 
as the dependent variable and the following variables were added as the predictor 
variables: MTHFR C677T genotype, serum and red cell folate, plasma homocysteine, and 
serum vitamin B12. The Forced Entry method relies on theoretical justification for the 
selection of predictor variables. In a second model, age (continuous), gender (male or 
female), ethnic group (white, black, other), cigarettes smoked and nutritional supplement 
use (user or non-user) were all added because preliminary tests suggested there was a 
relationship. For the categorical predictor variables, MTHFR C677T, CT and TT were tested 
against CC as the reference group and for ethnicity as a categorical predictor variable, 




5.3.1 Colonic tissue folate and systemic markers of folate status  
 
Median folate concentration in the colonic mucosa for all subjects (n=336) was 0.88 (IQR: 
0.59-1.23) nmol/g tissue, which is comparable to values previously described in the 
literature (range of 0.50-1.50 nmol/g) (Kim et al., 1998).The in-house folate 
microbiological assay enabled reproducible measurement of folate in 336 small tissue 





In addition to tissue folate, median (IQR) for serum and red cell folate, serum vitamin B12 
and plasma homocysteine in all subjects are displayed in Table 5.1.  
 
 
Table 5.1 Folate biomarkers and vitamin B12 for the whole sample 
 
  n Median IQR 
Colonic tissue folate 
(nmol/g) 
336 0.88 0.59-1.20 
Serum Folate (nmol/l) 332 25.5 17.1-38.0 
Red cell folate (nmol/l) 330 965 765-1139 
Serum B12 (pmol/l) 332 313 239-428 
Plasma homocysteine 
(µmol/l) 
330 16.1 12.7-21.1 
Data are median (IQR) 
5.3.2 Blood folates as predictors of colonic mucosal folate  
 
As shown in Table 5.2 and Figures 5.1-5.4, folate in the colonic mucosa correlated 
positively with serum folate and red cell folate, serum vitamin B12 and negatively with 
plasma homocysteine. 
 
Table 5.2 Association between colonic tissue folate and systemic markers of folate 
status and vitamin B12 
 
 
  n Correlation 
coefficient 
P value 
Serum folate  331 0.46 ˂0.001 
Red cell folate  329 0.29 ˂0.001 
Serum B12 329 0.17 0.002 
Plasma homocysteine  331 -0.14 0.01 
Data are Spearman's Rank Correlation Coefficient  
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Figure 5.1 Tissue folate versus serum folate (ρ =0.46, P˂0.001, n=331) 
 
 





Figure 5.3 Tissue folate versus serum B12 (ρ =0.17, P˂0.002, n=329)  
 
 









5.3.3 Colonic tissue folate, systemic markers of folate status and serum B12, by 
demographic and lifestyle subgroups 
 
Diet and lifestyle characteristics for the whole cohort in the current study are described 
in Chapter 3 (Table 3.1). Colonic tissue folate was shown by the MTHFR C677T genotype 
and no differences were seen in tissue folate levels across the three genotypes (Chapter 
3, Table 3.3). 
 
In this chapter, colonic tissue folate was assessed by demographic and lifestyle subgroups. 
Tissue folate did not differ between genders, but serum folate, red cell folate and vitamin 
B12 were all higher in women than in men. Plasma homocysteine was lower in women 
than in men (Table 5.3). 
 
Table 5.3 Biomarkers of folate status by gender  
  Male Female 
  n Median IQR n Median IQR P 
Colonic tissue 
folate (nmol/g) 
128 0.80 0.60-1.20 207 0.92 0.60-1.30 0.60 
Serum Folate 
(nmol/l) 
125 23.6 16.1-32.1 207 27.20 12.4-41.0 0.01 
Red cell folate 
(nmol/l) 
124 911 744-1049 206 994 777-1205 0.01 
Serum B12 
(pmol/l) 




125 18.5 14.3-29.2 205 15.20 12.1-19.7 ˂0.001 
Biomarkers are displayed as median (IQR). The Mann Whitney test was used to assess 
differences in folate biomarkers and serum B12 between males and females 
 
There were no differences in colonic tissue folate, serum folate or plasma homocysteine 
between ethnic subgroups but there was a significant difference between groups for red 
cell folate and vitamin B12. Further testing between two groups using the Mann-Whitney 
test revealed red cell folate was higher in the other group than in both the white and the 
black groups. Further testing revealed that serum B12 was higher in the black than the 









White Black Other 




226 0.89 0.57-1.20 68 0.82 0.62-1.20 29 1.1 0.59-1.50 0.44 
Serum Folate  
(nmol/l) 




223 979 768-1133 67 866 739-1079 29 1063 893-1261 0.03 
Serum B12  
(pmol/l) 




221 16.5 12.9-22.2 69 15.8 12.3-19.6 28 14.9 11.6-18.2 0.20 
Biomarkers are displayed as median and IQR. The Kruskal Wallis test was used to assess differences in folate 
biomarkers between ethnic groups 
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Tissue folate was significantly higher in non-smokers than in smokers (0.97nmol/g versus 
0.65nmol/g, P˂0.001). Serum and red cell folate and serum B12 were significantly higher 
in non-smokers than in smokers but there were no significant differences in plasma 
homocysteine levels between smokers and non-smokers (Table 5.5 and Figure 5.5). 
 








71 0.65 0.46-1.10 242 0.97 0.60-128 ˂0.001 
Serum folate  
(nmol/l) 
69 20.4 13.9-30.8 242 27.6 18.0-40.6 ˂0.001 
Red cell folate 
(nmol/l) 
70 903 705-1076 241 981 786-1178 0.02 




70 18.0 13.7-22.4 238 15.8 12.8-20.9 0.14 
Biomarkers are displayed as median and IQR. The Mann Whitney test was used to assess 






Figure 5.5 Tissue folate by smokers 0.65nmol/g (n=71) and non-smokers 0.97nmol/g 
(n=242), P ˂0.001 
 
 
There were no differences in any of the folate biomarkers between drinkers and non-





























Drinker  Non-drinker 
 
  n Median IQR n Median IQR P 
Colonic tissue 
folate (nmol/g) 
171 0.90 0.61-1.30 143 0.87 0.57-1.20 0.40 
Serum Folate 
(nmol/l) 
169 26.5 18.1-39.8 143 22.9 16.3-37.4 0.10 
Red cell folate 
(nmol/l) 
172 960 766-1117 140 977 773-1183 0.30 
Serum B12 
(pmol/l) 




168 16.0 12.9-21.1 141 17.0 12.6-22.0 0.60 
Biomarkers are displayed as median and IQR. The Mann Whitney test was used to 




Colonic tissue folate was higher in the folic acid supplement user group than in the non-
user group but no differences were observed in colonic tissue folate between nutritional 
supplement users and non-users. Serum and red cell folate and vitamin B12 levels were 
higher, and plasma homocysteine was lower, in both nutritional and folic acid supplement 
users than in non-users. (Table 5.7 and 5.8). 




Non -nutritional supplement 
user 
 




95 1.0 0.60-1.30 213 0.87 0.60-1.20 0.30 
Serum folate 
(nmol/l) 
94 33.50 20.3-54.4 212 23.80 16.3-33.1 ˂0.001 
Red cell folate 
(nmol/l) 


















Biomarkers are displayed as median and IQR. The Mann Whitney test was used to 





Table 5.8 Biomarkers of folate status by folic acid supplement use 
  
FA supplement user Non -FA supplement user 
 




44 1.0 0.60-1.20 264 0.90 0.60-1.20 0.03 
Serum folate 
(nmol/l) 
43 35.10 22.0-51.0 263 24.20 16.5-36.5 ˂0.001 
Red cell folate 
(nmol/l) 
43 1045 795-1278 263 952 759-1108 0.08 
Serum B12 
(pmol/l) 






259 17.20 13.30-22.0 ˂0.001 
Biomarkers are displayed as median and IQR. The Mann Whitney test was used to 













Spearman’s rank correlation coefficient was used to investigate associations between 
colonic tissue folate and continuous demographic and lifestyle variables. Colonic tissue 
folate correlated positively with age but only marginally (ρ=0.1, P=0.05) (Table 5.9 and 
Figure 5.6).  
 
Table 5.9 Association between colonic tissue folate concentration and demographic 






Age  336 0.10 0.05 
BMI  307 -0.03 0.60 
Alcohol intake  171 0.06 0.31 
Number of cigarettes 
smoked 
71 0.09 0.47 
Dietary folate  60 0.07 0.56 
Total folate intake 60 0.14 0.29 






























Figure 5.6 Tissue folate versus age (ρ =0.10, P˂0.05, n=336) 
 
 
Due to the correlation found between colonic tissue folate and age in Table 5.9, age was 
further investigated for associations with the other folate biomarkers and serum B12. 
Serum and red cell folate were positively correlated with age and negatively correlated 
with plasma homocysteine (Table 5.10). 
 
 





Colonic Tissue Folate 
336 0.10 0.05 
Serum folate   332 0.15 0.01 
Red cell folate  330 0.20 ˂0.001 
Serum B12 332 0.07 0.2 
Plasma homocysteine  330 -0.30 ˂0.001 
Data are Spearman's Rank Correlation Coefficient with all folate 








Finally, multiple linear regression analysis was used to assess and validate associations 
with between tissue folate and systemic markers of folate status and serum B12 with 
adjustment for the MTHFR genotypes. The model revealed a positive association between 
colonic tissue folate with serum folate (β=0.37; P<0.001) (Table 5.11a). 
 
Table 5.11a ANCOVA model with colonic tissue folate as the dependent variable, and 








MTHFR C677T   
CC (reference)   
CT -3.54 0.71 
TT 3.54 0.80 
Serum folate (nmol/l) 0.36 ˂0.001 
Red cell folate (nmol/l) 0.04 0.64 
Serum B12 (pmol/l) 0.12 0.09 
Plasma homocysteine (µmol/l) 0.06 0.43 
Multiple linear regression model (Forced Entry) 
All folate biomarkers are ranked variables 
Model summary: Adjusted R square = 0.15, F= 7.55, P˂0.001 
 
 
The same model was run again with additional adjustments made for age, gender, 
ethnicity, smoking and supplementation. A positive association between colonic tissue 
folate with serum folate remained (β=0.36; P<0.001) and a non-significant negative 













Table 5.11b ANCOVA model with colonic tissue folate as the dependent variable, and 
the MTHFR C677T genotype, systemic markers of folate status, and demographic and 












CT -5.04 0.60 
TT 0.68 0.96 
Serum folate (nmol/l) 0.36 ˂0.001 
Red cell folate (nmol/l) 0.03 0.73 
Serum B12 (pmol/l) 0.11 0.16 
Plasma homocysteine (µmol/l) 0.06 0.47 
Age (years) 0.19 0.56 
Gender -5.77 0.55 
Ethnicity White (reference)   
Black ethnic group 0.12 0.99 
Other ethnic group 13.2 0.19 
Supplement user -9.24 0.37 
Smoking -20.43 0.07 
Multiple linear regression model (Forced Entry) 
All folate biomarkers are ranked variables 
Model summary: Adjusted R square = 0.17, F= 4.36, P˂0.001 
 
 
5.4 Discussion  
 
The key aim of this study was to assess the relationship between folate levels in the colonic 
mucosa and systemic markers of folate status in a neoplasia-free population with 
adequate folate status. The influence of the MTHFR C677T genotype, demographic and 
lifestyle factors on colonic folate levels was also assessed. At the time that this study was 
conducted no updates of a similar kind had been reported. It was the largest prospective 
investigation of these associations, using a cohort who presented with no evidence of any 
pathology in the colon after colonoscopy. Subjects were recruited if they were free from 
colonic adenoma, CRC or any inflammation in the mucosa. 
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There were six main findings in the current study: 
 
1. Colonic tissue folate was positively correlated with serum, red cell folate and serum 
B12 and negatively correlated with plasma homocysteine. 
2. Colonic tissue folate was significantly higher in non-smokers than in smokers. 
3. Colonic tissue folate was marginally and positively correlated with age. 
4. Colonic tissue folate levels did not differ between genders, ethnic groups, and 
drinkers and non-drinkers. 
5. Colonic tissue folate was higher in the folic acid supplement user group than in the 
non-user group but no differences were observed in colonic tissue folate between 
nutritional supplement users and non-users. 
6. Multiple linear regression revealed a positive association between colonic tissue 
folate and serum folate and a negative non-significant association with smoking. 
 
Analysis of the subjects’ blood samples showed that none of the subjects were serum or 
red cell folate deficient. Data from FFQs completed by only 60 subjects (representing 
~18% of the cohort) indicated that the population consumed adequate levels of dietary 
folate. Upon colonoscopy, none of the subjects showed any sign of neoplasia or other 
colonic pathologies, despite having originally presented with symptoms of problems with 
the large bowel. 
 
Analysis of colonic tissue folate and biomarkers in this neoplasia-free cohort revealed 
significant positive associations between systemic and colonic folate status and regression 
analysis confirmed the positive association between colonic folate levels and serum folate. 
Interestingly, the strong positive association with serum folate and colonic tissue folate 
remained the same even after adjustment in the second regression model. These results 
were consistent with findings of Kim et al. (1998) who reported that concentrations of 
colonic mucosal folate were strongly correlated with folate biomarkers in blood and, in 
particular, serum homocysteine was the most sensitive indicator of colonic tissue folate in 
their study (Kim et al., 1998). Notably, the Kim et al (1998) study used normal recto-
sigmoid mucosa, but tissues were sampled from patients with excised colorectal polyps 
which could affect the biochemical composition of anatomically related normal tissue. In 
contrast, in the current study colonic mucosa from neoplasia-free subjects was assayed. 
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Serum folate rather than homocysteine was most closely correlated with colonic tissue 
folate, however the patients in the Kim study had all had polypectomies. 
 
Associations between folate in the colonic mucosa and serum of healthy volunteers could 
be useful in assessing CRC risk but this would need validation in larger studies. Colonic 
neoplasia originates in the mucosa, and folate metabolism is a critical factor for this 
cancer. In a key review, Brockton (2006) suggested that the beneficial relationship 
between folate in the colon and reduced CRC risk might be due to the fact that folate 
facilitates DNA stabilisation in colonic tissue (Brockton, 2006). Thus, accurate and fast 
determination of folate levels by a simple biochemical blood-based test could be an 
invaluable tool to estimate CRC risk when combined with other tests, genetic associations 
and other patient-related risk factors. Such combined tests could facilitate the biological 
understanding of disease pathogenesis.  
 
Another key aim of this study was to examine the relationship between the MTHFR C667T 
genotype and folate status in normal mucosa. In the current study, colonic tissue folate 
did not differ by the MTHFR C667T genotype in the colon of a neoplasia-free cohort with 
adequate folate status. 
 
Further examination into the demographic and lifestyle characteristics of the 336 subjects 
revealed that folate levels in colonic tissue were higher in non-smokers than in smokers. 
Cigarette smoke is a known source of free radicals and a major contributor of oxidative 
stress (Burke and Fitzgerald, 2003). It has been long been established that smoking is 
associated with lowered level of serum folate and red cell folate and that the association 
remains after adjustment for dietary intake (Walmsley et al., 1999, Piyathilake et al., 1994, 
Mannino et al., 2003). Vardavas et al. (2008) reported that smokers were likely to have 
different lifestyles including drinking more alcohol, and different dietary patterns 
compared to non-smokers, with lower consumption of fruit, vegetables and fibre but 
similar amounts of meat products. These dietary habits were associated with lower levels 
of serum folate, vitamin C and antioxidants but had little effect on serum iron or vitamin 
B12 (reflecting meat consumption) (Vardavas et al., 2008). The Vardavas et al report was 
based on healthy populations and provides useful insight for the interpretation of our 




The association between dietary variations in smokers and non-smokers reported by 
Vardavas et al. could not be explored further in this study due to the small number of diet-
related FFQs returned (60/336; ~18%). Additionally, the low number of completed FFQs 
prevented the accurate assessment of possible relationships between total dietary folate 
intake (or other micronutrients). Nevertheless, in a comparison of folic acid 
supplementation users and non-users, a significant increase in colonic tissue folate was 
observed (P=0.03;). Diet and lifestyle differences described by Vardavas et al. do not 
provide an explanation for the fact that lower folate has been reported in those exposed 
to second hand smoke (Ortega et al., 2004, Ortega et al., 2010), suggesting that smoking 
reduces the absorption of folate or affects folate metabolism and other one-carbon 
components of folate metabolism (Walmsley et al., 1999), especially as smoking was also 
shown to deplete vitamin B6 and B12 in parallel with tetrahydrofolate and 5, 10-
methylenetetrahydrofolate whilst pteroylmonoglutamate (folic acid) 
formyltetrahydrofolate and 5,10-methyenyltetrahydrofolate accumulated in the tissue.  
 
This study was the first of its kind to investigate folate coenzyme distribution in tissue, but 
samples were taken from the buccal mucosa which is directly exposed to the smoke, thus 
comparison with the colon is difficult (Gabriel et al., 2006). In rats, inhibition of the 
methionine synthase vitamin B12 complex in response to nitrous oxide (a particulate in 
cigarette smoke) caused reduction in tetrahydrofolate (Horne et al., 1989).  
 
In a nationally representative US sample, of all of the multiple demographic and lifestyle 
variables, age and smoking came out as the strongest correlates of biomarkers including 
folate. Biomarker concentrations increased with age and decreased with cigarette 
smoking (Pfeiffer et al., 2013) and this is continuous with the findings reported in this 
chapter. 
 
In summary, this study demonstrates that serum folate predicts folate levels in the colonic 
mucosa in a population free from colonic neoplasia (and not deficient in folate or vitamin 
B12) but the MTHFR C667T genotype does not influence colonic folate levels in this 
population. Systemic markers of folate status showed varying associations with 
demographic, lifestyle and folate intake and there were significant differences in the level 
of folate biomarkers between the population groups in the cohort for these variables (i.e. 
gender, ethnicity, smokers and non-smokers, and users and non-users of folate 
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supplementation), after adjustment with regression analysis these associations were not 





































6  Effects of short-term folate supplementation on DNA methylation and systemic 
folate biomarkers in the colorectal mucosa of subjects without colorectal neoplasia: 
A Randomised Controlled Trial.  
 
6.1 Introduction 
Folate plays a critical role in 1-carbon metabolism during DNA synthesis and methylation, 
and defective DNA processing could lead to carcinogenesis. Impaired DNA methylation in 
colorectal cancer could be bimodal, with hypomethylation of genomic DNA and 
concomitant hypermethylation of DNA in promoter regions of tumour suppressor genes. 
Findings on the role of folate supplementation in colorectal cancer is conflicting. Folic acid 
supplementation has been reported by some to reverse genomic DNA hypomethylation 
in individuals with adenoma (Cravo et al., 1994, Pufulete et al., 2005a) while others have 
shown folic acid to has no effect in adenoma patients (Figueiredo et al., 2009a), nor in 
healthy volunteers (Fenech et al., 1998, Basten et al., 2006). A summary of previous 
randomised controlled studies investigating the effects of folate supplementation on DNA 
methylation are described in Table 1.5 (Chapter 1, Section 1.5.4.3). In Chapter 3 of this 
thesis, DNA methylation and folates in the blood (from dietary intake and 
supplementation) were investigated for associations in neoplasia-free subjects. In order 
to investigate a causal relationship in this cohort, an intervention trial with folic acid 




1. Increasing folate levels with short-term dietary supplementation influences DNA 
methylation in the colonic mucosa of subjects without colorectal adenoma or 
cancer. 





3. To determine whether short-term folate supplementation causes changes in 
systemic and colonic folate status which modify DNA methylation. 





1. To conduct a randomised, double blind, randomised controlled trial (RCT) of folic 
acid supplementation or placebo in a subset of participants from the cross-
sectional study presented in Chapter 3 (Study 1). 
2. To compare the change from baseline in DNA methylation levels between 
subjects taking folic acid and those taking placebo. 
3. To examine whether DNA methylation changes differ according to the MTHFR 
C677T genotype. 
6.2     Methods 
6.2.1 Subject Recruitment  
 
The present study was conducted in a subgroup of subjects originally recruited into Study 
1 (Chapter 3), recruitment methods are described fully in Chapter 2. Briefly, of the 336 
subjects in Study 1, all of those with the CC and TT genotype were approached during 
their follow-up appointment and invited to take part in a randomised, controlled, double-
blind trial. Subjects who agreed to participate signed a consent form and were assigned 
to either folic acid or placebo for a period of 12 weeks. Throughout the study, subjects 
were telephoned every two weeks to monitor whether they were taking their tablets and 
if they were willing to continue in the trial. At the end of the intervention period, subjects 
were invited back to the hospital and asked to return their remaining tablets so that they 
could be counted for compliance. Repeat fasting blood samples and colorectal biopsies 
were collected, this time using sigmoidoscopy. Systemic and colonic folate levels, and DNA 
methylation in the colonic mucosa, were measured as described previously (see Chapter 
2, Sections 2.4). 
 
Originally, the aim was to measure uracil content as part of the intervention trial but it 
was not possible due to insufficient samples remaining. 
 
6.2.2  Statistical Analysis 
 
Sample size for the RCT was calculated from a previous folate intervention study 
performed in this laboratory which investigated genomic DNA methylation in patients 
with colorectal adenoma as an endpoint. In this study, the aim was to recruit 23 subjects 
159 
 
into each arm to receive either 400g/d of folic acid or placebo pills for 3 months. These 
numbers were calculated in order to detect a 0.8SD (136Bq/g/DNA) change in DNA 
methylation following folate supplementation, at P<0.05 (80% power) (Pufulete et al., 
2005a). In the current study the aim was to recruit a total of 60 subjects to allow for 
potential exclusions and to be able to compare equal numbers in each arm in relation to 
the MTHFR C677T polymorphism.  
 
6.3 Results 
6.3.1 Subject Recruitment 
 






































Figure 6.1 Flow diagram: Study 2 - Recruitment of subjects who were initially recruited 












































Serum folate, red cell folate, plasma homocysteine, colonic tissue 





Subjects included n=21 
 
336 subjects recruited 
into Study 1 after 





























6.3.  Subject characteristics 
 
A total of 15 subjects completed the 12-week study. Of these, six were randomised to 
placebo of which two subjects had the CC genotype and four subjects had the TT 
genotype. Nine subjects were randomised to folic acid of which six subjects had the CC 
genotype and three had the TT genotype. Subject characteristics are shown by treatment 
arm in Table 6.1. 
 
 
Table 6.1 Subject characteristics by treatment group at baseline  
 
 











Gender Male 3 2 
 









CC  2 6 
 
TT 4 3 
Smoking Non-smoker 4 7 
 
smoker 2 2 
Drinking Non-drinker 3 3 
 
Drinker 4 5 
Dietary folate 





Data are median (IQR) for age, BMI, dietary folate intake. Gender, the MTHFR C677T 
genotype, smoking and drinking are all displayed as frequencies 
 
 
Biomarkers of folate status, serum vitamin B12 and genomic DNA methylation pre- and 
post-intervention are shown by the placebo and folic acid arms in Table 6.2. Change from 
baseline values in the folic acid and placebo groups were compared using the Mann-
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Whitney test to determine whether folic acid supplementation affected biomarker 
profile.  
 
Genomic DNA methylation measured in the colonic mucosa did decrease as a result of 
folic acid supplementation but this was not significant. Change in serum folate from 
baseline was greater in the folic acid group (P=0.05) than the placebo group. There were 
no significant differences in red cell folate, colonic tissue, plasma homocysteine, and 






















Table 6.2 Change from baseline in biomarkers of folate status, serum B12 and DNA methylation after supplementation 
 































































































DNA Methylation  














Data are median (IQR) for baseline, post-intervention and change from baseline.  
Change from baseline (post-supplementation) between folic acid and placebo were tested using the Mann-Whitney U test. 
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An attempt was made to examine the effects of supplementation by genotype on the 
biomarkers. Table 6.2 was reproduced with each column split into CC and TT genotypes. 
Some of the groups were too small (n=2) to produce interquartile ranges and the 
information was very difficult to assimilate. Additionally groups were too small for change 
from baseline to be tested statistically. Table 6.3 is included in Appendix 5 for 





Given the role of folate in DNA methylation and the fact that impaired DNA methylation 
is an intermediary marker of cancer (Okugawa et al., 2015), the aims of the current study 
were to a) determine whether genomic DNA methylation in healthy colonic tissue was 
modified by short-term folic acid supplementation in subjects with adequate folate status; 
b) clarify the effects of folic acid supplementation on folate levels in the blood and in the 
colonic mucosa; and c) understand the influence of the MTHFR C677T genotype. Serum 
folate was the only variable that was significantly increased as a result of folate 
supplementation. Red cell folate, plasma homocysteine, serum vitamin B12 and genomic 
DNA methylation in the colon did not change following supplementation with folic acid.  
 
This study was powered to recruit 60 subjects in total and the aim was to recruit 30 
subjects into the placebo group and 30 subjects in the folic acid group. Subjects were 
recruited from the same cohort of 336 subjects participating in Study 1 (Chapter 3). 
Unfortunately, a number of logistical challenges affected recruitment of 60 subjects.  
 
All CC and TT subjects (identified by genotyping 336 subjects from Study 1) were asked to 
participate in this trial (Study 2) which involved daily intake of either folate or placebo for 
12 weeks and a request to return to the hospital for repeat sample collection. Biopsies 
were to be taken by sigmoidoscopy, an invasive procedure which can involve pain, stress 
and has some clinical risks. Thus, it is not surprising that many were reluctant to 
participate. 217 of the 336 subjects were approached but only 30 agreed to participate. 
Three developed pathologies that violated the inclusion criteria and six could no longer 
be contacted prior to commencing the study. A total of 21 subjects entered the study and 
received a supply of either folic acid or placebo. These subjects were followed throughout 
the study by phone to check if they were still participating and had remembered to take 
their pills. Maintaining compliance and retention in Study 2 was also challenging. Two 
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subjects lost their tablets, two subjects admitted to taking them sporadically with breaks 
of up to a week, and three subjects started treatment but it became impossible to contact 
them after the study commenced. Only subjects who had missed one day and had 
remembered to take 2 tablets the next day could remain in the study for further analysis. 
Eventually, only 15 subjects (placebo n=6 and folic acid n=9) completed the study and 
attended the follow-up for collection of repeat blood and colonic tissue samples. Thus, 
this study is severely underpowered and caution should be taken with the interpretation 
of results. Recruitment and retention may have been improved by putting more time and 
resources into preparation prior to study start-up and in obtaining more prior agreement 
from the hospital clinical team. The study is presented here as a pilot study to guide future 
work. In addition, limited availability of biopsy DNA samples did not allow examination of 
uracil misincorporation as samples were prioritised for analysis of DNA methylation. 
 
As previously discussed, folate deficiency has been suggested as one of the possible 
factors contributing to the development of CRC and tumour progression. DNA 
hypomethylation is often followed by hypermethylation of the promoter region of tumour 
suppressor genes and this can also affect tumour progression (Duthie et al., 2004). Folate 
supplementation was shown to reverse global DNA hypomethylation in disease-free 
rectal mucosa by the PI of this study. Supplementation with 400g/d for 10 weeks 
resulted in increased serum and red cell folate and a concurrent decrease in genomic DNA 
methylation by 31% in leucocytes and 25% in the colonic mucosa of adenoma patients 
(Pufulete et al., 2005a). Meanwhile folic acid has also been shown to cause an increase in 
DNA methylation on the promoter of specific genes (van den Donk et al., 2007a). 
 
Older rat and mouse studies suggest that folate insufficiency could predispose the normal 
epithelium to neoplasia while folate intake could suppress tumorigenesis. More 
specifically, physiological doses (2-400µg) of folic acid supplementation during the early 
stages of colorectal neoplasia were found to reduce tumour growth, whereas 
pharmacological doses after the onset of carcinogenesis were found to promote tumour 
growth (Kim et al., 1996b, Song et al., 2000b). This paradoxical effect has been termed the 
‘dual modulatory effect’ of folate supplementation (Kim, 2007b). An investigation into the 
effects of folic acid supplementation in rats during the early stages of colorectal cancer 
(aberrant crypt foci, ACF) found that tumour multiplicity was positively correlated with 
dietary folic acid dosage indicating that folic acid supplementation may promote the 
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progression of ACF to colorectal tumours (Lindzon et al., 2009). In mice with no 
precancerous lesions, Lin et al. (2011) found that folic acid supplementation was more 
effective in reducing CRC risk compared to those with adenocarcinomas (Lin et al., 2011).  
 
Human studies have also produced variable results with regards to folic acid 
supplementation both in patients with CRC or history of colorectal cancer and in healthy 
individuals. An intervention study in patients following resection of colorectal adenomas 
found that a high dose of folic acid supplementation (n=49; 5 mg/day 0.02) for 3 years 
significantly reduced recurrence of adenomas compared to a placebo group (n=45). It was 
also shown that the clinical response was improved in patients below 70 years of age 
(Jaszewski et al., 2008).  
 
In healthy volunteers, Basten et al. (2004) reported that short-term folic acid 
supplementation (12 weeks; 1.2 mg/day) could significantly increase red cell folate and 
total lymphocyte folate but tissue folate (buccal mucosa, not the colon) was unchanged. 
In a subsequent study in lymphocytes the same group showed no difference in global DNA 
methylation in healthy volunteers following supplementation in the folic acid group 
compared to placebo (Basten et al., 2006). They also suggested that DNA methylation was 
less sensitive to changes in folate status than other markers such as uracil 
misincorporation and reported that folic acid supplementation had significantly lowered 
plasma homocysteine levels. In another study, young Australian adults (aged 18-32) with 
adequate folate status (red cell folate) were given cereal supplemented with 700µg folic 
acid and 7mg vitamin B12 or identically matched cereal without supplementation. No 
effect on DNA methylation in lymphocytes was observed in the supplementation group 
but plasma homocysteine was decreased by 37% (Fenech et al., 1998). Two larger studies 
of healthy volunteers examined DNA methylation using the LC-ES MS/MS method in 
uncoagulated blood. One measured DNA methylation changes in coagulated and 
uncoagulated blood samples from women of reproductive age (n=195) after 
supplementation with 4mg/day for six months (Crider et al., 2011). The other measured 
DNA methylation changes in leucocytes of healthy volunteers (n=216) after daily 
supplementation of 800 µg/day for three years (Jung et al., 2011). Neither showed any 
effect of supplementation on DNA methylation apart from a minor effect seen in the 




In the few subjects who took part in the current study, an increase in serum folate was 
confirmed after 12 weeks of folic acid supplementation. A marginal decrease in genomic 
DNA methylation was found from baseline to post intervention in the folic acid group but 
this was not significant. As highlighted before, this cohort was underpowered but the 
results are in agreement with van den Donk et al. (2007a) results observed in patients 
with a history of adenoma. More importantly (for comparison with the current study) in 
healthy volunteers Fenech et al. (1998), Basten et al. (2006), Jung et al. (2011) and Crider 
et al. (2011) (the latter two both used LC-ESI-MS/MS employed in the current study) 
showed that DNA methylation was not significantly altered by short-term folic acid 
supplementation.  
 
In summary, the results from this pilot study show that short-term folic acid 
supplementation at physiological doses may increase serum folate status but this had no 
significant influence on colonic tissue folate or genomic DNA methylation in the colonic 
mucosa of healthy folate-replete subjects. Furthermore, a response was not seen 
according to the MTHFR C667T genotype but numbers were too small to perform 
meaningful analysis on the effects of folic acid and placebo according to the MTHFR 
genotype.  The results presented in this chapter are based on a very small cohort and not 
statistically powered to allow for robust conclusions.  
 
Future studies would need to involve larger cohorts of healthy volunteers and a carefully 
selected folic acid dosage. Folate and placebo supplementation would need to be tightly 
monitored for subject compliance. In addition, extensive and detailed data on subject 
lifestyle variables – especially diet, smoking and alcohol intake – must be collected in 
order to fully investigate confounders and ensure meaningful results. In order to recruit 
truly healthy volunteers, recruitment should involve pathology-free subjects with no 
history of bowel issues and no history of diagnostic colonoscopy. Obviously such a study 
design would be challenging because persuading subjects to volunteer for procedures 
with a risk of perforation would not be straightforward and would most likely require 








7 Discussion and Future Work 
 
7.1 Results Summary 
 
The results of this thesis were in contrast to the original hypothesis that the MTHFR C677T 
genotype and systemic folate biomarkers and colonic tissue folate influence genomic DNA 
methylation and uracil misincorporation in DNA in healthy, folate-replete subjects.  
 
The initial objectives in this study were: a) to determine the influence of the MTHFR C667T 
polymorphism on genomic DNA methylation and uracil misincorporation in DNA 
(precursors of colorectal neoplasia) in the colonic mucosa; b) to explore these associations 
in respect of demographic, lifestyle and folate intake (dietary and supplemental) 
characteristics of this population; c) to establish that systemic folate status could reliably 
predict colonic tissue folate status in healthy folate-replete subjects; and d) to assess the 
effect of folate supplementation on these relationships. 
The main findings in this thesis are summarised below: 
1. DNA methylation in the colon was inversely associated, albeit non-significantly, with 
red cell folate (i.e. DNA hypomethylation was associated with increased red cell 
folate). 
2. Uracil misincorporation into DNA in the colonic mucosa was positively associated with 
serum folate (significantly) and red cell folate (non-significantly). It was also higher in 
the colonic mucosa of nutritional supplement users (n=60) when compared with that 
of non-users. 
3. DNA methylation, uracil misincorporation, colonic tissue folate and systemic markers 
of folate status and serum vitamin B12 did not differ by the MTHFR C677T genotype. 
4. Colonic tissue folate significantly correlated with serum, red cell folate and serum B12 
and negatively correlated with plasma homocysteine, it was higher in non-smokers 
than in smokers, and higher in the folic acid supplement user group than in the non-
user group.  
5. Genomic DNA methylation in the colon did not change as a result of daily folic acid 
supplementation for three months when compared with placebo (n=15). Serum folate 
was the only variable that was significantly increased after 3 months of 
supplementation. 
 
At the time this clinical trial was underway, it was the largest (n=336) investigation of its 
kind to examine these relationships in a healthy, folate-replete population. The 
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distribution of MTHFR C667T alleles (55% CC, 35% CT and 10% TT) was in Hardy-Weinberg 
equilibrium (2=3.80) and also in agreement with the reported ethnic distribution of this 
genotype. Importantly, folate biomarkers were measured systemically and also in the 
colon, and DNA methylation and uracil misincorporation were measured in colonic tissue, 
the site of interest, enabling a comprehensive profile of subjects with regards to these 
markers. 
 
Unexpectedly, red cell folate was negatively correlated with genomic DNA methylation, 
and uracil misincorporation was positively correlated with serum and red cell folate and 
was higher in supplement-users. These results are in contrast to the general consensus 
that folate deficiency is associated with DNA hypomethylation and increased uracil 
misincorporation into DNA (Choi and Mason, 2000, Linhart et al., 2009). This data suggests 
that high folate status might increase CRC risk in healthy, folate replete subjects. To the 
best of my knowledge this is in line with only one other human study which found that 
promoter methylation and uracil misincorporation increased as a result of folate 
supplementation in subjects with a history of adenoma (van den Donk et al., 2007a). 
 
Common dietary habits in older populations (high bread and breakfast cereal 
consumption) (Smith et al., 2008), the number of subjects who were taking multivitamins 
and folic acid supplements and the fact that Bovril and Marmite (60-120µg of folate per 
serving) were the only drinks which could be consumed in the two days prior to 
colonoscopy may have all contributed to high levels of circulating folate in these subjects. 
Ideally, it would have been good to have Marmite and Bovril as an exclusion criteria but 
this would have been an extra pressure to place on subjects who were unable to consume 
anything other than these drinks and clear liquids in the run up to the procedure. Folic 
acid is known to be 100% bioavailable (compared with 50% bioavailability of dietary 
folates) and it is not clear whether higher concentrations of serum folate may have had a 
transient effect on DNA methylation and uracil misincorporation. Average serum folate 
levels were at the upper limits of normal. 40 subjects had levels which were above the 
upper limit of normal in the assay and only 2 out of 336 subjects had values indicative of 
deficiency (<6.3nmol/l). Nevertheless, no subject was defined as red cell folate deficient 
(<337nmol/l). Folate supplementation in animal models has been shown to be protective 
in healthy animals; but, importantly, at very high doses or in the early stages of neoplasia 




The MTHFR C677T genotype had no significant influence on genomic DNA methylation in 
this population and this was consistent with multiple previous studies (Narayanan et al., 
2004). Genomic DNA methylation has been shown to be strongly influenced by the MTHFR 
C667T genotype in disease-free folate-deficient subjects (Friso et al., 2002b) suggesting 
that the polymorphism may influence DNA methylation only when folate levels are low. 
Of note, another primary endpoint of this work which was led by another student in the 
laboratory demonstrated that gene-specific DNA methylation was also unaffected by the 
MTHFR C667T genotype in the same study population (Hanks et al., 2013). 
 
Analyses of the demographic and lifestyle characteristics of this cohort also revealed that 
these had little influence on genomic DNA methylation in the colonic mucosa. These 
relationships were confirmed by multiple linear regression after adjusting for MTHFR 
C677T genotype, age, gender, BMI, smoking, drinking, use of folic acid and systemic folate 
biomarkers (serum folate, red cell folate, plasma homocysteine and serum vitamin B12). 
In addition, the under-powered (n=15) short-term folic acid intervention with 
physiological doses (400 µg/day) increased serum folate but had no significant effect on 
genomic DNA methylation or on colonic tissue folate in the colonic mucosa in healthy, 
folate replete subjects. 
 
Despite the close relationship between folate status, the MTHFR C667T genotype and CRC 
risk, information specific to the colonic epithelia of neoplasia-free individuals with 
adequate folate status is scarce. This is partly due to the lack of effective, non-invasive 
methods to evaluate folate levels in the colonic mucosa of subjects without any history of 
bowel complaints and who are not undergoing surgery as part of their care. At the time 
of this study, much of the data on these relationships had been acquired from patients 
with colorectal neoplasms which are subject to the confounding effects of cancer (van 
den Donk et al., 2007b). Conversely studies in subjects free from colorectal adenoma or 
cancer have generally focused on systemic folate biomarkers. The key strength of this 
study include the fact that subjects were free from any obvious colorectal pathology, and 
this reduced the potential confounding effects that neoplasia may have exerted on tissue 
folate, DNA methylation and uracil misincorporation in the colon. It should be highlighted 
that although these subjects were classified as ‘normal’ healthy volunteers, they were 
undergoing colonoscopy because of specific bowel symptoms including bloating, 
bleeding, and pain. Thus it is possible that they might have had microscopic lesions or 
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gastrointestinal inflammation that were difficult to detect but could have contributed to 
changes in DNA methylation and uracil misincorporation (both biomarkers of damage in 
the colon). 
 
Other possible limitations include the assay which was employed in the hospital for 
routine measurement of folate. The traditional method of measuring red cell folate is the 
microbiological assay. Immune competitive binding assay used at King’s College Hospital 
(for the current study) is generally thought to be appropriate for assaying plasma and 
serum folate but falsely high results have been produced for red cell folate analysis due 
to a build of metabolites. The MBA measures total folate by growth of the organism 
whereas in the binding assay, folate in the human sample competes with a labelled folate 
standard and an unlabelled folate standard and binding is dependent on binding affinities 
with the protein. Different folates have different binding abilities. Folic acid tends to bind 
more than 5-methyl-THF and formyl THF. Additionally, monoglutamate standards and 
folylpolyglutamate standards bind with different affinities and polyglutamates known to 
show falsely high folate levels if conversion of red cell folate from the polyglutamate to 
the monoglutamate derivative is incomplete. These different binding affinities of the 
folates are not problematic if 5-methyl-THF is the main one-carbon present. However, 
when other one-carbon forms are present, for example in red blood cells of 
methylenetetrahydrofolate reductase 677C/T subjects, results have been shown to be 
less reliable (Shanes, 2011). In general, serum and red cell folate levels measured by these 
kits are considerably lower than the concentrations measured using the MBA. With the 
advent of folate fortification programmes, serum samples have contained higher 
concentrations than the upper limit that these assays are able to measure, and dilution is 
required in compensation for this and, on dilution, matrix effects can produce a mixture 
of results.  
 
It is important to note that in the current population, median serum and red cell folate 
are both unusually high for the whole sample, and there are no subjects with folate 
deficiencies representative of the UK population.  
 
Median serum folate was 25.5nmol/L (IQR 17.1-38.0), whereas in the national median 
level (reported in the NDNS Rolling programme between 2008-12) mean serum total 
folate concentration was 18.1nmol/L and 21.4nmol/L for 19-64-year-old men and women 
respectively and mean serum total folate concentration was 22.7nmol/L and, 27.6 nmol/L 
172 
 
for over 65 year-old men and women respectively. The proportion of adults in the whole 
population with a serum total folate concentration below the WHO threshold (10nmol/L), 
an indication of biochemical folate deficiency, was between 8.5-15.5%.Red cell folate was 
965 nmol/L (IQR 765-1139) compared with a national mean red blood cell folate 
concentration of 621nmol/L and 652nmol/L for 19-64-year-old men and women 
respectively and mean red blood cell folate concentration was 729nmol/L and 787nmol/L 
for over 65 year-old men and women respectively. The proportion of adults in the whole 
population with a mean red blood cell folate concentration below the WHO threshold 
(340nmol/L), an indication of biochemical folate deficiency, was between 6.8-10.8%. 
 
The Rolling NDNS programme used LC-MS/MS to measure serum folate and the MBA to 
measure red cell folate concentration and therefore it is not known whether the overall 
results in this population are higher due to a problem with the competitive binding assays 
for both serum and red cell folate (as described above) or, as mentioned previously, 
whether another external dietary factor may have caused this. 
 
  
As described previously, the lack of association between the MTHFR TT genotype and DNA 
methylation is in agreement with other studies in healthy subjects where DNA 
methylation was measured in lymphocyte DNA and similarly to our population, these 
subjects had adequate or high folate status whereas in studies with subjects possessing 
poor folate status, the TT genotype influences genomic DNA methylation in lymphocytes 
and TT individuals have lower levels of genomic DNA methylation  
 
An association between the MTHFR C677CT genotype and DNA methylation in the colon 
of neoplasia free subjects may only be observed when folate status is low. In the Friso 
study a difference in genomic DNA methylation (measured in lymphocytes) between CC 
and TT subjects was apparent only when serum folate was below the low. In the current 
study median serum folate was 25 nmol/L, approximately twice that in the Friso study 
(Friso et al,  2002a). 
 
The lack of association between the MTHFR TT genotype and DNA methylation in in this 
study could also have been due to the fact that differences in serum and red blood cell 




In addition to the primary endpoints, the multiple testing between subgroups such as 
smokers/non-smokers, drinkers/non drinkers, those who did/did not take daily folic acid 
supplementation (in Chapters 3, 4 and ) should be considered with caution because these 
were not prespecified endpoints and the P value was not adjusted accordingly to 
compensate for this, the disadvantage of this is sort of multiple statistical testing is that 































7.2 Future work  
 
Future experiments would need to be designed around the unanswered questions 
generated in this thesis. Large studies need to be designed to test the effect of folate 
status and supplementation in truly disease-free volunteers with no history of bowel 
symptoms (recruited directly for the study) on DNA methylation and uracil 
misincorporation. Given the sufficient folate status of subjects living in developed  
 
societies, it would be challenging to test a folate-deficient cohort over time (asking 
subjects to go through depletion would be controversial) but subjects could be stratified 
carefully in terms of different dietary folate levels. The challenge of low compliance of 
FFQ completion would also need to be overcome. 
 
If the only option was to do the same experiment again, and to recruit subjects at clinically 
indicated colonoscopy, data collection would need to be far more extensive, for example, 
on past medical history, family history of IBD and CRC, smoking and drinking habits and 
current dietary habits to assess confounders. Additionally, follow-up would need to occur 
at subsequent points in the future (i.e. at 6, 12 and 18 months) to determine whether the 
result of undetected pathology was reliable at the time or whether something underlying 
developed into inflammation (IBD, Crohn’s and Coeliac disease) or even neoplasia in the 
bowel. If the cohort was large enough, subjects could be split by phenotype for 
comparison of influence on DNA methylation and uracil misincorporation. 
 
To improve on the RCT design, numbers would need to be greatly increased for statistical 
power but this would be difficult without remuneration because of the risks associated 
with colonoscopies and sigmoidoscopies. In addition to the FFQ, details of folic acid 
supplementation and diet and lifestyle habits would need to be recorded during 
supplementation so that adjustment could be adjusted for confounders in the post-
supplementation analysis.  
 
Though less surprising than the results in Chapter 3 and Chapter 4, this study confirmed 
that smoking caused a reduction in folate levels in the colonic mucosa. This is the first 
report to examine this relationship in the colorectal tissue in disease-free volunteers. It 
would be useful to develop this and investigate the mechanism for depletion (whether  
folate is depleted by smoking particulates or folate is low as a result of diet and lifestyle 
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habits) and also to assess for relationships with other biomarkers of neoplasia in the 
colon. A future experiment might include more details on smoking, drinking and dietary 
habits (past and present) including consideration of important cofactors including serum 
vitamin B12 using a prospective design and careful monitoring of diet over time to examine 
folate change in relation to these biomarkers of damage in the colon. 
 
In addition to folate and B vitamins, other factors such as medications, alcohol, choline 
and methionine may play an important role in folate metabolism (Giovannucci, 2001). 
Although no effect was seen in this study, alcohol is a folate antagonist that reduces folate 
absorption and may influence folate metabolism. Folate and methionine deficient diets 
combined with high alcohol consumption are termed ‘methyl poor’ and have generally 
been associated with CRC risk (Hubner and Houlston, 2009).  
 
Collectively, the unexpected evidence of an association between genomic DNA 
methylation (non-significant) and uracil misincorporation, and systemic folate levels and 
folate supplementation suggest that current folate levels in the population may cause 
temporary non-favourable epigenetic changes. Important questions remain as to whether 
the effect seen in this cohort is robust, long-term and if it might be associated with future 
neoplastic changes. It is not known what the optimum level of folate (dietary and 
supplemental) is to avoid aberrations in markers such as genomic DNA methylation and 
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-------------------------------  --------------------------   ---------------------
------------------------------ 
Name of person taking consent  Date    Signature 




------------------------------  -------------------------   ---------------------
------------------------------- 
Researcher   Date    Signature 
 





































Dear Dr. X 
 
Re: The effect of folic acid supplementation on blood and tissue folate levels and 
markers of DNA damage in the colon 
I am writing to ask whether you have any objections to Mr name, D.O.B **/**/** of 
address participating in the above study, which will look at the relationship between folic 
acid and colorectal cancer. 
 
Epidemiological evidence has shown an inverse association between folate status and 
colorectal cancer risk. Folate supplements have been shown to reduce the incidence of 
neoplasia in patients with ulcerative colitis and polyp recurrence in patients with 
adenomas. Furthermore, a common mutation in a gene encoding a folate metabolising 
enzyme (5,10-methylenetetrahydrofolate reductase, MTHFR C677T) also influences 
disease risk. Folate plays a key role in DNA methylation and DNA synthesis, which are 
required to maintain the integrity of the genome. Aberrant DNA methylation and DNA 
damage are common phenomena of many cancers and have been observed in the early 
stages of colorectal carcinogenesis in humans. 
 
Folate supplementation in pharmacological and physiological doses has been shown to 
reverse aberrant DNA methylation in normal-appearing colonic mucosa of patients with 
adenoma and carcinoma. However, it is not known whether folate supplementation has 
a similar effect in people without colorectal neoplasia. Also, it is not known whether 
increasing folate status has a positive effect on markers of DNA damage associated with 
abnormal DNA synthesis. We propose to give patients with no colorectal abnormalities a 
400g/d folate supplement or a placebo for a period of 3 months. We will look at the 
effect this has on folate status (serum, red cell and bowel tissue folate levels) and markers 
of DNA damage (global and gene-specific DNA methylation and uracil misincorporation) 
in the colon. 
 
Please find enclosed a copy of the patient information sheet, detailing the procedure. 
 
The exclusion criteria for this study include: 
 
• Patients with tumours/polyps at colonoscopy 
• Patients with previous history of colorectal cancer, a strong family history of 
colorectal cancer or adenomatous polyposis coli 
• Patients with inflammatory bowel disease 
• Current or past history of gluten-sensitive enteropathy 
• Pregnancy, epilepsy, alcoholism, pernicious anaemia and the use of anti-folate (ie 
methotrexate) medication 
I would be grateful if you could spare a few minutes to complete and return the section 
below in the reply paid envelope, or fax it to ......................... on 0207 848 4185. Thank 











Re: The effect of folic acid supplementation on blood and tissue folate levels and 
markers of DNA damage in the colon 
 
Please tick the appropriate box 
 I am in agreement that Mr/Mrs name, D.O.B **/**/**, of address, taking part in the 
above study. 
































Health Screening Questionnaire 




Folate, genetic polymorphisms and markers of DNA damage in the colon. 
 
REC number no: 06/Q0703/29 
 
Thank you for agreeing to help us with our study.  Please answer all the 







  Subject number: …………………………………………… 
 























Have you  had anything to eat or drink in 






Did you eat Bovril/Marmite in last 48 
hours 




Have you eaten Bovril/Marmite in the 
last week? (how many days/how many 
teaspoons per day?) 
 
Do you smoke now?  
 Don’t smoke                    Yes, 
regularly   
 Occasionally 
 
If not, have you ever smoked? 
 Yes   
 No 
How old were you when you started 
smoking? 
 
How old were you when you stopped 
smoking? 






Do you suffer from any allergies? 
 
Do you suffer from any medical 
problems? 
Are you taking/have you taken any of the 
following medication? 
If so, how much, how often and for 
how many months in the last year? 
Co-trimoxazole  











Iron salts  
Lamotrigine  
Lometrexol  





(atovaquone & proguanil) 
 
Nitric oxide  
Oxcarbazepine  




















Have you taken any of the following in 
the last six months? 
If so, how much, how often and for how 
many months in the last year? 
Vitamin C  
Vitamin E  
Folic Acid  
Multivitamins  
Multivitamins and minerals  
Calcium  
Cod liver oil  
Evening primrose oil  
Garlic pearls  
Others (please specify)  
  
 
Do you have a family history of: If so, please give details: 
Colorectal cancer  
Irritable bowel syndrome (IBD)  
Coeliac disease  
Epilepsy  
  


















FREQUENCY OF CONSUMPTION 
 
 

















Number of days 
per week 





          Type                                 Pints    ¼   ½    1   2 
• ……………………………..       
• ………………...…………...       






          Type                                 Pints    ¼    ½   1   2 
• ……………………………..       
• ………………...…………...       
• ………………...………...…       
                                           
                                          Bottles 1    2    3   
4 
• ………………...…………...             
• ………………...…………...         
 
                                          Cans     1    2    3   
4 
• ………………...…………...             
• ………………...…………...         
 
WINE (white, 
red or rose) 
 
                                                Glasses    1     2   3   
4 
 
• ……………………………..       
OR 








                                                Glasses    1     2   3   
4 
 




whisky, gin, etc) 
                                     Pub measures    1    2    3   
4 
 
• ……………………………..       





Food Frequency Questionnaire 
 
Food Frequency Questionnaire 




Folate, genetic polymorphisms and markers of DNA damage in the colon. 
 
REC number no: 06/Q0703/29 
 
Thank you for agreeing to help us with our study.  Please answer all the questions as 





  Subject name: ……………………………………………… 
 
  Subject number: …………………………………………… 
 


























How to complete the FOOD QUESTIONNAIRE 
 





FREQUENCY OF CONSUMPTION 
 
 














Number of days per 
week 
 
Describe amounts using the 
measures in PHOTO 1 and PHOTO 
2 































 Type of cereal                      
Number of bowls  
                                            [R in 
PHOTO 1]  

















 Type                                      Number 
of slices  
















          Type                                  Number 
and size of  
                                     spoonfuls 







          
✓ 






Column A:    Lists the foods/food groups of interest. 
Columns B to E:    Tick one box to show how often you eat the food. 
Column F: Write down the exact names of the foods you eat and, where indicated, 
describe the amounts using the household measures in PHOTO 1 and PHOTO 2. Alternatively, 












FREQUENCY OF CONSUMPTION 
 
 













Number of days per 
week 
 
Describe amounts using the 
measures in PHOTO 1 and PHOTO 2  
    1 2 3 4 5 6 7  
 
BREAKFAS







          Type of cereal                      Number of 
bowls  
                                            [R in PHOTO 
1]  










          Type                                      Number of 
slices  
            [Thick       Medium          
Thin ] 
White ……………………………………….. 















          Type                                      Number of 
slices  
            [Thick       Medium          
Thin ] 
White ……………………………………….. 








          Type                             Number of 
rolls/pieces 













































FREQUENCY OF CONSUMPTION 
 
 




















Number of days 
per week 
 
Describe amounts using the 
measures in PHOTO 1 and PHOTO 2 






          Type                                  Number and 
size of  















                                                    Number and 
size of  







          Type                                 Number of 
slices or  
                                     spoonfuls 






























          Type                               Volume 
[PHOTO 1] 

















          Type                   Number of spoonfuls 









          Type                                  Number and 
size of  


























FREQUENCY OF CONSUMPTION 
 
 














Number of days per 
week 
 
Describe amounts using the 
measures in PHOTO 1 and 
PHOTO 2 




          Type                                      





          Type                                      






          Type                                  Number 
and size of  
                                     spoonfuls 







          Type                                  Fraction 
consumed  
                   [¼     ½     ¾     







          Type of dish                      
Number and size of  








          Type of dish                      
Number and size of  






           Type                                                  
Amount  






          Type                                      






Roast or boiled 







                                                           
Number & size  






                                                           
Number & size  




dishes (chilli con 
carne, shepherd’s 
pie etc) 
          Type                                  Number 
and size of  






Meat stew or 
casserole 
                Number and size of 







FREQUENCY OF CONSUMPTION 
 
 


















Describe amounts using the 
measures in PHOTO 1 and 
PHOTO 2 





          Type                                      
Number of slices  
………………………………………….. 
…………………………………………. 
Steak and kidney 
pie 
                                                        





                                                       





                                                        
Amount on plate 
                   [¼     ½     ¾     





                                                                     
Number 






                                                    Number 
and size of  






                                                       






                                                      
Number of carrots 
           [Small       Medium          
Large ] 






                                                        





                                                       





                                                      
Number of florets 
208 
 




                                                      






                Number and size of 
spoonfuls [PHOTO 2] 







                                                     Number 







FREQUENCY OF CONSUMPTION 
 
 














Number of days per 
week 
 
Describe amounts using the 
measures in PHOTO 1 and 
PHOTO 2 







                Number and size of 
spoonfuls [PHOTO 2] 









                Number and size of 






sugar snaps etc) 
                Number and size of 
spoonfuls [PHOTO 2] 









                Number and size of 





                                                        
Number of slices 
…..………………………………………….. 
 
Tomato                                                   Number 
of tomatoes  





Pepper                              [¼     ½     ¾     








                Number and size of 
spoonfuls [PHOTO 2] 






                Number and size of 





                                                        





                Number and size of 







                Number and size of 






          Number and size of spoonfuls 
[PHOTO 2] or    fraction of can 







FREQUENCY OF CONSUMPTION 
 
 














Number of days per 
week 
 
Describe amounts using the 
measures in PHOTO 1 and 
PHOTO 2 






beans, dahl etc) 
          Type                                  Number 
and size of  









                                                         
Number & size 







                                                         
Number & size 
210 
 















                                                         
Number & size 








          Type                                  Number 
and size of  








          Type                                  Number 
and size of  







NUTS AND SEEDS 
(sunflower, 
sesame etc) 
                                                    Number 
and size of  









          Type                                  Number 
of packets  
………………………………………….. 
………………………………………….. 
LIVER PATE                 Number and size of 





                                                        





          Type                                     
Number of bowls  








FREQUENCY OF CONSUMPTION 
 
 
















Number of days per 
week 
 
Describe amounts using the 
measures in PHOTO 1 and 
PHOTO 2 





















          Type                                    
Number & size of  













































































Table 6.3a Biomarkers –RCT - change from baseline split by MTHFR C677 CC and TT genotype – placebo and folic acid subjects 
 
Placebo arm 
` Baseline Post RCT Change from baseline 





















































DNA Methylation  















Folic acid arm 
 




























































DNA Methylation  








Data are median (IQR) for biomarkers at baseline, post-intervention and change from baseline 
Median only is shown where n<4 and group too small for quartile range to be shown 
n/a - where no output produced in SPSS 
 
